

Is exposure to chemical pollutants associated with sleep outcomes? A systematic review

Danielle A. Wallace¹⁻³, Jayden Pace Gallagher³, Shenita R. Peterson⁴, Seyni Ndiaye-Gueye^{1,2}, Kathleen Fox⁴, Susan Redline^{1,2}, Dayna A. Johnson^{3,5}

¹Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA.

²Harvard Medical School, Boston, MA.

³Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA

⁴Woodruff Health Sciences Center Library, Emory University, Atlanta, GA

⁵Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.

Address correspondence to:

Danielle Wallace, MPH, PhD, Division of Sleep and Circadian Disorders, 221 Longwood Ave, Room BL-252, Boston, MA 02115, USA

Email: dclarkson-townsend@bwh.harvard.edu

ABSTRACT

Background: Sleep disruption is a public health concern and environmental exposures that influence the biological processes underpinning sleep may contribute to impaired sleep health. However, the contributions of environmental chemical pollutants to sleep health have not been systematically investigated.

Objectives: This systematic literature review sought to identify, evaluate, summarize, and synthesize the existing evidence between environmental chemical pollutant exposure and dimensions of sleep health in humans. We sought to evaluate potential mechanisms underlying exposure-outcome relationships and recommend areas for future research.

Methods: Databases were searched for peer-reviewed published research on chemical environmental pollutants and sleep health and disorders with no date restriction up to the last search date of April 2021 (registered protocol PROSPERO # CRD42021256918), resulting in 9,918 records. Two reviewers independently screened identified records against inclusion and exclusion criteria, extracted study information, and performed risk of bias assessments.

Results: We identified 204 studies of exposure to air pollution, exposures related to the Gulf War and other conflicts, endocrine disruptors, metals, pesticides, and solvents with dimensions of sleep health (architecture, duration, quality, timing) and sleep disorders (sleeping pill use, insomnia, sleep-disordered breathing) for inclusion in this review. Metals were the most frequently evaluated pollutants, while sleep maintenance/insomnia and quality were the most reported sleep outcomes. Synthesis of the evidence suggests mechanisms related to cholinergic signaling, neurotransmission, and inflammation as the most shared pathways.

Discussion: Evidence indicates that exposure to particulate matter, secondhand smoke, dioxins and dioxin-like compounds, lead, mercury, pesticides, solvents, and exposures related to the Gulf War are associated with worse sleep health and disorders. Chemical pollutants are likely key environmental determinants of sleep health and disorders; thus, there is a need to improve measurement of pollutants and sleep, study rigor, and determine the populations most vulnerable to the effects of exposure.

13 INTRODUCTION

14 Sleep is as vital to life as air or water and is essential for metabolic, immunologic, developmental, and
 15 cognitive functions[1]. Healthy sleep is a multidimensional construct defined by sleep duration, efficiency,
 16 timing, alertness, and quality[2]. However, disrupted sleep is prevalent and of public health concern[3–5]; for
 17 example, two thirds of high school students[6] and a third of adults[7] in the United States experience disrupted
 18 sleep. In the U.S., approximately 31-40% of people younger than 18 years of age do not attain the
 19 recommended sleep duration for their age group[8], and 11% of adults report sleeping 5 hours or less per
 20 night[8]. Obstructive sleep apnea (OSA), a form of sleep-disordered breathing (SDB) characterized by
 21 breathing cessations that disrupts sleep, is estimated to affect a billion people worldwide[9]. Chronic insomnia
 22 – difficulty falling asleep and maintaining sleep – is another common sleep disorder affecting approximately 6%
 23 of the population[10]. The pervasiveness of these outcomes is alarming because disrupted sleep acts as an
 24 endocrine disruptor, preventing or altering the secretion of growth hormone, prolactin, cortisol, and other
 25 hormones[11–14], and is associated with inflammation[15–18] and cardiovascular[19–21], and cardiometabolic
 26 diseases [22–29].

27 Sleep is a dynamic neurophysiological process characterized by cycles of non-rapid eye movement
 28 (NREM) and rapid eye movement (REM) states. Sleep is regulated by a 2-part process composed of a 1)
 29 homeostatic sleep drive (Process S) and 2) and a circadian rhythm in wakefulness (Process C)[30]. These
 30 processes are governed by neurological circuits, neurotransmitters, and hormones that drive or inhibit arousal
 31 and sleep, with interaction from the circadian system to influence the timing, latency, and quality of sleep.
 32 Pathways that promote arousal include monoaminergic, cholinergic, glutamatergic, histaminergic, and
 33 GABAergic neurotransmission from the midbrain, basal forebrain, and other regions[31–33]; during sleep
 34 promotion, these pathways are inhibited and somnogens such as adenosine, cytokines, and melatonin aid to
 35 induce sleep. These processes and sleep-wake behavior can be altered by untreated OSA, insomnia,
 36 individual behaviors and health status, socioeconomic status[34], occupation[35,36], interpersonal
 37 relationships, social and cultural factors, societal factors[37–39], and environmental factors[38]. To improve
 38 sleep at a population-level, further understanding of environmental factors is warranted.

39 Environmental exposures are particularly important for sleep health, and chemical pollutants are
 40 common environmental exposures with potential for chronic effects on the respiratory system, cardiovascular

system, central nervous system, and neuroendocrine system. Prior systematic reviews of environmental exposures and sleep have reported summarized associations with these physical components, such as reviews on sleep and noise pollution[40,41], light pollution[42], greenspace[43], climate change[44], and other aspects of the built environment[45]. Other environmental exposures, such as air pollution[45–49], second-hand smoke exposure[50,51], micronutrients[52], and occupational exposures[35], have also been reviewed as contributors to sleep health.

While understanding of the social and environmental factors that affect sleep is growing, less is known regarding the effects of chemical pollutants such as pesticides, heavy metals, solvents, and endocrine-disrupting chemicals (EDCs) on sleep health. Chemical pollutants have been shown to affect neurotransmitter systems and other sleep-relevant processes such as inflammation[53–55]. For example, animal and in vitro studies have shown that lead exposure alters GABA release[56], and a study in monkeys reported that treatment with lead during infancy caused insomnia[57]. Experimental and epidemiological evidence links exposure to air pollution and inflammation[58,59], an established risk factor for sleep disturbances[17] and OSA[60], and pulmonary impairment due to air pollution may contribute to SDB[61]. Altered cholinergic signaling has also been implicated in upper airway collapsibility and OSA[62–64], and this may be a pathway by which environmental exposures that act on the cholinergic system, such as pesticides, influence SDB. For example, a rat study showed that exposure to chlorpyrifos, a commonly used pesticide, during early development resulted in a higher sleep apnea index and lower diaphragm acetylcholinesterase (AChE) activity later in life, compared to rats not developmentally exposed to chlorpyrifos[65]. Therefore, exposure to chemical pollutants may result in disturbed sleep by acting upon the biological pathways that regulate sleep-wake behavior, with developmental windows of vulnerability; however, the connections between environmental chemical exposures and sleep disturbance are not well-established.

Importantly, environmental pollution does not affect all people equally, with systematic differences in pollution exposure by race/ethnicity and class[66]; disturbed sleep and sleep disorders are also more common among historically marginalized racial groups and individuals of lower socioeconomic status. Due to environmental racism, marginalized communities face a disproportionately higher burden of adverse environmental exposures[67], with environmental disparities in housing[68] and ambient pollution[69], which may contribute to sleep health disparities[70–72]. Individuals living in these communities also have a greater

burden of disease associated with these adverse exposures, such as higher rates of asthma[73] and OSA morbidity and mortality[74,75]. Early exposure during childhood influences health trajectories later in life, and research in environmental determinants of sleep health can benefit from a life course approach with particular focus on environmental exposures during vulnerable developmental windows and critical periods[76]. Thus, identifying the environmental factors that lead to disrupted sleep in both childhood and adulthood can inform public health efforts to improve sleep health and address disparities in sleep and related morbidity [75,77–79].

In summary, chemical pollutants may contribute to sleep disruption by influencing the underlying biology of sleep-wake behavior, with possible age-specific effects and disparities in exposure. Prior studies have assessed links between chemical pollutants and sleep outcomes, but this literature has not yet been evaluated in a comprehensive, systematic way; doing so would provide a starting point from which to assess the interactions between chemical environmental exposures and sleep health. Therefore, to address these gaps in knowledge and to synthesize the current epidemiological evidence, we conducted a systematic review of the relationships between chemical pollutants and sleep health and disorders. Furthermore, we discuss potential mechanisms linking pollutants to sleep outcomes and areas for future research.

METHODS

Data Sources and Literature Search Strategy

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was used as a guideline for conducting this review. We registered our protocol with the international prospective register of systematic reviews, PROSPERO (#CRD42021256918, first submitted May 27, 2021). As outlined by the PROSPERO protocol, a comprehensive search was created by the research team and executed by information specialists (SP and KF) in 6 bibliographic databases: Agricultural & Environmental Science Collection (ProQuest), PubMed, Embase (Elsevier), Environment Complete (Ebsco), Web of Science Core Collection [Science Citation Index Expanded, Social Sciences Citation Index, Arts & Humanities Citation Index, Emerging Sources Citation Index, Conference Proceedings Citation Index, Book Citation Index, Current Chemical Reactions, Index Chemicus], and Scopus (Elsevier) in the Spring of 2021. The search was crafted of various keywords and controlled vocabulary concerning the concept of ‘environmental pollutants’ and the sleep outcomes listed in the inclusion criteria. Searches were limited to articles and reviews written in English. We

did not restrict by date. Animal studies were excluded from the PubMed and Embase searches. Search terms, search dates, and additional details are provided in **Supplemental File 1**. The database search retrieved 9,918 citations. Studies were imported into EndNote X9 for data management and deduplication. Additional duplicates were removed by the web-based evidence synthesis tool Covidence, which was used for screening and data extraction.

Inclusion criteria

Inclusion criteria included: research in humans, chemical pollutant as an exposure (such as metals, pesticides, flame retardants, etc.), sleep health or disorder (such as sleep quality or SDB), sleep measurement (polysomnography (PSG), actigraphy, etc.), and quantitative data. Studies of in vitro or cultured tissue, completely modeled data, or non-human data were excluded from the analysis. Of the environmental exposure literature, studies of noise pollution, light pollution, radiation, smell, green space, nutrition, allergens, and/or mold were excluded from the analysis. A recent systematic review by Liu et al[46] summarized the air pollution and sleep literature (n=22 articles) up until the last search date of October 2019; therefore, we excluded those studies of air pollution and sleep already reviewed by Liu et al[46] and include discussion of our findings with the previously reviewed literature. Metals are common environmental pollutants[80], and while we excluded most studies of micronutrients and sleep, we included those of manganese, copper, and selenium, because they have relevance to pesticide use and as environmental contaminants. Studies of Parkinson's disease, Alzheimer's disease, and Wilson's disease were identified and excluded. Symptoms of sleep disorders such as snoring, restless legs syndrome, and REM sleep behavior disorder were also identified and excluded due to being outside the scope of this review. Lastly, studies with only qualitative data, not available in English, not peer-reviewed, or epidemiologic studies without a control or comparator group, such as varying levels of exposure, were also excluded. Studies with multiple measures of sleep that met inclusion criteria but also evaluated snoring, for example, were extracted with information on valid sleep outcome(s) only. Inclusion categories were further reviewed during mutual group discussions (DW, JPG, DAJ).

Screening

The resulting papers were screened by two independent reviewers (DW and JP) against inclusion and exclusion criteria using Covidence. The number of articles screened during the two steps can be found in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart in **Figure 1**. The search resulted in 4,464 unique citations identified for screening after de-duplication. After the full-text screening, bibliographies of 20 review articles (**Supplemental File 2**) were searched for additional citations in February 2022, resulting in an additional 58 articles (2 duplicates) added to Covidence for title/abstract and full-text screening. Of the initial 4,464 papers and 58 papers identified from reviews, 3,984 articles were considered irrelevant and excluded during the title/abstract screening process. Full text review of the remaining 538 papers resulted in 204 studies included for data extraction, 15 of which were identified from the review articles. Of the included articles, 74% (n=151) were epidemiological studies and 26% (n=53) were case reports or case series. Consensus was arbitrated by the first author during title/abstract and full-text screening, and, in the instance of discordant responses, consensus was determined by mutual discussion (DW and JPG).

Data Extraction

Data on year, study location, study design, exposure and exposure measurement, outcome and outcome measurement, and risk of bias (RoB, details below) for the 204 included studies was independently extracted by two reviewers (DW and JPG) using Covidence and Google Forms (abstraction forms available in **Supplemental File 3**). PSG studies inclusive of sleep stages were considered measures of sleep architecture, which refers to sleep stage composition (stages N1, N2, N3 and REM) and the cycles of REM and NREM. Outcomes of sleeplessness, inability to sleep, sleep onset latency, problems with sleep maintenance (such as wake after sleep onset or sleep fragmentation), and early morning awakening were considered measures of sleep maintenance/insomnia. Studies where the sleep outcome was described as a sleep problem or disorder (not insomnia or SDB), sleep disturbance, or sleep efficiency were included in the sleep quality group. Outcomes related to sleep timing or sleep midpoint were included in the sleep timing group.

However, we recognize that extracted exposure or outcome categories are not exclusive, and that an exposure or an outcome listed in one group may also have characteristics that overlap with another group (for example, antimony is a heavy metal that is also used as a flame retardant). Studies where exposure and outcome of interest were measured concurrently were considered cross-sectional. Results were merged, and

in the instance of discordant responses, consensus determined by mutual discussion. For studies on smoking and/or secondhand smoke (SHS) exposure, only results pertaining to ambient or secondhand smoke exposure, and not active smoking or in utero exposure, were included. For all studies, only relevant information on included exposures and sleep outcomes were extracted. Studies involving participants younger than 18 years of age were considered pediatric populations. Estimates were rounded to the nearest 2 decimals, and, in some instances, unadjusted estimates were calculated from the provided data where indicated. Due to heterogeneity, meta-analysis and comparison of effect estimates was not performed.

Risk of Bias (RoB) Assessment

Included epidemiologic studies were rated for risk of bias (RoB) according to human-related research questions adapted from both the NIEHS and National Toxicology Program's Office of Health Assessment and Translation tool (https://ntp.niehs.nih.gov/ntp/ohat/pubs/riskofbiastool_508.pdf) as well as the Cochrane ROBINS-I tool (template tool available in **Supplemental File 4**). RoB was independently assessed by two reviewers (DW and JPG) using Covidence and Google Forms; when responses differed between reviewers, consensus was reached after discussion. For each study, reviewers evaluated whether there was a "Definitely low", "Probably low", "Probably high", "Definitely high", or "No information" RoB for the following components: selection bias, confounding, exposure assessment, attrition/exclusion bias, outcome assessment, reporting bias, and other bias. The "other" bias group included bias due to improper statistical methods or factors not captured by other bias groups that could influence the validity of the study. The overall RoB for epidemiologic studies was assessed first by intervention domains and then weighted across the domains considered most important for a final RoB determination; these domains included: selection bias, confounding, exposure assessment, and outcome assessment. For case reports and case series, RoB was graded according to a tool proposed by Murad et al[81]; this tool rates the quality of case studies according to 4 areas: selection, ascertainment, causality, and reporting (template tool available in **Supplemental File 4**). Overall judgement of case study quality was ascertained as recommended[81], with ratings of "poor", "fair", or "good", and greater weight given to areas perceived most important for the study. Results were visualized using R version 4.1. Data extraction and quality assessment responses for epidemiological studies are provided in **Supplemental File 5** and for case studies in **Supplemental File 6**.

RESULTS

The included epidemiologic studies (n=151) evaluated exposure to air pollution (19%), conflict-related exposures (10.5%), EDCs/other (8%), metals (34%), pesticides (8%), solvents (20.5%), and exposures with sleep outcomes related to sleep architecture (2.6%), dreams/nightmares (6%), duration (26.5%), quality (47.7%), timing (2.6%), sleeping pill use (4%), sleep maintenance/insomnia (37.1%), and SDB (23.8%), as shown in **Table 1**. The majority of case studies (n=53) reported exposure to metals (64%) and sleep outcomes such as insomnia (50.8%) and quality (29.2%) (**Table 2**); there were no case studies of air pollution, conflict-related exposures, or sleep timing. The majority of included studies were conducted in adults, with only 17.6% of epidemiologic and case studies including pediatric populations. Of the 22 epidemiologic and 14 case study articles with pediatric populations included in this review, the most common exposures were to metals (47%) and/or air pollution (28%), particularly secondhand smoke. Most epidemiologic studies relied on device-based measures of the exposure (61%) and self-reported measures of sleep (77%)(**Table 3**) using questionnaires such as the Pittsburgh Sleep Quality Index (PSQI, N=16)[82]. Among device-based sleep measures, PSG was most common (N=17), and only 5 studies assessed sleep via actigraphy with commercially-available wrist-worn devices; 2 additional studies relied upon static charge sensitive beds.

Air Pollution

Pollutants in the air pollution category comprised: particulate matter (PM₁, PM_{2.5}, PM₁₀), nitrogen oxides (NO_x), ozone (O₃), sulfur oxides (SO_x), secondhand smoke (SHS) or environmental tobacco smoke (ETS), and volcanic ash (**Table 4**). Of the 29 included epidemiologic studies of air pollution, most occurred in urban environments in Asia and Europe, relied on device-based measures of exposure (65.5%), and evaluated self-reported measures (79%) of sleep quality or insomnia. Most air pollution studies of adult populations reported an association between ambient air pollution and disrupted sleep. Findings from the Henan Rural Cohort Study supported associations between PM and nitrogen dioxide (NO₂) with longer sleep latency[83] and worse sleep quality[84,85]; PM and NO₂ levels were also linked to incident sleep disorders in a prospective cohort study in China[86]. However, smaller studies in Europe and the U.S. did not replicate these findings[87,88]. The few pediatric studies of ambient air pollution investigated SDB, with heterogenous findings[89–91]. A study of UK

Biobank data reported an association between NO_x and 7% increased odds of sleep disorders (which included insomnia and sleep apnea) when modelled as a singular pollutant, but a protective effect between NO₂ and sleep disorders when PM_{2.5}, PM₁₀, and NO_x were included as covariates in the model[92]. An ecological study in Europe reported an association between NO₂ exposure and SDB in children[90]. AQI, a measure of air quality and pollution in relation to national standards, was also found to be associated with insomnia in an ecological study[93] and admission for sleep disorders[94]. There were no associations between SO₂ or CO and sleep, and no studies of ambient air pollution and sleep architecture or timing in adult or pediatric populations. The overall quality of the included studies was mixed (**Figure 2**).

Of the 5 studies which investigated indoor air pollution or household air pollution (HAP), the only study with device-based indoor air measurement reported null findings with SDB in children[89]; 2 studies reported associations between questionnaire-assessed solid fuel use and poor sleep quality[95] and biomass use and SDB and sleep disruption[96]; however, a larger study reported null findings between stove use and pediatric SDB[91]. One study with measures of urinary polycyclic aromatic hydrocarbon metabolites found an association between PAH exposure and poor sleep quality[97].

The majority of the 11 reviewed studies with ETS or SHS exposure reported positive associations between exposure and sleep disruption. Of these studies, only one included device-based measured sleep (PSG)[98] and found no association, and most assessed tobacco exposure through self-report. Of the 5 studies with measures of cotinine (a metabolite of nicotine), 2 reported associations with sleep impairment, while other results were null. ETS/SHS exposure measurement was heterogeneous; for example, some studies did not ask specifically about tobacco smoke exposure, but rather measured proximity to smokers or avoidance behavior[99]. Most pediatric studies demonstrated an association between ETS or SHS and self-reported SDB, insomnia, and poorer quality sleep.

Conflict-related Exposures

There were 16 included epidemiologic studies with exposures related to the Gulf War and Gulf War Illness (GWI), the World Trade Center (WTC) toxic dust exposures of first responders, and other conflict-related exposures (**Table 5**). All investigations of GWI relied on self-reported measures, whereas WTC studies relied on self-reported exposures (known occupational history, response time to WTC site, duration of work at

site) and mostly PSG or home sleep apnea test (HSAT) measures of SDB. Some of the included studies of GWI focused on the categorization and case definition of GWI, which included sleep symptoms[112–114]. Of the WTC studies, a majority (5 of 7 studies) did not support an association between exposure duration or dose and SDB[115–119]; however, the largest study of responders (n=11,701 total) reported an association between arrival time and incident OSA, with earlier arrival time to the WTC site linked to higher odds of incident OSA[120]. Follow-up studies reported similar findings, with earlier response time and exposure to the dust cloud associated with greater log AHI[118] and severe, but not mild or moderate, OSA[121]. Among the two studies of sarin exposure, an OP compound, an older study by Duffy et al from 1979[122] reported differences in sleep architecture (as measured by EEG), such as increased REM sleep, among male workers occupationally exposed to sarin. Among civilians, sarin exposure was also linked to a higher frequency of insomnia, but not bad dreams, 3 years following a sarin attack, compared to unexposed[123]. The only study of sulfur mustard exposure thoroughly evaluated sleep health using both validated questionnaires (PSQI and STOP-Bang) and device-measured sleep (PSG), as well as serum melatonin, reporting detrimental effects of occupational sulfur mustard exposure on all of these outcomes[124]. Study quality was mixed (**Figure 3**), with overall supporting evidence between Gulf War exposures, sarin, and sulfur mustard with impaired sleep quality, insomnia, SDB, and altered sleep architecture.

Endocrine Disrupting Chemicals (EDCs) / Other

This category included 12 epidemiologic studies and 3 case studies of EDCs and other chemicals that weren't well captured by other categories. Pollutants included: bisphenol A (BPA), dioxins, per- and polyfluoroalkyl substances (PFAS), phthalates, polybrominated diphenyl ethers (PBDEs), and polychlorinated biphenyls (PCBs). Among epidemiologic studies, the most common sources of exposure to this class were unknown or occupational, and most relied on questionnaire data for outcome measurement (**Table 6**). Among pollutants represented by more than one study, BPA was reported to be protective of short sleep (continuous or dichotomized) in an NHANES analysis, but this relationship did not remain across BPA quartiles[128]; in another study, higher BPA levels were reported in patients with OSA compared to adults without OSA[129]. In a prospective birth cohort, female, but not male, children with the highest tertile of cord-blood measured PBDE had greater problems sleeping compared to those in the lowest tertile at four years old[130]. PCBs and dioxins

were also linked to problems sleeping[131,132], although in one case, exposure was due to a fire, and stress may be a confounder in the association[132]. Of the two studies of phthalates exposure, an analysis in the Midlife Women's Health Study did not report an association with insomnia or sleep disturbance except in former smokers; an analysis of NHANES participants ages 16-17 did report higher odds for short (<8 hours) weekday sleep duration among those in the highest quartile of phthalate exposure, but did not consider school start times or the influence of puberty and chronotype on the outcome[133]. An analysis of 140 people exposed to PCBs from contaminated rice bran reported worse sleep quality and higher prevalence of difficulty initiating sleep among those in the highest quartile of exposure[134]. Case studies of residents living in methamphetamine-contaminated homes [135] and homes with off-gassing from polyurethane foam insulation[136] highlighted reports of sleep disturbance and insomnia. The overall quality of studies varied (Figure 4, Supplemental Figure 1, Table 7), with no clear consistent associations, possibly compounded by the heterogeneity of the pollutants. However, persistent EDCs such as dioxins, PCBs, and PBDEs showed the strongest evidence for sleep disruption.

Metals

There were 51 epidemiologic studies and 34 case studies of exposure to metals included in the results. Most focused on exposure to lead or mercury, but a few also investigated exposure to aluminum, antimony, arsenic, cadmium, coal ash, copper, fluoride, lead, manganese, mercury, selenium, and thallium (Table 8). The most common sources were workplace or occupational, particularly welding and/or metallurgy work, as well as dental work and amalgams. Among metals represented by more than one epidemiologic study, working with aluminum was linked to insomnia[143,144]. Studies of mercury and insomnia or sleep quality were inconsistent; however, positive associations were more often reported with higher occupational exposure to mercury[145,146], whereas most studies of dental amalgams and dentistry workers reported null associations[147–150]. In both adult and pediatric populations, exposure to lead was most consistently associated with insomnia[151–153] and shorter sleep duration[154–156], whereas associations with sleep quality were mixed. Thallium exposure was also linked to sleep disruption[157–159], although some of these findings may be confounded by smoking. The evidence between metals exposure and SDB were inconsistent. Associations between arsenic and sleep were null[160,161], and the majority of studies did not support an

association between metals exposure and sleep duration in adult populations (**Figure 5**). Findings from the pediatric literature was also inconsistent, with most studies of sleep quality reporting null associations and mixed associations with sleep timing, with positive findings in relation to self-reported sleep[156,162] and null findings with actigraphy measured sleep[163,164]. In contrast to the epidemiologic literature, most case studies in adults and children reported an association with insomnia and sleep quality and were of fair or good quality (**Table 9, Supplemental Figure 1**). A case study with multiple biological measures of mercury exposure and environmental sampling reported sleep disturbances among 70% of 18 adults living in a town polluted by mercury due to gold mining[165]. Other case studies reported symptoms of sleep disturbance among male welders following exposure to lead[166,167], manganese[168,169], and other metals from welding fumes. Overall, findings supported a link between exposure to mercury or lead and insomnia.

Pesticides

Of the 12 epidemiologic and 5 case studies of pesticide exposure, most included pesticides in the organophosphate (OP), organochlorine, and/or carbamate class (**Table 10**) from a rural/farmland source in the Middle East, Africa, or North America and had a small sample size. Some of the included studies relied on farm work as a proxy for pesticide use and exposure, while others did not explicitly state the pesticide class or chemical(s) evaluated. All of the studies relied on self-reported pesticide use and/or blood measures of cholinesterase and all but one[227] utilized self-reported measures of sleep. One study comparing female pickers of Bt cotton, a genetically modified crop that may require less pesticide use, and non-Bt cotton reported higher frequency of insomnia among non-Bt pickers (12% to 39%)[228]; however, in reporting frequencies rather than adjusted model results for insomnia, factors such as socioeconomic status were not evaluated in this association. In another study, male pesticide applicators in the Agricultural Lung Health Study with self-reported exposure to carbamates, but not OPs, had higher self-reported doctor-diagnosed sleep apnea, with or without adjustment for BMI[229]. In a cross-sectional study of 1,336 greenhouse farmers exposed to pesticides, farmers with both medium and high cumulative exposure to pesticides had worse sleep quality and more trouble falling asleep compared to farmers with low cumulative exposure; the highly exposed farmers also had 56% higher odds of short (≤ 6 hours) sleep duration compared to those with low exposure[230]; however, results were not differentiated by pesticide class. An investigation by Rubin et al of households in Ohio that had

been illegally treated with an OP compound reported 28% of participants in the contaminated households experienced night waking, and in one case a 4 month old infant with disrupted sleep was brought to the emergency room after their sleeping area was sprayed[231]. In another case, an adult male developed sleep apnea after their home was improperly treated with Carbaryl, a carbamate compound[232]. None of the included studies specifically evaluated a pediatric population. Most epidemiologic studies of pesticide exposure and insomnia reported an association[228,233–235], whereas associations with sleep duration, quality, and SDB were inconclusive. In summary, the overall epidemiologic evidence between pesticide exposure and sleep disruption was of low quality (**Figure 6**), in contrast with the overall evidence in case studies, which was good (**Table 11, Supplemental Figure 1**). Insomnia was the sleep outcome most consistently associated with pesticide exposure.

Solvents

There were 31 epidemiologic and 11 case studies of solvent exposure among the included results. Studies in this category evaluated occupational or workplace exposures to solvents, including benzene, toluene, and xylenes, among others (**Table 12**). Numerous studies investigated solvent exposures in painters. Only one study included children, but it did not specifically evaluate exposure in a pediatric population. Solvent exposure was most consistently associated with insomnia symptoms. Of the 7 studies that evaluated solvent exposure and SDB or OSA, the majority relied on PSG or oximetry for outcome measurement and supported a positive association[247,249–252]. One study by Monstad et al. repeatedly measured a subset of solvent-exposed workers with OSA, reporting overall decreases in AHI following exposure cessation and increased AHI shortly after re-exposure within participants[249]. Studies of sleep quality were mixed but suggestive of an inverse association; a study by Lundberg et al reported a worse sleep quality and greater fragmentation but no difference in other insomnia-related symptoms or OSA as exposure increased[248]. Most findings of solvent exposure and sleep duration were null, but a case study reported increased sleep requirement among 26% of 19 adult males following occupational exposure to benzene and toluene[253]. Most self-reported data was collected using tools such as the NSC-60 and the Euroquest questionnaire, which have not been validated for use in epidemiologic studies of sleep measurement. Overall, the quality of epidemiologic evidence for solvents was low (**Figure 7**), but the more rigorous studies suggested associations with sleep architecture, duration,

and SDB among more highly exposed; the quality of evidence from case studies was fair (**Table 13, Supplemental Figure 1**).

DISCUSSION

This review adds new information to the existing literature by systematically identifying and evaluating 204 studies of exposure to air pollution, other pollutants/endocrine disrupting compounds, metals, pesticides, solvents, and conflict-related exposures in relation to sleep health and sleep disorders and highlights possible biological mechanisms underlying these relationships. Overall, particulate matter and nitrogen dioxide were linked with poor sleep quality, and secondhand smoke in pediatric populations associated with SDB; dioxins, PCBs, and PBDEs were tied to sleep disruption and insomnia, and exposure to lead, mercury, and pesticides were also associated with insomnia. Solvents such as toluene were linked to disrupted sleep timing and SDB. Studies of conflict-related exposures relevant to GWI supported associations with poor sleep quality, insomnia, SDB, and altered sleep architecture. Pesticide exposure, particularly in pediatric populations, was not well explored. In general, the evidence presented in this review indicates environmental pollutants are detrimental to sleep health and disorders among adult and pediatric populations.

Synthesis and Potential Mechanisms

Numerous mechanistic pathways, some shared by multiple exposures, may link environmental chemical pollutant exposure to impaired sleep health and sleep disorders. Broadly, common characteristics of exposures with consistent associations with sleep outcomes include: acting on the cholinergic system, inducing oxidative stress or inflammation, altering neurotransmission, and endocrine disruption (**Figure 8**); other possible mechanisms that weren't explored in the literature include acting on components of the circadian clock and affecting melatonin and other relevant hormones.

Air pollution

Air pollution comprises a heterogeneous mix of particulates and gases. PM and NO₂ were most consistently associated with poor sleep quality, and, in pediatric populations, SHS with insomnia, worse quality, and SDB. PM may be composed of many different types of compounds, and is categorized by size, with PM_{2.5}

the benchmark at which particles are small enough to pass directly from the lungs into the capillary blood supply and across the blood-brain barrier[54]. PM can also co-transport other chemicals, such as pesticides[287]. PM_{2.5} can induce inflammation[53] and neuroinflammatory responses[55,288–290], leading to damage and cell death. PM may disrupt sleep via systemic and/or pulmonary inflammation, but the evidence from included studies was mixed. In contrast to PM, gaseous components of air pollution may influence sleep by affecting neurotransmission. One high-quality study measured actigraphy over a 6-week period and evaluated within-person associations between air pollutants (O₃, PM_{2.5}, SO₂, NO₂, CO) and wake after sleep onset, sleep efficiency, sleep duration, and self-reported sleep quality, and reported an association between daily maximum ozone levels and longer sleep duration[87]. Experimental evidence suggests that O₃ exposure increases slow wave sleep (SWS)[291–293] and alters serotonin levels[294,295], possibly due to altered acetylcholine signaling[292]. While the other 3 included studies with O₃ measures did not report associations, sleep outcomes were ascertained using questionnaires, ICD-10 codes, or text-mining rather than actigraphy or PSG. Findings of the included literature were similar to those presented in Liu et al, which reported overall adverse, though heterogenous, associations between ambient and indoor air pollution on sleep health[46], mostly in adult populations.

Air pollution may also influence immune system sensitization to allergens, promoting inflammation[296] and asthma incidence and exacerbation[297]. For example, NO₂ has been linked both to pediatric asthma[298] and SDB[90], and studies previously reviewed in Liu et al[46] also supported a positive relationship between NO₂ and greater odds of OSA[299]. Given the overlap between asthma and SDB in children[300], future studies should investigate co-exposures of air pollution and allergens as possible environmental drivers of pediatric OSA.

Furthermore, SHS exposure constitutes an additional form of environmental and household air pollution. Nicotine has well-established effects on sleep disruption, impairing initiation, maintenance, and duration[301], and affecting sleep architecture[301,302]. However, the impact of SHS on sleep outcomes is less conclusive[51,303]. SHS exposure is linked to higher blood inflammatory markers[304], and may be of particular concern for infants and children due to immature detoxification mechanisms and greater biological vulnerability to the effects of SHS. Heavy metals in tobacco smoke, such as cadmium, may act as co-exposures. Additionally, while vaping has grown in popularity in the last decade, no included studies

specifically mentioned exposure to vaping. Therefore, the current evidence is limited, and future studies of tobacco smoke exposure should aim to capture cotinine measures in addition to device-based sleep outcomes, such as with actigraphy and PSG.

Conflict-related Exposures (Gulf War, WTC, Other)

Conflict-related exposures during the Persian Gulf War, the 9/11 attacks on the World Trade Center, and nerve agents were among the included studies, which were predominantly conducted among male samples. Multiple studies reported associations between exposures related to military service during the 1990-1991 Persian Gulf War and insomnia and sleep quality issues associated with Gulf War Illness (GWI). During the Gulf War, military personnel may have been exposed to OP compounds (sarin) in addition to pyridostigmine bromide (a carbamate compound), pesticides, mustard gas, air pollution from oil well fires, and uranium. Numerous reports have concluded that psychological stress and/or post-traumatic stress disorder are unlikely causes of GWI[305], suggesting an environmental etiology. Many of the symptoms of GWI overlap with those of OP and nerve agent poisoning, and while the cause and mechanism of GWI is unknown, individuals with GWI have chronic inflammation, and it is suspected that exposure to OP compounds, pyridostigmine bromide, and oil well fires may be the most likely contributors to symptoms[305]. Findings from a rat model of Gulf War exposures (permethrin, DEET, and pyridostigmine bromide over 4 weeks) supports a causal relationship, with exposure causing neurological deficits and inflammation[306]. Similar to mechanistic studies supporting a link between pesticide exposure and sleep impairment, sarin and cyclosarin are OP nerve agents that act on AChE, and experimental evidence supports a link between sarin and altered EEG patterns during sleep[307].

Four of the included studies reported associations between environmental exposures of first responders to the 2001 World Trade Center (WTC) attack with OSA. The toxic dust cloud and smoke produced by the ensuing building collapse and fire contained fine particulate matter (PM_{2.5}), concrete, gypsum, and, at lower concentrations, asbestos, heavy metals, dioxins, pesticides, phthalates, PBDEs, and polyaromatic hydrocarbons[308,309]. Chronic inflammation of the airways caused by this exposure could have increased the risk for development of OSA. However, the highly observed nature of these cohorts may have increased case detection.

EDCs/Other

EDCs such as BPA, phthalates, PCBs, PBDEs, and dioxins, can bind to nuclear hormone receptors[310], such as estrogen receptors and the aryl hydrocarbon receptor (AhR). EDCs may influence sleep via hormone signaling. For example, sleep traits exhibit sex differences[311,312], and research in rats support a role for gonadal hormones in mediating sleep behavior in adulthood and during critical developmental windows to promote long-lasting differences in sleep behavior[313]; disruption of these processes, such as through EDCs, could potentially elicit changes in sleep behavior. For example, some phthalates, used as plasticizers, have been shown to exert estrogenic activity[314]. However, compared to an NHANES study that reported an association with shorter sleep duration[133], phthalates were not associated with sleep outcomes in premenopausal and perimenopausal participants in a prospective cohort study[137]. In contrast, dioxins, PCBs, and PBDEs were linked to insomnia and disrupted sleep. PBDEs are structurally similar to thyroid hormones[315] and could potentially influence sleep by disrupting thyroid hormone signaling[316]. Additionally, AhR activation may affect AChE and cholinergic signaling[317] as well as circadian clock function[318], additional pathways by which dioxins, PCBs, and PBDEs may be acting upon via AhR. Two studies reported positive associations between BPA levels and short sleep duration[128] and OSA[129], and additional studies reported positive associations between PCBs, PBDEs, or dioxins and sleep impairment. As lipophilic pollutants, these compounds build up in body fat over time[319] and their accumulation, or body burden, may differ by age and body fat; however, adiposity may also increase OSA risk and is associated with short sleep duration[320,321], potentially confounding associations between lipophilic pollutants and sleep outcomes. Possible bidirectionality between sleep and fat storage may also muddy associations, as these lipophilic pollutants may promote fat development and obesity[322], but can be mobilized from fat stores to the systemic blood supply during weight loss[323]. Additionally, because dietary sources and food packaging may be main sources of phthalate and BPA body burden[324], these pollutants may be chemical proxies for diet quality and processed food consumption. Given the existing links between BMI, diet, and sleep disruption, future studies of EDCs and sleep should be specially designed to prospectively evaluate these relationships.

Metals

Metals were the most frequent exposure among included studies, yet no prior systematic reviews have evaluated metal pollutant exposure and sleep. Metals may impact sleep through interactions with components of the circadian clock[325], by promoting inflammation, by influencing neurotransmission, and/or by affecting the cholinergic system. There were multiple studies of copper and/or selenium (in non-occupational settings), essential trace elements that may be toxic in large amounts, with inconclusive findings; however, experimental studies in rats have shown that selenium compounds such as sodium selenite reduce sleep[326], possibly by inhibiting the enzyme that catalyzes prostaglandin D2[327], a sleep-promoting factor[328]. Lead, a toxic substance to which children are more vulnerable than adults, was most consistently associated with insomnia and quality. Lead may affect sleep by influencing neurotransmission[329], and/or by promoting inflammation as an immunotoxin[330,331]. A few studies evaluated exposure to manganese, a micronutrient as well as an occupational hazard for welders and metal workers. During welding, manganese may become airborne, inhaled, and taken up by the olfactory or trigeminal nerves, or ingested following mucociliary clearance from the lungs[332]. Notably, high manganese exposure can cause manganism, a neurodegenerative disease with symptoms similar to Parkinson's Disease, including sleep irregularities. In the brain, high manganese levels may affect dopaminergic[332] and cholinergic neurotransmission, such as through AChE inhibition[333]. Rodent models of chronic manganese exposure also exhibit sleep disruption[334–336]. Epidemiologic studies of occupational manganese exposure with sleep duration and insomnia were null or inconclusive, but one study of air pollution manganese exposure reported shorter sleep duration and greater use of hypnotic medication among residents in areas with higher air manganese exposure[190]. Case studies were mostly supportive of metal exposure with sleep disturbance and insomnia. Mercury was the most commonly evaluated pollutant and may cause insomnia and sleep disruption via cholinergic signaling. Mercury has high attraction for sulfhydryl groups[337] and can inhibit numerous enzymes, including cholineacetyl transferase[338–340], an enzyme responsible for synthesizing acetylcholine, and muscarinic acetylcholine receptors[341]; this may lead to increased expression of muscarinic acetylcholine receptors in the brain[342]. Experimental animal studies support a causal link between methylmercury and altered sleep-wake rhythms and sleep architecture [343,344]. Like other metals, mercury may also affect sleep through ROS and inflammation[337]. The overall evidence between metals and sleep outcomes were mixed, but results supported a link between lead or

mercury exposure and insomnia; findings were more consistent in highly exposed groups and/or case studies of overt heavy metal poisoning.

Pesticides

The included studies evaluated exposure to pesticides in the organophosphate (OP), pyrethroid[345], and/or carbamate class. OP compounds and carbamates inhibit AChE. AChE is an enzyme that breaks down acetylcholine, a neuromodulator and neurotransmitter[346] that plays an important role in sleep[347,348], to prevent further neurotransmission. However, if AChE is inhibited, acetylcholine remains bound to post-synaptic receptors, leading to excessive cholinergic signaling. As the cholinergic system is an important regulator of sleep, with acetylcholine playing a role in wakefulness and REM sleep[349], acute or chronic inhibition of AChE by pesticides may affect sleep through cholinergic signaling[350]. Experimental studies in humans support a relationship between exposure to AChE agents and insomnia[351], and animal studies also support a causal relationship between pesticide exposure and sleep impairment. Interestingly, AChE inhibitor drugs are also used in treating Alzheimer's disease symptoms; among the documented side effects of these drugs are insomnia[352] and altered sleep architecture[353,354]. Rats exposed to chlorpyrifos, an OP, exhibited decreased sleep and sleep spindles[355] and increased sleep apnea index score[65]. OPs may also affect sleep via secondary mechanisms, such as inhibiting fatty acid amide hydrolase[356], the enzyme responsible for breaking down anandamide and oleamide[357], sleep-promoting lipids[358,359]. In addition to inhibiting AChE, carbamates may affect sleep by binding to melatonin receptors, phase-shifting circadian rhythms, and altering pineal melatonin synthesis[360–363]; an *in silico* binding study demonstrated the ability of carbaryl and carbofuran to bind the MT1 and MT2 receptors[361]. While not evaluated in the reviewed articles, neonicotinoids, a class of pesticides that act similarly to nicotine by binding to nicotinic acetylcholine receptors, have also been shown to disrupt sleep in honeybees[364,365]. Similar to metals, the overall epidemiologic evidence for pesticides were mixed, whereas case study findings tended to support an association. This may be due to reporting bias, in that case studies may be more likely to report the presence, rather than absence, of sleeping problems. Additionally, case studies tended to evaluate acute, high exposure or outright poisoning, whereas epidemiologic studies relied on farm work as proxy or self-reported data on prior pesticide poisoning symptoms, for example. Despite possible mechanistic pathways, the overall epidemiologic evidence for

pesticides and sleep disruption was weaker than the evidence for air pollution or metals due to lack of device-based exposure and/or outcome measurements.

Solvents

Solvents, such as toluene, benzene, and xylenes, are well-established occupational hazards; chronic or acute exposure can lead to solvent-induced encephalopathy. Solvents are mucosal irritants which can cross the blood-brain barrier and act as central depressants[366], inhibiting glutamatergic transmission and promoting GABAergic and glycinergic signaling[367]. Experimental evidence suggests toluene may stimulate dopamine release[368], alter GABA_A receptor function[369], and/or inhibit nicotinic acetylcholine signaling[370]. Animal studies have also shown that toluene exposure alters monoamines and SWS in rats [371–375]. Solvents may act through mechanisms similar to that of anesthetics[367], which have been shown to decrease muscle tone and increase upper airway collapsibility[376], a primary risk factor for OSA. Therefore, it is possible that solvents may influence OSA development by promoting inflammation and airway collapse. However, the overall evidence between SDB/OSA and solvent exposure was low, with most studies lacking device-based exposure and/or outcome measures with small sample sizes and/or unadjusted for potential confounders. Therefore, the association between occupational solvent exposure and OSA is unclear within the realm of current workplace standards, and large prospective cohort studies of solvent exposure should consider including validated sleep and SDB measures as health outcomes.

Pediatric Considerations

Most of the included studies were conducted among adult populations, with few comprehensive assessments of pediatric sleep health. Compared to the adult literature, there were no pediatric studies with environmental exposure to conflict-related exposures and few studies of pesticides; there was one pediatric case study of solvent exposure. Additionally, 86% of pediatric studies included device-based measures of exposure, whereas only 19% included device-based sleep outcome measures.

Among pediatric populations, the most common reported exposures to metals were lead (n=8) and mercury (n=7). A cross-sectional study reported that blood lead levels ≥ 10 $\mu\text{g/dL}$ were associated with decreased sleep duration in Mexican children aged 6–8 years[156]. Follow-up longitudinal studies in

China[153] and Mexico City[155] similarly reported that elevated blood lead levels in early childhood were associated with an increased risk of insomnia and excessive daytime sleepiness[153] and decreased sleep duration[155] in later childhood. Moreover, in a prospective birth cohort, lead levels were measured in maternal blood in early and late pregnancies, in cord blood at birth, and in 2, 3, and 5-year-old children's blood. Interestingly, postnatal blood lead levels at 2 years old were associated with sleep problems in females only, not in males. The authors suggested that differing sexual brain development between sexes may partially explain these findings. A cross-sectional study of children ages 9 to 11 reported that higher blood mercury levels were associated with shorter sleep duration[163]. However, a more recent cross-sectional study of Mexican children did not support an association between urinary mercury and sleep duration[164], although toxicokinetics and measurement in different biomatrices may explain discordant findings. Overall, there is good evidence for negative consequences of early lead exposure and poorer sleep outcomes.

There's mixed evidence for SHS and sleep symptoms, however, this mostly depended on the study population being evaluated. In healthy children, self-reported SHS exposure was associated with increased Sleep-Related Breathing Disorder (SRBD) scores in school-aged children in Chile[105] and Turkey[91]. In Japanese adolescents, self-reported SHS exposure was associated with self-reported symptoms of difficulty with initiating sleep, maintaining sleep, early morning awakening, insufficient sleep, and short sleep duration[108]. Additionally, in a cohort of healthy children ages 2-5 years with SHS measured by hair nicotine, there was an association with self-reported sleep-related breathing problems. In children with asthma from Cincinnati ages 5-13 years, serum cotinine levels were associated with elevated SRBD scores and self-reported sleep problems including longer sleep onset delay, parasomnias, daytime sleepiness, and overall sleep disturbance[108]. However, in children ages 7-11 years with overweight or obesity, there was no association between SRBD scores and passive smoke exposure when measured by plasma cotinine assay[104]. Also, in a small cohort of 31 neonates referred for PSG with suspected gastroesophageal reflux disease (GERD), there were no differences in sleep outcomes between exposed vs unexposed (as measured by urine cotinine assay), but there was a 2-fold greater number of reflux events in infants with exposure to passive smoke[98]. Overall, there's good evidence that SHS exposure is associated with poor sleep outcomes in healthy children and with asthma, however, a limitation of the evidence is that all the studies have a cross-sectional design; therefore, a causal association for adverse sleep outcomes could not be ascertained.

Only one pediatric study evaluated the association between air pollution and device-based measures of SDB. SDB was characterized by AHI >1 event per hour (often used as a pediatric cutoff for mild SDB) among children admitted to a hospital in Italy who had a sleep study to evaluate for SDB due to sleep-related breathing symptoms. The authors then used geographical monitoring data to determine the mean NO₂ levels and reported a positive correlation between mean AHI and NO₂ levels, with strongest association among children living in an area characterized by a high density of traffic-related pollutants[90]. However, in addition to the ecological study design, a limitation of this study is the low AHI threshold used to define the outcome; the use of a higher AHI threshold may have provided more clinically meaningful information. Overall, there is weak evidence that elevated air pollution influences the prevalence of SDB in children.

Limitations of this Review

The findings presented in this review are not without limitations. Due to the heterogeneity of pollutants and how sleep outcomes were measured, we did not perform a meta-analysis of the results or compare effect estimates. In some cases, multiple exposures or sleep outcomes were grouped together as a single item, limiting our ability to tease apart specific health associations and making interpretation difficult; for example, a study with an outcome of “sleep disorders” which comprised ICD-10 codes for insomnias, hypersomnias, sleep-wake disorders, cataplexy/narcolepsy, and sleep apnea[92]. Additionally, while we present results on SHS/ETS and conflict-related exposures, the search strategy was not designed with these exposures in mind; in particular, the findings presented on SHS/ETS are not a comprehensive presentation of the literature, and prior systematic reviews on this topic should be sought for further coverage on the topic[50,51].

Current Gaps and Future Directions

Sleep is multi-dimensional, and due to the heterogeneity of how sleep health was evaluated, comparison across studies was limited. The majority of studies relied on questionnaire data, although such measures of sleep are prone to measurement error and reporting bias. For example, self-reported sleep duration is an overestimate of actigraphy-measured sleep[377], and the amount of overestimation may differ by race and ethnicity[378]. Many studies relied on one or limited measures of sleep health, thus preventing the evaluation of multiple dimensions of sleep health. Questionnaires such as the PSQI or STOP-BANG have

been evaluated for use in studies of sleep, but a significant portion of included studies did not employ validated instruments and/or relied upon a single sleep-related question as an outcome. Additionally, insomnia is a self-reported condition that is diagnosed clinically by interview and patient response, but most studies of questionnaire-assessed insomnia did not consider chronicity or associated daytime impairment – features needed to diagnose insomnia as a clinical disorder [10]. In summary, self-reported sleep outcomes may be capturing different elements of sleep than device-based measures that are nevertheless important for health, and future studies with self-reported sleep measures should aim to assess sleep in a comprehensive way.

Among device-based measures, PSG is considered the gold standard for sleep measurement and captures sleep architecture in addition to OSA diagnosis and sleep continuity. PSG generally occurs overnight in a sleep laboratory, which can be expensive, time-consuming, and affected by the “first night effect” if measured over a single night. However, home-based PSG systems or PSG-like systems measure participants in their home environment and may represent a viable study design option for community-based studies. Actigraphy, which is based on detecting rest and activity patterns, can also be employed to derive measures of sleep-wake behavior and may be less onerous, more cost-effective, and allow for longer measurement than PSG. While the myriad specifications of these devices should be thoroughly considered in study design[379], in-home PSG and actigraphy both have the potential to advance our understanding of environmental contributors to sleep health, particularly among low-income populations that may face barriers to undergoing overnight in-lab sleep studies.

Another gap in the current research is investigation of the extent to which sleeping and circadian phase influence pollutant exposure and vulnerability. Vulnerability to toxicants may differ by time of the day[380] due to rhythmic fluctuation in detoxification systems; certain exposures may be more harmful at night, for example. Rhythmicity in excretion or biomarkers, such as daily rhythms in urine production, further complicates these relationships when measuring exposure[381]. Unfortunately, most studies did not provide details on the timing of sample collection or measurement or take circadian phase into account. Surprisingly, only one study included a measure of melatonin[124], and few studies investigated sleep timing. Furthermore, people spend approximately a third of their lifetimes sleeping, but the effect of indoor sleep environments on pollutant exposure has received limited attention. For example, numerous studies have examined outdoor air pollution and sleep, but fewer have focused on HAP or indoor air pollution with device-based measures of

exposure[89,97]. In summary, future research would benefit from integrating measures of circadian phase in the exposure/outcome measurement or as an interaction in the exposure-outcome relationship and timing of measurement and sample collection in study design. Shift work or other exposures which may disrupt circadian rhythms should also be considered. Additionally, future studies should evaluate the contribution of the sleep environment to pollutant exposure.

Statistical modeling is another important aspect of current and future research. Studies of sleep quality and OSA commonly dichotomize outcomes based on thresholds for the PSQI or AHI, for example, which may bias results depending on the placement of the cutoff value. Additionally, few studies have considered bidirectionality in exposures and outcomes, but people with impaired sleep and/or circadian misalignment may be more vulnerable to the effects of pollution or have altered detoxification/metabolic pathways that influence biological exposure measurement[382–384]. For example, there may be a bidirectional relationship between sleep and oxidative stress, where sleep helps protect against negative consequences of reactive oxygen species (ROS) and impaired sleep increases vulnerability to ROS[385], although further research in humans is necessary. Co-exposures were rarely considered in the included literature, which is another limitation of the current research; for example, areas with air pollution due to vehicle emissions may consequently also have higher burden of light at night and noise pollution. Future studies would benefit from considering continuous outcomes, bidirectionality, and co-exposures in study design and model building.

Environmental pollutant exposures tend to be patterned by socioeconomic status and race/ethnicity. Due to systematic racism and redlining policies that resulted in segregated, under-resourced neighborhoods, marginalized communities in the U.S. are more likely to be exposed to environmental chemical pollutants and adverse characteristics of the built environment[71], such as older housing and lead exposure[68] and pesticide use[386]. Data demonstrates that racial minorities are more likely to have exposure to air pollution[69]; yet few of the U.S.-based studies reviewed were conducted among these populations. Racial/ethnic minorities and lower socioeconomic individuals have a high prevalence of adverse sleep health and OSA[387,388], yet few studies examine environmental pollutants as contributors to sleep disparities. Future studies in the U.S. and globally should aim to expand study samples to enroll sufficient sample sizes of minoritized individuals, in addition to including measures of environmental pollutant exposure in sleep health disparities research studies.

This review of current evidence of environmental exposures and sleep outcomes in adults and children reveals the need for future research to consider a life course approach. Few of the included pediatric sleep studies considered school start times, bedtime routines, and puberty-related hormonal shifts in chronotype in the study design and analysis. Additionally, children may be more vulnerable to pollutants' effects on brain development and sleep health; harmful environmental exposures potentially differ by age, and pediatric populations are of special interest because infants and children have no or underdeveloped detoxification systems. While the adult literature between pesticide use and sleep outcomes was also somewhat sparse, the lack of studies investigating pediatric pesticide exposure and sleep outcomes should be considered as a gap in knowledge, given the known detrimental effects of pesticides on children's health[389]. Future directions should include evaluating pediatric exposures to pesticides, metals, EDCs, and air pollution in relation to sleep health.

Conclusions

There is documented evidence that air pollutants, conflict-related exposures, EDCs, metals, pesticides, and solvents are classes of environmental pollutants associated with sleep health. Possible biological pathways underlying pollutant-sleep relationships included cholinergic signaling, inflammation, neurotransmission, and hormonal signaling. Main limitations of the current research include lack of device-based sleep measurement, lack of prospective investigation, and little to no mechanistic evaluation. Based on the limitations, future studies should aim to include measures of circadian phase and timing of sample collection, evaluate bidirectionality and co-exposures, capture device-based measures of both exposure and sleep outcomes, include pediatric populations and historically minoritized individuals, and consider a life course approach in study design and interpretation to develop a more intersectional and holistic understanding of how our environment influences sleep health. To improve collaboration and scientific discovery, future and existing studies should strive to make their data accessible and well-annotated; researchers can contribute to the sleep research community by sharing data in repositories such as the National Sleep Research Resource (NSRR, <https://sleepdata.org/>), supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health. There is a large gap in current knowledge around environmental pollutant exposure and pediatric sleep health, especially regarding pesticides. Overall, future studies should be robustly designed to evaluate

environmental exposures and sleep health, with device-based measures of exposures and outcomes. Longitudinal study design incorporating measures of actigraphy and wearable devices, including representation of diverse backgrounds, as well as clear reporting and data availability will advance our understanding of the environmental contributions to sleep health across the life course.

ACKNOWLEDGEMENTS

Supported by funding from the National Institutes of Health (NICHD F31-HD097918 and NIH-NHLBI T32HL007901 [to DW and SGN], R35 HL135818 [to SR], and K01HL138211 [to DJ]). DW proposed and designed the study, performed screening and data extraction, created summary tables and figures, and wrote and edited the manuscript. JG performed screening and data extraction. SP developed the search strategy, performed the literature search, wrote the search methods, created the PRISMA chart, and edited the manuscript. SG-N contributed to writing and synthesis of the pediatric literature. KF contributed to search strategy and methods. SR contributed to results interpretation, synthesis, and edited the manuscript. All authors reviewed and edited the manuscript. DAJ contributed to study design, classification of exposures and outcomes, results interpretation, synthesis, and edited the manuscript.

Data Availability: The search terms and extracted data used for plotting the RoB figures is provided in Supplemental Files.

Figure 1. PRISMA flowchart detailing screening and inclusion of studies in this review.




Figure 1. PRISMA flow chart detailing screening and inclusion of studies in this review.

Table 1. Breakdown of included epidemiologic studies (n=151) by pollutant exposure category and sleep outcome.

Pollutant			Sleep Outcome						
	Architecture	Dreams/ nightmares	Duration	Quality	Timing	Sleeping Pill Use	Sleep Maintenance/ Insomnia	SDB	**Total
Air (N=29)	1	-	7	17	-	-	8	9	42
Conflict-related (N=16)	1	1	-	6	-		4	9	21
EDCs/Other (N=12)	-	-	2	9	-	1	2	1	15
Metals (N=51)	-	-	18	20	3	3	24	8	76
Pesticides (N=12)	1	2	2	6	-	1	6	2	20
Solvents (N=31)	1	6	11	14	1	1	12	7	53
**Total	4	9	40	72	4	6	56	36	227

**Total does not add up to 151 because some studies included multiple sleep outcomes

“-“ indicates that no studies occurred in this group

Table 2. Breakdown of included case studies (n=53) by pollutant exposure category and sleep outcome.

Pollutant	Sleep Outcome								
	Architecture	Dreams/ nightmares	Duration	Quality	Timing	Sleeping Pill Use	Sleep Maintenance/ Insomnia	SDB	**Total
EDCs/Other (N=3)	-	1	-	2	-	-	2	1	6
Metals (N=34)	1	-	-	14	-	-	23	1	39
Pesticides (N=5)	1	-	1	1	-	-	3	1	7
Solvents (N=11)	-	-	1	2	-	-	5	5	13
**Total	2	1	2	19	0	0	33	8	65

***Total does not add up to 53 because some studies included multiple sleep outcomes*
“-“ indicates that no studies occurred in this group

Table 3. Frequency table of self-reported and device-measured exposure and outcome of included epidemiologic studies*.

Pollutant Exposure	Sleep Outcome		
	Device-measured	Self-reported	Total
Device-measured	18	74	92
Self-reported	17	42	59
Total	35	116	151

**if exposure or outcome measured with both device and self-report, grouped under device-measured.*

Table 4. Summary table of epidemiologic studies of air pollutants/SHS and sleep outcomes.

First Author, Year	Design (Location)	Characteristics (age group)	Pollutant Measure (method)	Sleep Measure (method)	Findings	Direction†
Ambient air pollution						
He, 2021[84]	CS (Asia)	N=27,572 with exposure and PSQI score in Henan Rural Cohort Study (Adults)	PM1 (land use models with monitoring data, averaged over 3 years prior to questionnaire)	Quality (PSQI, Chinese version)	PM1 levels positively associated with PSQI scores (worse sleep quality) ($\beta=1.05$, 1.03-1.10)	▼
Chen, 2019[85]	CS (Asia)	N=27,417 with exposure and PSQI score in Henan Rural Cohort Study (Adults)	PM2.5, PM10, NO2 (land use models with monitoring data, averaged over 3 years prior to questionnaire)	Quality (PSQI, Chinese version)	PM2.5 (OR=1.15, 1.03-1.29), PM10 (OR=1.11, 1.02-1.21), and NO2 (OR=1.14, 1.03-1.25), levels positively associated with greater odds poor sleep quality (PSQI>5)	▼
Wang, 2020[83]	CS (Asia)	N=27,935 with exposure and PSQI score in Henan Rural Cohort Study (Adults)	PM1, PM2.5, PM10, NO2 (land use models with monitoring data, averaged over 3 years prior to questionnaire)	Onset latency (PSQI, Chinese version)	NO2 (OR=1.59, 1.33-1.90), PM1 (OR=1.23, 1.13-1.33), PM2.5 (OR=1.28, 1.13-1.45) and PM10 (OR=1.43, 1.22-1.67) levels positively associated with odds of sleep latency >30 minutes	▼
Yu, 2017[100]	PC (Asia)	N=848-890	PM2.5 (ambiently)	Duration	PM2.5 levels positively	▲

		university retirees at annual reunion (Adults)	measured from Beijing monitoring sites 7 days prior to reunion party)	(questionnaire, measured at annual reunion)	associated with greater sleep duration ($\beta=1.75$, 1.24-2.26)	
Yu, 2021[86]	PC (Asia)	N=38,775 (Adults)	PM2.5, PM10, NO2 (land use spatial-temporal models specified to residence, averaged over 1 year)	Sleep disorders (ICD-10 codes)	PM2.5 (OR=1.89, 1.70-2.11), PM10 (OR=1.95, 1.75-2.18), and NO2 (1.85, 1.66-2.07) quintiles positively associated with odds of prevalent sleep disorders; PM2.5 (HR=1.33, 1.08-1.65), PM10 (HR=1.32, 1.08-1.61), and NO2 (HR=1.77, 1.44-2.17) levels positively associated with chance of incident sleep disorders	▼
Li, 2020[87]	PC (North America)	N=98 (Adults)	PM2.5, SO2, NO2, O3, CO (EPA Air Quality monitoring of Boston, MA)	Duration, WASO, efficiency (actigraphy with Actiwatch Spectrum) and onset latency, quality (sleep diaries)	O3 positively associated with duration, but not PM2.5/SO2/NO2/CO; no associations between other pollutants and sleep outcomes	—▲
Tang, 2020[94]	E (Asia)	N=395,651 aged 60+ years (Adults)	PM2.5, PM10, NO2, SO2, O3, AQI (daily site measures within 7 days of hospital visit)	Sleep disorders (ICD-10 codes)	IQR increase in AQI ($\beta=1.41\%$, 0.35-2.48%) positively associated with sleep disorder admissions, and excess risk for NO2 (ER=1.81, 0.22-3.42) on lag days 2-3, SO2 (ER=3.41, 1.55-5.32), and O3 (ER=2.07, 0.04-4.15) on lag day 5.	▼—
Li, 2020[92]	CS (Europe)	N=457,358 (duration), N=103,136 (sleep disorders) UKB participants (Adults)	PM2.5, PM10, NO2, NOx (land use regression models)	Sleep disorders (ICD-10 codes for insomnia, hypersomnia, sleep apnea grouped together) and sleep duration (UKB questionnaire)	Modelled individually, PM2.5 (OR=2.39, 1.64-3.48) and NOx (OR=1.03, 1.00-1.06) positively associated with sleep disorders, but not PM10 or NO2; PM2.5 ($\beta=-0.14$, -0.18-0.10), PM10 ($\beta=-0.12$, -0.14- -0.10), NO2 ($\beta=-0.02$, -0.03- -0.02), and NOx ($\beta=-0.01$, -0.02- -0.01) each associated with decreased sleep duration. With all four in model, PM2.5 associated with increased (OR=4.42, 2.3-8.26) and NO2 associated with decreased (OR=0.91, 0.84-0.98) odds of sleep disorders; only PM10 ($\beta=-0.09$, -0.12, -0.06) associated with decreased sleep duration	▼—▲
Pelgrims, 2021[88]	CS (Europe)	N=1,325 (Both)	PM2.5, PM10, NO2, O3, black carbon (land use models specified to residence, averaged over 1 year)	Sleep disorders (questionnaire, Symptom Checklist-90-R)	Pollutant tertiles not associated with sleeping disorders	—
Heyes,	E (Asia)	N=13,870	PM2.5, PM10,	Sleeplessness	A 1 standard deviation in	▼—

2019[93]		Weibo users (NA)	CO, NO ₂ , SO ₂ , O ₃ , AQI (daily average measures)	(text mining Weibo)	AQI levels or PM _{2.5} levels associated with a 11.6% or 12.8% increase in reported sleeplessness	
Manzoni, 2018[90]	E (Europe)	N=754 (Pediatric)	NO ₂ (mean annual concentration from regional monitoring)	SDB (Embletta Gold sleep system)	NO ₂ levels positively associated with SDB relative risk (RR=1.31, 1.16-1.48)	▼
Ju, 2021[101]	CS (Asia)	N=162,797 questioned in the Korea Community Health Survey (Adults)	Perceived air/water/soil pollution (questionnaire)	Quality (PSQI)	Perceived air (OR=1.10, 1.06-1.15), water (OR=1.04, 0.99-1.10), or soil (OR=1.17, 1.11-1.23) pollution positively associated with poor sleep quality (PSQI>5)	▼
Gokdemir, 2021[91]	CS (Middle East)	N=1,908 (air pollution), N=3,265 (SHS), N=6,342 (stove emissions) (Pediatric)	SHS, HAP, general air pollution (questionnaire)	SDB (SRBD scale of PSQ, guardian-reported)	Living near roadway air pollution (OR=1.41, 1.11-1.79) and SHS exposure (OR=1.48, 1.19-1.85) positively associated with SDB, but not stove use	▼—
Accinelli, 2015[89]	CS (South America)	N=19 households (Pediatric)	HAP PM _{2.5} , CO (24-hour indoor monitoring with Berkley Air UCB-PATS)	SDB symptoms (difficulty breathing during sleep, apneic episodes), nocturnal awakening [survey and interview of symptoms]	There were no associations between levels of indoor air pollutants and SDB	—
Chen, 2020[95]	CS (Asia)	N=823 solid fuel users, N=793 natural gas users 80+ (Adults)	HAP (questionnaire, solid fuel use over 5 years)	Quality (PSQI)	Solid fuel use positively associated with poor sleep quality (PSQI>5)(OR=1.66, 1.24-2.21, propensity matching) and PSQI score (β =0.66, 1.14-1.18, propensity matching)	▼
Ekici, 2008[96]	CS (Middle East)	N=903 biomass users (all from rural areas), N=11,867 unexposed (Adults)	HAP (questionnaire, children interviewed grandparents with Modified Sleep and Health Questionnaire)	Apnea during sleep (SDB), awakening after falling asleep [Modified Sleep and Health Questionnaire]	Biomass use positively associated with apnea frequency (β =0.05) and frequent awakening (β =0.02), and in women in rural areas (unOR=1.6, CI=1.1-2.49)	▼
Gan, 2020[97]	CS (Asia)	N=365 with exposure measures (Adults)	HAP (urinary PAHs)	Quality (PSQI)	1-hydroxy-naphthalene (1-OHNAp) and total urinary hydroxy polycyclic aromatic hydrocarbons (OH-PAHs), but not 2-hydroxy-naphthalene (2-OHNAp), were positively associated with poor sleep quality (PSQI>5)	▼—
Environmental tobacco smoke (ETS) or passive smoke exposure						
Nakata, 2008[102]	CS (Asia)	N=613 never smokers exposed to SHS, N=373 unexposed never smokers, factory workers (Adults)	SHS (questionnaire)	Difficulty initiating sleep, maintaining sleep, early morning awakening, short sleep duration	No associations between SHS and sleep outcomes, except men with occasional, but not regular, SHS exposure and decreased sleep duration (OR=1.81, 1.11-2.94)	▼—

Zhou, 2018[103]	CS (Asia)	N=562 with passive smoke exposure, N=307 non-smokers (Adults)	SHS (questionnaire) and 1-hydroxypyrene levels (HPLC)	(questionnaire) Quality, latency, efficiency, duration, disturbance, sleeping medication use (PSQI)	SHS exposure (but not 1-HOP levels) associated with poorer sleep latency (OR=1.45, 1.0-2.11), short sleep duration (OR=1.94, 1.01-3.71), and PQSI total score (OR=1.34, 1.0-1.79), but not sleep efficiency, sleep disturbances, or use of sleeping medication.	▼—
Veronda, 2020[99]	CS (North America)	N=320 exposed and N=491 unexposed among rare/never smokers (Adults)	Avoidance of smoke exposure (questionnaire, Avoidance of Environmental Tobacco Smoke Scale)	Quality (PSQI)	Low avoidance of exposure positively associated with PSQI scores (worse quality) (5.63, 5.31-5.95 for moderate vs. 5.02, 4.76-5.28 for low)	▼
Davis, 2016[104]	CS (North America)	N=88 exposed, N=134 unexposed (Pediatric)	Passive smoke exposure (plasma cotinine)	SDB (SRBD scale of PSQ, guardian-reported)	No differences in SDB by passive smoke exposure	—
Sánchez, 2018[105]	CS (South America)	N=225 exposed, N=339 unexposed (Pediatric)	Passive smoke exposure (questionnaire)	SDB (SRBD scale of PSQ, guardian-reported)	Passive smoke exposure positively associated with SDB (53% vs 37%, p=0.003)	▼
Newman, 2010[106]	PC (North America)	N=790 exposed to SHS with asthma during pregnancy, N=1,011 unexposed during pregnancy (Adults)	Passive smoke exposure (questionnaire and urinary cotinine levels)	Total nights sleep disturbance (questionnaire, sleep diary)	No differences in sleep outcomes in pregnant participants with asthma by passive smoke exposure	—
Djeddi, 2018[98]	CS (Europe)	N=21 exposed, N=10 unexposed (Pediatric)	Passive smoke exposure (questionnaire on maternal smoking, urine cotinine)	Architecture (PSG, Brainnet-Morpheus system)	No differences in REM or NREM sleep duration by passive smoke exposure	—
Groner, 2019[107]	CS (North America)	N=138 infants aged 2-5 with cotinine (Pediatric)	SHS [infant's hair cotinine, parental self-report]	SDB (SRBD scale item of PSQ, guardian-reported)	In mediation analysis, SHS exposure, as measured by log hair nicotine, was associated with sometimes/any or almost always noticing SDB in infants (OR=2.02)	▼
Yolton, 2010[108]	CS (North America)	N=219 with asthma and cotinine (Pediatric)	SHS (survey, guardian-reported, and serum cotinine)	Onset delay, duration, night wakings, parasomnias, SDB, sleep disturbance (interview with Children's Sleep Habits Questionnaire (CSHQ))	In children with asthma, SHS positively associated with sleep onset delay (OR=1.53, 1.15-2.03), SDB (OR=1.26, 1.04-1.52) and total sleep disturbance (OR=1.14, 0.54-1.74), but not sleep duration or night waking	▼—
Morioka, 2018[109]	CS (Asia)	N=29,593 exposed, N=46,163 unexposed (Pediatric)	SHS (questionnaire)	Insomnia, difficulty initiating sleep, difficulty maintaining sleep, early morning awakening, short duration,	SHS exposure among never-smoking students positively associated with difficulty initiating sleep (OR=1.36, 1.28-1.44), difficulty maintaining sleep (OR=1.50, 1.36-1.65), early morning awakenings (OR=1.25, 1.17-1.40),	▼

				insufficient sleep (questionnaire)	insomnia (OR=1.40, 1.34-1.48), short sleep duration (OR=1.15, 1.10-1.21), and insufficient sleep (OR=1.28, 1.22-1.34)	
Other						
Tjalvin, 2015[110]	CS (Europe)	N=147 exposed, N=137 unexposed workers (Adults)	PAHs, mercaptans, VOCs, sulfurous compounds from oil tank explosion (proximity to site, 6km)	Sleep problems (Subjective Health Complaints Inventory questionnaire)	Exposure to oil tank fire smoke positively associated with sleep problems	▼
Hlodversdottir, 2016[111]	PC (Europe)	N=1,096 exposed, N=475 unexposed in 2013 (Adults)	Volcanic ash (proximity to eruption site)	Insomnia, difficulty falling asleep, difficulty staying asleep, frequency waking up in night, feeling well rested (questionnaire)	Compared to their responses in 2010, in 2013 exposed had higher odds of self-reported insomnia (OR=1.53, 1.01-2.30), difficulty staying asleep (1.58, 1.20-2.08), and frequency waking up at night (1.32, 1.01-1.73), but not difficulty falling asleep or feeling well rested; compared to unexposed, exposed did not have lower or higher odds of sleep complaints.	▼—
<p>[†]Downward pointing red triangle symbol represents sleep disruption, black dash symbol represents null finding, and upward pointing blue triangle represents improved sleep outcome (not necessarily indicative of a healthy outcome) in relation to exposure.</p> <p>Abbreviations: CS=cross-sectional; E=ecological; ETS=environmental tobacco smoke; HAP=household air pollution; HPLC=high-performance liquid chromatography; PAHs=polycyclic aromatic hydrocarbons; PC=prospective cohort; PM=particulate matter; N=number; PSG=polysomnography; PSQ=Pediatric Sleep Questionnaire; PSQI=Pittsburgh Sleep Quality Index; OR=odds ratio; RR=risk ratio; SDB=sleep-disordered breathing; SRBD=sleep-related breathing disorder; SHS=second-hand smoke; UKB=UK Biobank; unOR=unadjusted odds ratio; VOCs=volatile organic compounds</p>						

L5
L6




Figure 2. Chart depicting RoB ratings across evaluation domains for included epidemiologic studies on air pollution exposure.

Table 5. Summary table of epidemiologic studies of conflict-related exposures and sleep outcomes.

First Author, Year	Design (Location)	Characteristics (age group)	Pollutant Measure (method)	Sleep Measure (method)	Findings	Direction [†]
World Trade Center-related 9/11 exposures						
Sunderram, 2019[115]	PC (North America)	N=601 patients from WTC responder clinics (Adults)	WTC dust (self-reported exposure based on duration and occupational history and classified as high, intermediate, or low)	OSA (HSAT, ARES Unicorder)	WTC responders with very high or intermediate exposure did not have higher prevalence of OSA compared to those with low exposure	—
Glaser, 2014[121]	CS (North America)	N=636 WTC FDNY responders, all males (Adults)	WTC dust (self-reported occupational history and arrival at WTC site within first 2 weeks; comparing responders who arrived on 9/11 versus responders who arrived over the next two weeks)	OSA, AHI (PSG)	Responders with earliest exposure to WTC (arrived on 9/11) had higher odds of severe (but not mild or moderate) OSA (OR=1.91, 1.15-3.17) compared to those who arrived within 2 weeks following	▼ —

de la Hoz, 2010[116]	PC (North America)	N=100 WTC responders (Adults)	WTC dust (self-reported occupational history and arrival at WTC site within 48 hours)	OSA, AHI (PSG, Embla)	WTC exposure duration was not significantly associated with AHI	—
de la Hoz, 2012[117]	CS (North America)	N=272 exposed WTC responders, N=384 unexposed (Adults)	WTC dust (self-reported occupational history and treatment sought at WTC clinic)	OSA, AHI, REM-related OSA, UARS (PSG, Embla)	WTC exposure was not associated with OSA or any of the other PSG diagnoses (SDB, REM-related OSA, UARS)	—
Ahuja, 2018[118]	CS (North America)	N=143 exposed WTC responders (Adults)	WTC dust (self-report of degree of exposure to dust cloud)	SDB/OSA, AHI (PSG in lab or HSAT)	WTC exposure was not associated with OSA diagnosis, but exposure to dust cloud was positively associated with log AHI $\geq 4\%$	▼ —
Webber, 2011[120]	PC (North America)	N=11,701 total exposed WTC responders; N=1,879 arrival group 1, N=7,165 arrival group 2, N=1,477 arrival group 3, N=1,180 arrival group 4 (Adults)	WTC dust (self-report of occupational exposure and FDNY-WTC Exposure Intensity Index)	OSA (modified Berlin questionnaire for OSA risk and self-reported physician-diagnosed OSA)	Responders in arrival groups 1 (OR=2.24, 1.47-3.41), 2 (OR=2.06, 1.42-2.99), and 3 (OR=1.86, 1.19-2.92) had higher odds of incident OSA (but not prevalent OSA) at follow up compared to those in group 4. Responders with ≥ 4 months work duration at the WTC site had higher odds of incident OSA at follow-up (OR=1.26, 1.05-1.52)	▼
Sunderram, 2011[119]	CS (North America)	N=50 exposed male WTC responders, N=50 unexposed (Adults)	WTC dust (occupational history)	AHI measures, sleep quality (PSG and questionnaire for sleep quality)	Responders had worse sleep quality (p=0.046) compared to non-responders (p=0.12) but lower AHI (22.7 vs 43.4, p=0.0004) and fewer apneas (28.7 vs 43.7, p=0.023)	▼ —
Exposures related to serving in the Gulf War						
Kroenke, 1998[113]	CS (North America)	N=18,495 Gulf War veterans (Adults)	Gulf War exposures (questionnaire and occupational history)	Sleep disturbance (questionnaire asking about sleep problems)	Among Gulf War veterans, prevalence of sleep problems ~3% before the war and ~33.5-17% during and after the war; approximately 33% of Gulf War veterans reported sleep problems. Prevalence of self-reported sleep problems was 33% in participants exposed to diesel fuel, tent heater fumes, and/or pyridostigmine, 34% in participants exposed to oil-fire smoke, solvents, CARC paint, and/or pesticides, 39% of participants exposed to mustard gas, and 40% of participants exposed to nerve gas	▼
Chao, 2016[125]	CS (North America)	N=98 Gulf War veterans; N=77	Gulf War exposures (Kansas Gulf War	Sleep quality (PSQI),	Compared to Gulf War veterans without GWI,	▼ —

		cases and N=21 controls by CDC case definition, N=47 cases and 26 controls by Kansas definition (Adults)	Military History and Health Questionnaire for GWI status)	SDB/OSA (OSA STOP score), insomnia (insomnia severity index), sleep disturbance	those with GWI had higher STOP scores, and predicted nerve agent exposure was sig associated with STOP scores (but other covariates were null)(Spearman's: 0.73, p<0.001); GWI veterans had greater insomnia and worse sleep PSQI, but these were sig associated with PTSD (not nerve agent)	
Fukuda, 1998[112]	CS (North America)	N=1,163 Gulf War veterans and N=2,538 non-deployed personnel (Adults)	Gulf War exposures (deployment record, occupational history)	Difficulty sleeping (questionnaire)	Air force Gulf war veterans had higher prevalence of sleep disturbance than nondeployed (self-calculated unOR=2.6, 2.19-3.10)	▼
Gray, 2002[126]	CS (North America)	N=3,831 Gulf War deployed Seabees, N=8,037 Seabees non-deployed or deployed elsewhere (Adults)	Gulf War exposures (deployment history, occupational history)	Trouble sleeping (questionnaire)	Seabees deployed in the Gulf War had higher prevalence of trouble sleeping post deployment compared to deployed elsewhere (OR=3.02, 2.72-3.35) and nondeployed Seabees (OR=3.08, 2.71-3.50)	▼
Proctor, 1998[127]	CS (North America)	N=252 exposed veterans, N=48 unexposed (Adults)	Gulf War exposures (Health Symptom checklist questionnaire, deployment)	Inability to fall asleep (Expanded Health Symptom Checklist)	Higher prevalence of insomnia among Gulf-deployed than Germany deployed veterans (OR=3.4 and 3.6, no CI provided but stated it excludes 1)	▼
Steele, 2000[114]	CS (North America)	N=1,435 exposed veterans, N=409 unexposed (Adults)	Gulf War exposures (deployment history, occupational history)	Problems falling or staying asleep (interview)	Gulf War veterans had higher prevalence of problems falling or staying asleep compared to non-PGW veterans (OR=2.98, 2.18-4.08)	▼
Other						
Duffy, 1979[122]	CS (North America)	N=77 exposed workers, N=38 unexposed (Adults)	Sarin (occupational history of at least 1 exposure)	Architecture (EEG recorded via Ampex FR 1300 tape deck)	Exposure associated with greater time in REM sleep, both as absolute duration and as a percentage of total sleep	▲
Nakajima, 1999[123]	PC (Asia)	N=318 exposed (N=167 with 3-year data), N=919 unexposed (N=669 with 3-year data) (Adults)	Sarin (self-reported exposure and vicinity to attack)	Insomnia, bad dreams (questionnaire)	Exposure was not associated with cholinesterase activity between those who reported bad dreams or insomnia; when measured 3 years after the incident, sarin-exposed participants (n=167) had slightly higher frequency of self-reported insomnia, but not bad dreams, compared to non-exposed (n=669)(OR=2.48, CI:1.07-5.78)	▼ —

Mousavi, 2017[124]	CS (Middle East)	N=30 exposed, N=10 unexposed males (Adults)	Sulfur Mustard (occupational history, documented exposure)	Sleep quality (PSQI), AHI, ODI, O ₂ saturation, RDI (PSG, ALICE 5 Health dyne, and STOP-Bang questionnaire), AHI (PSG), melatonin levels (serum melatonin with ELISA)	Exposure associated with greater mean PSQI score (11.76 vs. 2.78, p<0.001), STOP-Bang score (5.03 vs. 1.18, p=0.003), AHI (20.06 vs. 3.42, p<0.001), lower O ₂ saturation (78 vs 95, p<0.0001), higher ODI (37.19 vs. 4.44, p=0.003), and lower serum melatonin (29 vs 78, p=0.005)	▼
<p>[†]Downward pointing red triangle symbol represents sleep disruption, black dash symbol represents null finding, and upward pointing blue triangle represents improved sleep outcome (not necessarily indicative of a healthy outcome) in relation to exposure.</p> <p>Abbreviations: AAS=atomic absorption spectrometry; AHI=apnea-hypopnea index; CS=cross-sectional; E=ecological; EEG=electroencephalography; ELISA=enzyme-linked immunoassay; FDNY=New York City Fire Department; GWI=Gulf War Illness; HPLC=high-performance liquid chromatography; HSAT=Home Sleep Apnea Test; ICP-MS=inductively coupled mass spectrometry; N=number; NHANES=National Health and Nutrition Examination Survey; PC=prospective cohort; PGW=Persian Gulf War; PSG=polysomnography; PSQI=Pittsburgh Sleep Quality Index; ODI=Oxygen Desaturation Index; OR=odds ratio; SDB=sleep-disordered breathing; UARS=Upper Airway Resistance Syndrome; WTC=World Trade Center</p>						




Figure 3. Chart depicting RoB ratings across evaluation domains for included epidemiologic studies on conflict-related chemical pollutant exposures.

Table 6. Summary table of epidemiologic studies of EDCs/other and sleep outcomes.						
First Author, Year	Design (Location)	Characteristics (age group)	Pollutant Measure (method)	Sleep Measure (method)	Findings	Direction [†]
Beydoun, 2016[128]	CS (North America)	N=5,034 in 2005-2010 NHANES (Adults)	BPA (urinary measured by SPE-HPLC-Isotope dilution-MS/MS)	Duration, trouble sleeping, self-reported doctor-diagnosed sleep disorder (NHANES questionnaire)	BPA levels inversely associated with sleep duration <6 (OR=0.88, 0.79-0.98) or <5 hours (OR=0.79, 0.67-0.94), but not with sleep duration as continuous	▼ —

					or BPA quartiles, or with doctor-diagnosed sleep outcomes in fully adjusted models.	
Erden, 2014[129]	CS (Middle East)	N=128 with BPA measures (N=85 with OSA, N=43 controls) (Adults)	BPA (serum measured with HPLC)	SDB (PSG, Compumedics Profusion PSG3)	BPA levels positively associated with OSA (OR=1.38, 1.06-1.80)	▼
Hatcher, 2020[137]	PC (North America)	N=762 from the Midlife Women's Health Study (Adults)	Phthalates (DEHP, DnOP, BBzP, DEP, DBP, DiBP) and metabolites (MEHHP, MEHP, MEOHP, MECPP, MCP, MBzP, MEP, MBP, MiBP)[urine measured once a week for 4 weeks with HPLC-MS/MS]	Insomnia, sleep disturbances, restless sleep (questionnaire)	Phthalates were not associated with sleep outcomes, except when stratified by smoking status; phthalates were inversely associated with sleep outcomes in former smokers.	▼ —
Sears, 2021[133]	CS (North America)	N=322 in 2005-2010 NHANES ages 16-17 (Pediatric)	Phthalates (MEP, MBzP, MCNP, MCOP, MBP, MIBP, MCP, mono-(2-ethyl)-hexyl phthalate, mono-(2-ethyl-5-hydroxyhexyl) phthalate, mono-(2-ethyl-5-ox-hexyl) phthalate, and mono-2-ethyl-5-carboxypentyl phthalate) (urine measured HPLC-MS/MS)	Weekday/workday sleep duration (<8, 8+ via NHANES questionnaire)	Sum phthalate levels (highest quartile) (OR=2.76, 1.23-6.19) and MCNP (OR=2.63, 1.13-6.12) positively associated with short sleep duration (<8 hours)	▼
Ji, 2019[130]	PC (Asia)	N=340 mother-infant pairs in Shanghai-Minhang Birth Cohort Study; N=199 at 2 years old, N=307 at 4 years old (Pediatric)	PBDEs (congeners PBDE-28, -47, -66, -85, -99, -100, -153, -154, and -183) (cord blood measured with HRGC/HRMS)	Sleep problems (Chinese version of preschool form of CBCL/1.5-5 by trained interviewers)	PBDE-47 (highest tertile) in females positively associated with sleep problems (OR=1.51, 1.0-2.29) at 4, but not 2, years old; sum of PBDE congeners (middle tertile) in females positively associated with sleep problems at 2 years (OR=1.93, 1.06-3.52) and 4 years old (OR=1.55, 1.07-2.27). PBDEs were not associated with sleep in males	▼ —
Fitzgerald, 1989[132]	PC (North America)	N=377 from medical surveillance of people exposed to transformer fire (Adults)	PCBs (electrical transformer fire soot with PCB-1254, TCDD, TCDF) (serum, air, and soot samples)	Sleep problems (questionnaire)	Exposure to PCB fire positively associated with relative risk of "nervousness or sleep problems" (RR=3.49; 1.68-11.59) comparing high to low exposure, but not medium to low exposure	▼ —
Neuberger, 1998[131]	CS (Europe)	N=50 exposed from Austrian IARC subcohort, N=50 unexposed (Adults)	Dioxins (mainly 2,3,7,8-TCDD during production of 2,4,5-trichlorophenol) (blood and urine measures, documented occupational exposure)	Quality (questionnaire)	TCDD exposure positively associated with prevalence of sleep disturbances (44% vs. 30%).	▼

Bowler, 2002[138]	CS (North America)	N=509 exposed, N=655 unexposed (Adults)	Catacarb (diethanolamine, potassium metavanadate, potassium borate, potassium carbonate) (proximity to accidental industrial Catacarb release)	Sleep disorders, sleep medication use (symptom questionnaire followed by medical record confirmation in subset)	Catacarb exposure positively associated with sleep disorders (OR=2.3, 1.8-3.1) but no difference in sleeping pill medication use	▼ —
Yalçın, 2020 [139]	CS (Middle East)	N=36 exposed, N=54 unexposed (Pediatric)	Melamine (breast milk measured with array kit)	Infant sleep problems (questionnaire, maternal-reported)	Melamine levels were not associated with infant sleep problems	—
Gallicchio, 2011[140]	CS (North America)	N=450 exposed (cosmetologists), N=511 unexposed (Adults)	Salon chemicals (cleaning supplies, hair products, nail care products) (questionnaire)	Sleep disturbances (questionnaire)	Handling cleaning supplies (>3 hours/week) was positively associated with frequent sleep disturbances (OR=1.76, 1.11-2.78), but no associations with bleaching hair, perming hair, straightening hair, or texturizing hair	▼ —
Shiue, 2015[141]	CS (North America)	N=20,293 in NHANES 2009-2012 (Adults)	Perchlorate, nitrate, thiocyanate (urinary levels measured with LC-MS/MS)	Sleep disorder, sleep complaint (NHANES questionnaire)	Urinary thiocyanates, but not urinary nitrates or perchlorates, associated with sleep complaints in NHANES (OR=1.17, CI 1.08-1.27), but not sleep disorders	▼ —
Shiue, 2017[142]	CS (North America)	N=5,563 in NHANES 2005-2006 (Adults)	Arsenic, phthalates, and polyfluoroalkyls (urinary arsenic measured by ICP-MS, urinary phthalates measured by LC-MS/MS, and blood PFCs via solid phase extraction coupled to High Performance Liquid Chromatography-Turbo Ion Spray ionization-tandem Mass Spectrometry)	Waking up at night (NHANES questionnaire)	No associations of waking up at night with arsenic, phthalates, and PFCs except Trimethylarsine oxide (OR=1.51, CI=1.29-1.76), Mono-2-ethyl-5-carboxypentyl (OR=0.9, CI=0.80-1.00), Monocyclohexyl (OR=1.88, CI=1.02-3.46), 2-(N-ethyl-PFOA) and acetate (OR=1.5, CI=1.08-2.09)	▼ —
<p>[†]Downward pointing red triangle symbol represents sleep disruption, black dash symbol represents null finding, and upward pointing blue triangle represents improved sleep outcome (not necessarily indicative of a healthy outcome) in relation to exposure.</p> <p>Abbreviations: BPA=bisphenyl A; CS=cross-sectional; E=ecological; HPLC=high-performance liquid chromatography; IARC=International Agency for Research on Cancer; N=number; NHANES=National Health and Nutrition Examination Survey; PBDEs=polybrominated diphenyl ethers; PC=prospective cohort; PCBs=polychlorinated biphenyls; PSG=polysonnography; PSQI=Pittsburgh Sleep Quality Index; OR=odds ratio; SDB=sleep-disordered breathing</p>						

Table 7. Summary table of case studies / case series of EDCs/other and sleep outcomes.					
First Author, Year	Location	Characteristics (age group)	Pollutant Measure (method)	Sleep Measure (method)*	Findings
Kondo, 2018[134]	Asia	N=140 ate contaminated rice bran (Adults)	PCBs (such as 2,3,4,7,8,-PeCDF) (blood measured every few years)	Insomnia (Insomnia Severity Index, self-report),	PeCDF not associated with SDB, but PeCDF (fourth quartile) associated with PSQI ≥ 8 (OR=4.84, 1.10-21.25) (but

				quality (PSQI), SDB (pulse oximetry)	not PSQI ≥ 6) and higher prevalence of difficulty initiating sleep; overall evidence is good
Huang, 2014[136]	North America	N=13 across 10 households, N=5 females aged 33-57, N=8 males aged 35-82 (Adult)	Spray polyurethane foam for housing insulation (known application and some with indoor air sampling for VOCs, measured with HPLC)	Insomnia (self-report)	VOCs present in all households, insomnia experienced by 12/13 people, sampling taken before and after foam removal confirmed source; overall evidence is fair
Wright, 2020[135]	Oceania / Australia	N=65 people across 25 case studies, N=37 adults, N=28 children, inadvertently exposed after moving into contaminated residence (Both)	Methamphetamine residue from drug manufacture and/or use (surface wiping tests and hair analysis)	Quality, difficulty sleeping (self-report)	N=23/37 adults and N=21/28 children experienced sleep impairment after exposure; symptoms resolved after changing residence; overall evidence is good

**Note: method of self-report for sleep outcomes were not always explicitly stated in case studies, symptoms assumed reported to physician unless stated otherwise.*
Abbreviations: HPLC=high throughput liquid chromatography; N=number; PCBs=polychlorinated biphenyls; PSQI=Pittsburgh Sleep Quality Index; SDB=sleep-disordered breathing; VOCs=volatile organic compounds




Figure 4. Chart depicting RoB ratings across evaluation domains for included epidemiologic studies on EDCs and pollutants not captured by other categories.

Table 8. Summary table of epidemiologic studies of metals and sleep outcomes.						
First Author, Year	Design (Location)	Characteristics (age group)	Pollutant Measure (method)	Sleep Measure (method)	Findings	Direction [†]
Aluminum						
Sińczuk-Walczak, 2003[143]	CS	N=67 male aluminum foundry workers, N=57 unexposed (Adults)	Aluminum oxide (personal air sampling and urinary aluminum measured with AAS)	Insomnia (questionnaire)	Aluminum foundry workers more likely to report insomnia than controls (p=0.01)	▼
Handra, 2019[144]	CS (Europe)	N=99 exposed smelters, electrochemical	Occupation as proxy for aluminum	Insomnia (questionnaire)	Occupations that handle aluminum had higher	▼

		workers, or locksmiths, N=36 unexposed (Adults)	exposure (occupational history)		prevalence of insomnia compared to controls (p<0.05)	
Antimony						
Scinicariello, 2017[170]	CS (North America)	N=2,654 in 2005-2006 and 2007-2008 NHANES (Adults)	Antimony (urinary measured by ICP-MS)	Duration, onset latency, sleep apnea, sleep problems (NHANES questionnaire)	Higher quartiles of antimony exposure associated with short (≤ 6 hrs) sleep (OR=1.73, 1.04-2.91), longer onset latency (OR=1.21, 1.04-1.41) and OSA (OR 1.57, 1.05-2.34)	▼
Arsenic						
Sińczuk-Walczak, 2010[161]	CS	N=21 exposed male copper smelter workers, N=16 unexposed (Adults)	Arsenic (urinary and workplace air measured by ICP-MS)	Sleeplessness (questionnaire)	No correlation between exposure duration, urinary arsenic level, or workplace air arsenic level and insomnia	—
Li, 2020[160]	CS (Asia)	N=464 with arsenic measures and outcome (Adults)	Arsenic (hair measured with spectrometry, skin indicators measured by a dermatologist, questionnaire on occupational arsenic exposure)	Quality (PSQI)	No association between PSQI score and pigmentary changes, hyperkeratosis, or hair arsenic concentrations	—
Cadmium						
Asker, 2015[171]	CS (Middle East)	N=97 (Adults)	Cadmium, cobalt, copper, manganese, lead (blood levels measured with AAS)	OSA (PSG with 32-channel Embla recorder)	Higher levels of cadmium, cobalt, copper, and manganese and lower levels of lead among OSA patients compared to controls	▼▲
Coal ash						
Sears, 2017[172]	CS (North America)	N=61 exposed living near coal ash, N=50 unexposed (Pediatric)	Coal ash (proximity)	Duration, difficulty falling asleep, frequent night awakenings (questionnaire)	No differences in sleep duration, but exposed had greater difficulty falling asleep (OR=3.26, 1.4-7.6) and night awakenings (OR=8.64, 2.9-25.5)	▼—
Copper, selenium						
Luoju, 2015[173]	CS (Europe)	N=2,570 males (Adults)	Copper (blood measured with AAS)	Duration (questionnaire)	Copper was associated with 7 hours of sleep duration ($\beta=1.32$, $p=0.017$), but not short or long sleep	—
Song, 2012[174]	CS (Asia)	N=126 females 21-72 years old (Adults)	Copper (blood and hair measured with mass spectrometry)	Duration (questionnaire)	Higher tertiles of hair copper levels, but not serum copper levels, associated with decreased sleep duration ($p=0.01$)	▼—

Hashimoto, 2020[175]	CS (Asia)	N=80 females 18-27 years old (Adults)	Copper (dietary questionnaire)	Latency, duration, efficiency, sleep disturbances, use of sleeping medication, quality [measured with actigraphy using ActiGraph over 7 days and PSQI]	Dietary copper (but not manganese) intake is associated with greater sleep efficiency (low SE=0.51, mid SE=0.55, high SE=0.61, p=.022)	—▲
Akyuz, 2013[176]	CS (Middle East)	N=30 (Adults)	Copper (blood measured with AAS)	OSA, AHI, SO ₂ (PSG)	Copper levels were not correlated with AHI or oxygen saturation	—
Cofta, 2005[177]	CS (Europe)	N=39 (Adults)	Copper (blood measured with AAS)	OSA as defined by ODI (somnography with Poly Mesam device)	Severe sleep apnea (ODI >50) was associated with lower levels of copper, but people with ODI 31-50 had higher levels compared to those with ODI <10	▼—
Xu, 2021[178]	CS (Asia)	N=121 maintenance hemodialysis patients (Adults)	Copper, manganese, selenium, lead (blood levels before dialysis measured with ICP-MS)	Sleep disturbance (PSQI)	Patients on dialysis with higher selenium levels had lower odds of severe sleep disruption (OR=0.968, 0.941-0.995, p=0.021), but no associations with copper, manganese, or lead	—▲
Chen, 2013[179]	CS (Asia)	N=64 (Adults)	Copper, selenium (blood measured with AAS)	OSA, AHI (PSG)	Copper positively correlated (r=0.52, p<0.05) and selenium negatively correlated (r=-0.39, p<0.05) with AHI	▼▲
Grandner, 2013[180]	CS (North America)	N=4,548 in 2007-2008 NHANES (Adults)	Copper, selenium (NHANES dietary questionnaire, 24-hour recall)	Duration (NHANES questionnaire)	Dietary copper not associated with sleep duration, but decreased dietary selenium associated with very short (<5 hrs) sleep compared to normal (7-8 hrs) (RR=0.49, 0.36-0.68), but not short (5-6 hrs) or long (9+ hrs)	▼—
Zhu, 2021[181]	CS (North America)	N=1,783 pre/peri-menopausal or post-menopausal females in 2007-2008 NHANES (Adults)	Copper, selenium (NHANES dietary questionnaire, 24-hour recall)	Duration (NHANES questionnaire)	No associations between selenium or copper and sleep duration except in pre/peri-menopausal participants, where selenium levels	▼—

					were inversely associated with sleep duration <5 hours (p<0.05)	
Li, 2012[182]	CS (Asia)	N=485 with dietary information (Adults)	Selenium (blood and 7-day dietary intake questionnaire)	Duration (questionnaire)	Selenium not associated with sleep duration <8 or 8+ hours, but was associated with sleep duration hours (r=0.116, p=0.02)	—▲
Saruhan, 2021[183]	CS (Middle East)	N=146 with selenium measures (Adults)	Selenium (blood measured with AAS)	OSA (PSG, Embla N7000 system)	Selenium levels higher in patients with OSA compared to controls (p=0.008)	▼
Fluoride						
Malin, 2019[162]	CS (North America)	N=512 ages 16-19 in 2015-2016 NHANES (Pediatric)	Fluoride (blood and tap water measured with ion-specific electrode)	Duration, sleep apnea symptoms, trouble sleeping, wake and bed time (NHANES questionnaire)	Higher water fluoride concentrations associated with greater odds of sleep apnea (OR =1.97, 1.27-3.05) and later bed (β=0.40, 0.10-0.70) and wake times (β=0.43, 0.13-0.73)	▼
Lead						
Awad, 1986[151]	CS (Africa)	N=92 exposed workers from lead battery plant, N=40 unexposed workers (Adults)	Lead (air monitoring and blood lead levels measured with AAS)	Insomnia (interview with clinician of medical history)	Insomnia more common among exposed (50%) compared to unexposed (10%)	▼
Bener, 2001[184]	CS (Middle East)	N=100 exposed workers, N=100 unexposed workers (Adults)	Lead (blood lead measured using AAS)	Insomnia (interview questionnaire)	Lead exposure not associated with insomnia	—
Malekiran, 2010[152]	CS (Middle East)	N=67 exposed males, N=67 unexposed (Adults)	Lead (blood levels measured with AAS)	Insomnia (questionnaire)	Lead exposure was correlated with insomnia (r ² =0.43, p<0.0001)	▼
Lilis, 1985[185]	CS (North America)	N=774 exposed (Adults)	Lead, arsenic (blood lead, urinary arsenic, blood zinc protoporphyrin)	Sleep disturbance (physician-administered questionnaire)	Lead and arsenic were not associated with sleep disturbances; however, those reporting sleep disturbances had greater zinc protoporphyrin levels, a marker of chronic lead exposure (mean ZPP=52.3+-29 vs. 47.8+-25, p=0.027). Among smelter workers, blood lead and zinc protoporphyrin positively associated with sleep disturbances.	▼—

Jeyaratnam, 1986[186]	CS (Asia)	N=49 exposed, N=36 unexposed (Adults)	Lead (blood lead measured with AAS)	Sleep disturbance (questionnaire)	No differences in sleep disturbance between exposed and unexposed	—
Mohammadyan, 2019[187]	CS (Middle East)	N=40 exposed (Adults)	Lead (workplace air sampling and blood lead measured with AAS)	Quality (PSQI, translated into Farsi)	Air lead level was inversely correlated to sleep quality ($r=-0.78$, $p=0.02$), as was blood lead and sleep quality ($r=-0.19$, $p=0.03$); exposure to lead ($B=-0.13$, $p=0.03$) and blood lead levels ($B=-0.01$, $p=0.04$) were inversely associated with sleep quality	▼
Mohammed, 2020[188]	CS (Africa)	N=75 exposed, N=75 unexposed (Adults)	Lead, aluminum, manganese (blood measured with AAS)	Quality, disturbance, duration, latency, function, efficacy, quality (PSQI, Arabic version)	Neither foundry work exposure nor lead, manganese, or aluminum were associated with sleep quality measures, except for shorter sleep duration ($p=0.03$)	▼ —
Kruger, 2017[154]	CS (North America)	N=834 exposed to tap water during crisis in Flint (Adults)	Lead (questionnaire about tap water quality)	Duration, quality (questionnaire)	Self-reported poor tap water quality was significantly associated with shorter sleep duration ($B=7.08$, $p<0.01$) and poorer sleep quality ($B=0.15$, $p<0.001$) during the Flint, Michigan Municipal Water Crisis	▼
Liu, 2015[153]	PC (Asia)	N=665 (Pediatric)	Lead (blood lead measured with AAS)	Duration, onset latency, night wakings, parasomnias, SDB, insomnia symptoms, sleep medication use (Children's Sleep Habits Questionnaire, Chinese version, and Adolescent Health Questionnaire)	Lead levels >10 ug/dL at 3-5 years old associated with higher prevalence of self-reported insomnia at 9-13 years ($OR=2.01$, $CI:1.03-3.95$), but not difficulty initiating sleep, maintaining sleep, or early morning awakening; Blood lead level was positively associated with delay in self-reported sleep onset ($B=0.033$, $p=0.006$) but not sleep duration, night wakings, parasomnias, SDB, or sleeping pill use	▼ —
Jansen, 2019[155]	PC (North America)	N=375 (Pediatric)	Lead (blood lead measured with AAS)	Duration, sleep fragmentation (7 day	Lead quartiles associated with decreased sleep	▼ —

				actigraphy measured with Actigraph GT3x+)	duration (p trend=0.006) but not increased sleep fragmentation (p trend=0.12); when stratified by age, stronger associations between lead and shorter sleep duration and greater fragmentation among younger participants; highest quartile of exposure had 23 minutes shorter average sleep ($\beta=-23$, -39- -7, p trend=0.02)	
Joo, 2018[189]	PC (North America)	N=562 (Pediatric)	Lead (blood lead measures during pregnancy and post-partum with AAS)	Sleep problems (Korean version of Child Behavior Checklist CBCL 1.5-5)	Child (postnatal) blood lead levels at 2 years old were associated with sleep problems in females only, not males ($\beta=3.82$, 1.25-6.39)	▼—
Kordas, 2007[156]	CS (North America)	N=597 (Pediatric)	Lead, arsenic (blood lead and urinary arsenic measured with AAS)	Bed and wake timing, latency, quality, waking during sleep, short (<7 hrs) sleep duration (questionnaire)	Blood lead levels ≥ 10 mg/dL associated with short (<7 hrs) sleep duration (OR=2.6, 1.0-6.5) and later wake time (OR=9.6, 5.7-13.5), but not other sleep outcomes	▼—
Manganese						
Bowler, 2016[190]	CS (North America)	N=186 exposed, N=90 unexposed	Manganese (EPA outdoor air monitoring data over 10 years)	Sleep duration, medication use (interview and questionnaire)	Participants living in Mn-air exposed towns had lower sleep duration (6.6 hours/night +/- 1.5 hours vs. 7 hours/night +/- 1 hour) and greater use of sleep medications than control town	▼
Qin, 2014[191]	CS (Asia)	N=301 exposed male welders, N=305 unexposed (Adults)	Welding as proxy for manganese and other metals (occupational history)	Duration, insomnia (questionnaire)	No associations between welding and sleep duration or insomnia	—
Sińczuk-Walczak, 2001[192]	CS	N=75 exposed male welders, N=62 unexposed (Adults)	Manganese (ambient air and personal sampling measured with AAS)	Sleeplessness (questionnaire)	No differences in insomnia between welders and non-welders	—
Bouchard, 2008[193]	RC (North America)	N=71 exposed male Mn-alloy workers, N=71 unexposed (Adults)	Manganese (air sampling)	Insomnia / nightmares / difficulty falling asleep (symptom)	In original study (1990), middle tertile of Mn-exposure associated with	▼—

				frequency questionnaire)	greater complaints of sleep issues (F=3.5), but no dose-effects; no difference in any tertile at 14-year follow-up	
Mercury						
Naimi-Akbar, 2013[148]	CS (Europe)	N=264 (Adults)	Dental amalgam as proxy for metals exposure (questionnaire)	Sleep problems (questionnaire)	No difference in sleep problems among participants who did and did not replace dental amalgams	—
Hilt, 2011[149]	CS (Europe)	N=406 dentists, N=217 non-dentists (Adults)	Dentistry as proxy for exposure to mercury amalgams (occupational history, urinary mercury for subset of dentists)	Sleep disturbance (Norwegian version of Euroquest questionnaire)	Sleep disturbances did not differ between dentists and non-dentists	—
Decharat, 2018[146]	CS (Asia)	N=79 exposed (Adults)	Mercury, e-waste (questionnaire, urinary mercury measured with AAS, worksite air mercury measured with AAS)	Insomnia (questionnaire)	E-waste workers with higher, compared to lower, exposure to mercury had higher prevalence of insomnia symptoms	▼
Nilsson, 1990[150]	CS (Europe)	N=501 exposed dental personnel, N=41 unexposed (Adults)	Mercury via dental amalgams (urinary mercury measured with AAS, air sampling, occupational questionnaire)	Insomnia (questionnaire)	No differences in insomnia frequency between exposed dental personnel and unexposed	—
Moen, 2008[194]	CS (Europe)	N=41 exposed dental assistants, N=64 unexposed females (Adults)	Dental personnel as proxy for mercury exposure (occupational history)	Sleep disturbance (Euroquest questionnaire)	Dental assistants had greater sleep disturbance than assistant nurses ($\beta=0.52$, $p=0.01$, $R^2=0.338$)	▼
Piikivi, 1989[195]	CS (Europe)	N=60 exposed workers from chlorine-alkali plant, N=60 unexposed (Adults)	Mercury (blood and urinary mercury measured with AAS)	Sleep disorders (questionnaire)	Exposure associated with sleep disorders, but when stratified by shift work, only exposed shift workers had higher self-reported sleep disorder score compared to unexposed workers, who were all dayworkers ($p<0.01$)	▼—
Siblerud, 1994[196]	CS (North America)	N=25 exposed females with dental amalgams, N=23 unexposed (Adults)	Dental amalgams as proxy for mercury exposure (number of	Insomnia (Beck Depression Inventory questionnaire)	Greater number of amalgams associated with higher insomnia score compared to those with no	▼

			dental amalgams confirmed by dental assistant and mercury vapor in mouth measured with vapor analyzer)		amalgams (p=0.04)	
Lönnroth, 1997 [147]	CS (Europe)	N=176 exposed dental personnel, N=163 unexposed (Adults)	Dental personnel as proxy for mercury exposure (occupational history)	Insomnia (questionnaire)	No associations between exposure and insomnia among dental personnel; protective effect with fewer fillings in controls when comparing to dental personnel (OR=0.49, 0.28-0.89, p=0.018)	▼ —
Smith, 1970[145]	CS (North America)	N=567 exposed male workers, N=382 unexposed workers (Adults)	Mercury (occupational history, blood and urinary mercury, and workplace air mercury)	Insomnia (interview with physician)	Exposure associated with insomnia prevalence in a dose-response pattern (p<0.001)	▼
Gump, 2014[163]	CS (North America)	N=100 measured 9-11 years old (Pediatric)	Mercury, lead (blood levels measured with ICP-MS)	Duration (actigraphy measured with GT1M)	Mercury exposure inversely associated with sleep duration ($\beta=-0.24$, p<0.05), but not sleep quality or time going to sleep (lead not evaluated)	▼ —
Jansen, 2020[164]	PC (North America)	N=371 8-12 year-olds (Pediatric)	Mercury (urine, blood, and hair levels measured)	Weekday duration, weekday sleep midpoint, fragmentation index (actigraphy with ActiGraph GT3X+ for 7 days)	No associations between concurrent urinary mercury and sleep outcomes; females with moderate Hg (compared to those with high or low Hg) had longer sleep duration	— ▲
Metallic dust						
Ahumada, 1998[197]	CS (North America)	N=596 exposed living near recycling plant, N=743 unexposed (Adults)	Metallic dust (residence proximity to recycling plant with metallic dusts)	Sleep disturbance (interviewer-administered questionnaire)	Those living near the plant had higher prevalence of sleep disturbance	▼
Thallium						
Brockhaus, 1981[157]	CS (Europe)	N=1,265 participants in an exposed town with urine samples, N=41 unexposed (Adults)	Thallium (urinary and hair measured with AAS)	Sleep disorders (questionnaire)	Sleep disturbances increased with thallium exposure, but no statistical test	▼
Apra, 2020[158]	CS (Europe)	N=1,939 exposed to contaminated water, N=217 unexposed (Adults)	Thallium (water, hair, and urine measured with ICP-MS; questionnaire on water exposure)	Sleep disturbance (questionnaire)	Sleep disturbances positively associated with hair (OR=1.27, 1.04-1.55) and nearly associated with urinary (OR=1.2, 0.99-	▼

Ghaderi, 2018[159]	CS (Middle East)	N=56 smokers, N=53 non-smokers (Adults)	Thallium (urinary levels measured with AAS)	Insomnia (questionnaire)	1.46) thallium. Among smokers, those experiencing insomnia had higher thallium; correlation between thallium and insomnia (0.26, p<0.05)	▼
<p>[†]Downward pointing red triangle symbol represents sleep disruption, black dash symbol represents null finding, and upward pointing blue triangle represents improved/increased sleep outcome (not necessarily indicative of a healthy outcome) in relation to exposure.</p> <p>Abbreviations: AAS=atomic absorption spectrometry; CS=cross-sectional; E=ecological; HPLC=high-performance liquid chromatography; ICP-MS=inductively coupled mass spectrometry; N=number; NHANES=National Health and Nutrition Examination Survey; PC=prospective cohort; PSG=polysomnography; PSQI=Pittsburgh Sleep Quality Index; OR=odds ratio; SDB=sleep-disordered breathing</p>						

Table 9. Summary table of case studies / case series of metals and sleep outcomes.

First Author, Year	Location	Characteristics (age group)	Pollutant Measure (method)	Sleep Measure (method)*	Findings
Dani, 2019[198]	Europe	N=1 16 year old female (Pediatric)	Arsenic (blood and urine measured with ICP-MS)	Insomnia (self-report)	Patient was taking homeopathic containing arsenic, but evidence linking arsenic exposure to insomnia is poor
Hasanato, 2015[199]	Middle East	N=1 39-year old female (Adult)	Arsenic (urinary arsenic measured)	Insomnia (self-report)	Patient with celiac disease (rice consumption suspected cause) whose symptoms improved with chelation, overall evidence is fair
Jones, 1990[200]	Europe	N=1 79-year old male (Adult)	Bismuth (blood measured)	Sleeping difficulty (self-report)	Bismuth-laden gauze from wound packing caused bismuth levels to increase, and health improved after gauze removal, but overall evidence is poor
Kilburn, 1996[201]	North America	N=2 males aged 38 and 43 (Adults)	Cadmium, nickel, arsenic, lead, mercury, thallium, polyvinyl chloride (fire in a train nickel-cadmium battery box, self-report and urinary measure of metals)	Insomnia (self-report)	Overall evidence linking metals exposure to insomnia is fair
Mitsumoto, 1982[202]	North America	N=1 30-year old male (Adult)	Gold (blood measured with AAS)	Insomnia (self-report)	Overall evidence between injected gold sodium thiomalate (gold therapy) and insomnia is fair
Boris, 1996[203]	NA	N=1 male followed from 3-12 years old (Pediatric)	Lead (blood level measured)	Architecture (EEG, PSG)	Confirmed lead exposure from 3.5 years old, overall evidence is fair
Cristante, 2010[204]	NA	N=1 30-year old male with bullet wound (Adult)	Lead (blood level and erythrocyte sedimentation rate measured)	Insomnia (self-report)	Unclear whether insomnia explained by other factors, overall evidence is fair
Goldings, 1982[205]	North America	N=1 15-year old male with history of sniffing gasoline (Pediatric)	Lead (blood levels measured and bone screen for lead lines)	Insomnia (self-report)	Unclear whether insomnia explained by other factors, overall evidence is poor
Fischbein, 1991[206]	North America	N=3 family members, including 5-year old female (Both)	Lead (blood levels measured with AAS, erythrocyte protoporphyrin, gum lead line evaluated; known occupation of mother as a potter)	Sleep disturbances (self-report, N=1)	Mother did not report sleep disturbances; overall evidence is poor
Farzaneh, 2017[207]	Middle East	N=17 male opium users (Adults)	Lead (blood level measured)	Sleep disturbance (self-report)	Drug use as possible confounder, overall evidence is poor
Rae,	North	N=10 male construction	Lead (blood levels and	Sleep	One patient reported sleep

1991[167]	America	workers aged 21-50 (Adults)	zinc protoporphyrin measured)	disturbance (self-reported, N=1)	disturbance and received chelation therapy, overall evidence is fair
CDC, 1993[166]	North America	N=4 males aged 24-54 (Adults)	Lead, others from welding fumes (blood lead levels and personal air sampling)	Sleep disturbance (self-reported)	Symptoms consistent across cases and became worse as work exposure went on; overall evidence is fair
Verhoeven, 2011[208]	NA	N=1 49-year old male welder (Adult)	Manganese (blood manganese levels and occupational history)	Sleep disturbances (self-report)	Overall evidence between manganese and sleep disturbance is fair
Bowler, 2007[168]	North America	N=11 male welders (Adults)	Manganese, lead, others from welding fumes (blood and urinary manganese, blood lead, blood copper, and manganese air levels measured on Bay Bridge project)	Sleep disturbances (clinical interview)	Most severe cases (N=11) reported, with Parkinsonism symptoms, all had sleep disturbances; overall evidence is fair
Haug, 1989[209]	NA	N=1 67-year old male (Adult)	Manganese, chromium, lead, others (manganese blood levels measured)	Insomnia (self-reported)	Worked in metallurgic industries, high manganese levels; overall evidence is fair
Josephs, 2005[169]	North America	N=8 male welders aged 22-63 (Adults)	Manganese, others from welding fumes (blood manganese and occupational history)	Sleep disorders (self-report)	2-4 cases with OSA, others with insomnia, and chelation improved outcome in 1 patient; overall evidence is fair
Barber, 1978[210]	NA	N=21 males (Adults)	Mercury vapors, mercury (organic), mercuric oxide (urinary mercury, workplace and personal air sampling)	Insomnia, sleep disturbance (self-report and neurological exam)	Overall evidence between mercury exposure and sleep is fair
Carter, 2017[211]	North America	N=1 12-year old male (Pediatric)	Mercury (elemental), mercury vapors (blood and urine levels measured)	Insomnia, poor sleep (self-report)	Overall evidence between mercury exposure and sleep is good
Florentine, 1991[212]	North America	N=3 siblings, 1 4-year old female, 1 11-year old female, and 1 10-year old male (Pediatric)	Mercury (elemental) (blood and urine levels measured, household levels measured, self-report)	Insomnia (self-report)	Symptoms similar across patients, overall evidence is fair
Foley, 2020[213]	NA	N=1 91-year old male diagnosed with Alzheimer's Disease (Adult)	Mercury (blood, hair, and urine measured, self-report swordfish consumption)	Insomnia (self-report)	Overall evidence is poor
Haas, 2003[214]	North America	N=1 64-year old female (Adult)	Mercury (elemental) (blood levels measured, X-ray imaging, known rupture of Cantor tube)	Insomnia (self-report)	Temporality, overall evidence is fair
Harada, 2001[215] **	South America	N=5, 2 males aged 18 and 56 and 3 females aged 20, 23, and 44 (Adults)	Mercury (hair levels measured)	Insomnia (self-report)	Overall evidence is fair
Henningsson, 1993[216]	NA	N=1 14-year old male (Pediatric)	Mercury (blood and urine levels measured, self-report)	Insomnia (self-report)	Overall evidence is fair
Huang, 2014[217]	Asia	N=1 42-year old male (Adult)	Mercury (blood, urine, and traditional Chinese medicine levels measured with ICP-MS)	Insomnia, sleep-related disorders (self-report and clinician observed)	Exposure and source ascertained, sleep disturbances witnessed by physician; overall evidence is good
Do, 2017[218]	Asia	N=20 workers dismantling fluorescent lamp facility (Adults)	Mercury vapor (blood and urine levels measured)	Sleep disturbance (self-report)	30% had sleep disturbance; overall evidence is fair
Knobeloch, 2006[219]	North America	N=15, 8 males and 7 females (Adults)	Mercury (blood and hair levels measured)	Sleep difficulty (self-report)	Sleep difficulties mentioned by 1 case; overall evidence is poor
Michaeli-Yossef,	NA	N=1 2-year old female (Pediatric)	Mercury (blood and urine levels measured)	Insomnia (guardian-	Observed outcome, overall evidence is good

2007[220]				reported)	
Pelclova, 2017[221]	NA	N=1 41-year old male (Adult)	Mercury (blood and urine levels measured, CT scan and chest radiograph, self-report)	Insomnia (self-report)	Overall evidence is fair
Roach, 2004[222]	NA	N=2 males aboard a ship	Mercury (blood and urine levels measured, self-report)	Insomnia, trouble sleeping (self-report)	Case with higher exposure reported insomnia symptoms, overall evidence is good
Vahabzadeh, 2016[223]	Middle East	N=3 male gilders aged 20, 30, and 53 (Adults)	Mercury (urine levels measured)	Insomnia (self-report)	Overall evidence is fair
Wössmann, 1999[224]	Europe	N=1 11-year old female (Pediatric)	Mercury (blood and urine levels measured)	Insomnia (guardian-reported)	Overall evidence is good
Zhou, 2014[225]	Asia	N=3, 1 33-year old female and 2 males aged 39 and 42 (Adults)	Mercury (blood and urine levels measured)	Insomnia (self-report)	All cases reported insomnia, overall evidence is good
Bose-O'Reilly, 2016[165]	Asia	N=18 people aged 23-82 (Adults)	Mercury (blood, hair, and urine levels measured)	Sleep disturbance (self-report)	About 70% of cases reported sleep disturbance, overall evidence is good
Meggs, 1994[226]	NA	N=4 people who ate poisoned food (Adults)	Thallium (urine and food levels measured with AAS, radiographic analysis of food)	Insomnia (self-report)	Insomnia reported in 1 case, overall evidence is good
<p><i>*Note: Method of self-report for sleep outcomes were not always explicitly stated in case studies, symptoms assumed reported to physician unless stated otherwise.</i></p> <p><i>Abbreviations: AAS=atomic absorption spectrometry; CS=cross-sectional; CT=computed tomography; E=ecological; EEG=electroencephalography; HPLC=high-performance liquid chromatography; ICP-MS=inductively coupled mass spectrometry; N=number; NHANES=National Health and Nutrition Examination Survey; PC=prospective cohort; PSG=polysomnography; PSQI=Pittsburgh Sleep Quality Index; OR=odds ratio; SDB=sleep-disordered breathing</i></p> <p><i>**For Harada et al, study design sampled more people but didn't provide comparisons, but did highlight cases, so included as case study</i></p>					

13
14




Figure 5. Chart depicting RoB ratings across evaluation domains for included epidemiologic studies on metals.

Table 10. Summary table of epidemiologic studies of pesticides and sleep outcomes.						
First Author, Year	Design (Location)	Characteristics (age group)	Pollutant Measure (method)	Sleep Measure (method)	Findings	Direction [†]
Malekiran, 2013[235]	CS (Middle East)	N=187 farmers and N=187 controls (Adults)	Pesticides (farmwork as proxy for OP exposure)	Insomnia (self-report, General Health Questionnaire-28)	Higher prevalence of anxiety/insomnia among farmers compared to non-farmers	▼
El-Desouky, 1978[234]	CS (Middle East)	N=321 male exposed workers and N=46 unexposed (Adults)	Pesticides (OPs and organochlorines) (blood cholinesterase, carboxyhaemoglobin, questionnaire on occupational history)	Insomnia (questionnaire)	No difference in insomnia between exposed and unexposed; but OP-exposed and those with >4 years exposure had greater prevalence of insomnia	▼ —
Tawfik, 2016[236]	CS (Africa)	N=30 exposed, N=29 unexposed (Adults)	Pesticides (OPs) (blood pseudocholinesterase activity and occupational	Sleep disorders (self-reported)	No difference in prevalence of sleep disorders by	—

			history)		exposure duration category	
Beshwari, 1999[233]	CS (Middle East)	N=103 exposed male farmers and N=105 unexposed (Adults)	Pesticides (farmwork as proxy for pesticide exposure) (questionnaire on pesticide use habits)	Insomnia (questionnaire)	Farmers had higher prevalence of insomnia than non-farmers (*OR=3.78, 1.68-8.53)	▼
Li, 2019[230]	CS (Asia)	N=1336 greenhouse farmers (Adults)	Pesticides (occupational history of exposure to at least 1 pesticide, questionnaire on use)	Quality, duration, sleep disorders, OSA, sleep medication use, insomnia, nightmares (questionnaire)	Medium exposure had greater frequency of sleep quality problems (OR=1.48, 1.10-2.00) and trouble falling asleep (OR=1.52, 1.02-2.24), but no differences in sleep duration, medication use, or nightmares; high exposure associated with impaired sleep quality (OR=2.5, CI:1.83-3.40), trouble falling asleep (OR=1.74, CI: 1.16-2.62), and short sleep duration (OR=1.56, CI: 1.02-3.38), but not long sleep duration	▼ —
Sosan, 2009[237]	CS (Africa)	N=150 exposed male cocoa farmers (Adults)	Pesticides (lindane (OC), diazinon (OP), endosulfan (OC), propoxur(carbamate)) (questionnaire)	Difficulty sleeping (questionnaire)	Farmers with ≥20 years experience had higher prevalence of sleeping difficulty	▼
Stallones, 2002[238]	CS (North America)	N=69 with pesticide-related illness and N=692 without pesticide-related illness, rural farm residents (Adults)	Pesticides (interview about occupational exposure to pesticides)	Difficulty falling asleep, long sleep duration (interview on health symptoms)	Pesticide-related illness positively associated with sleeping more than usual (OR=3.58, 1.95-6.58) but not difficulty falling asleep (OR=1.45, 0.84-2.53)	▼ —
Machado, 2018[239]	CS (South America)	N=85/1,421 with previous pesticide poisoning (Adults)	Pesticides (pesticide poisoning as proxy for pesticide exposure, questionnaire)	Sleep problems, from composite score (Mini Sleep Questionnaire)	People uncertain of pesticide poisoning, compared to never, had higher odds of sleep problems (OR=2.59, 1.08-4.10); however, people certain of prior pesticide poisoning did not have a significantly higher odds of sleep problems (OR=3.02, 0.97-5.08)	▼ —
Kori, 2018[240]	CS (Asia)	N=248 exposed male farmers (Adults)	Pesticides (OPs, pyrethroids, carbamates, organochlorines; questionnaire and interview about use)	Sleep problems (questionnaire and interview)	High exposure to pesticides positively associated with prevalence of sleep problems compared to medium exposure (41.6% vs 36.2%); sleep problems higher among those who stored pesticides at home ($\chi^2=11.23$); higher prevalence of sleep problems among people who	▼

					used protective measures	
Baumert, 2018[229]	CS (North America)	N=1,569 male pesticide applicators (Adults)	Pesticides (majority), herbicides, insecticides, fungicides (questionnaire from Agricultural Lung Health Study)	Self-reported doctor-diagnosed OSA (computer-assisted telephone interview)	Exposure to carbamate carbofuran, but not other compounds, associated with OSA (OR=1.83, 1.34-2.51).	▼ —
Metcalf, 1969[227]	CS (North America)	N=56 exposed, N=22 unexposed (Adults)	Pesticides (OPs) (interview, occupational history)	Trouble sleeping, increased dreaming, architecture (interview, subset with all-night EEG)	No differences in self-reported sleep outcomes by exposure; mention 9/12 showed "narcoleptic" type sleep EEG recordings but exposure not stated	▼ —
Amr, 1993[241]	CS (Africa)	N=208 exposed to pesticides, N=72 unexposed (Adults)	Pesticides (blood cholinesterase enzyme levels measured)	Insomnia (clinical assessment)	Pesticide exposure not associated with insomnia	—
Bakhsh, 2016[228]	CS (Middle East)	N=74 households picking non-Bt cotton and N=196 households picking Bt cotton, females aged 14-40+ (Both)	Pesticides (non-Bt cotton picking as a proxy for greater pesticide use compared to Bt cotton)	Sleeplessness (questionnaire with interviewer)	non-Bt cotton pickers had higher prevalence of sleeplessness (N=29/74, 39%) compared to Bt cotton pickers (N=24/196, 12%)	▼
<p>[†]Downward pointing red triangle symbol represents sleep disruption, black dash symbol represents null finding, and upward pointing blue triangle represents improved sleep outcome (not necessarily indicative of a healthy outcome) in relation to exposure.</p> <p>Abbreviations: AAS=atomic absorption spectrometry; CS=cross-sectional; E=ecological; EEG=electroencephalography; HPLC=high-performance liquid chromatography; ICP-MS=inductively coupled mass spectrometry; N=number; OC=organochlorine; OP=organophosphate; NHANES=National Health and Nutrition Examination Survey; PC=prospective cohort; PSG=polysomnography; PSQI=Pittsburgh Sleep Quality Index; OR=odds ratio; SDB=sleep-disordered breathing</p>						

Table 11. Summary table of case studies / case series of pesticides and sleep outcomes.					
First Author, Year	Location	Characteristics (age group)	Pollutant Measure (method)	Sleep Measure (method)*	Findings
Bradwell, 1994[242]	Europe	N=1 male aged 21 working on farm (Adult)	Pesticides and herbicides (OPs, demeton-S-methyl [duratox], and aphid spray) (blood tests, known occupational exposure)	Duration (hypersomnia) and insomnia (self-report to clinician and family report)	Patient followed over time and clear occupational exposure; family history of mental health episodes; overall evidence is fair
Branch, 1986[232]	North America	N=1-3 family in household, focus on 1 male aged 75 (Adult)	Carbamate pesticide (carbaryl [Sevin]) (known regular treatment of home, blood cholinesterase levels reduced, contamination confirmed by Georgia Department of Agriculture inspector)	SDB (self-report to clinician)	All family members experienced symptoms that resolved after moving; temporality in OSA development as late clinical effect; overall evidence is good
Wood, 1971[243]	North America	N=1 male aged 34, duster pilot (Adult)	Pesticides (OPs, phosdrin, trichlorofon, demeton) (blood cholinesterase and known occupational history)	Sleep disturbance (self-reported), architecture (REM sleep study)	Following exposure after OP spraying and regular occupational exposure, disturbed sleep up to 17 months later, decreased REM, greater stage 2-3 sleep and 4 NREM sleep; overall evidence is good
Rubin, 2002[231]	North America	N=626 people from 254 homes with complete information (Both)	Pesticides (OP: methyl parathion) (urinary levels of p-nitrophenol measured with GC-MS)	Night waking (interview)	28% of participants reported night waking, overall evidence is good

Tabershaw, 1966[244]	North America	N=114 people aged 14-60+ (Both)	Pesticides (OPs) (blood levels measured, interview, and/or self-report)	Insomnia (interview)	2 cases reported insomnia, overall evidence is fair
----------------------	---------------	---------------------------------	---	----------------------	---

**Note: Method of self-report for sleep outcomes were not always explicitly stated in case studies, symptoms assumed reported to physician unless stated otherwise.*
Abbreviations: GC-MS= gas chromatography mass spectrometry; N=number; NREM=non-rapid eye movement sleep; OP=organophosphate pesticide; OSA=obstructive sleep apnea; REM=rapid eye movement sleep; SDB=sleep-disordered breathing




Figure 6. Chart depicting RoB ratings across evaluation domains for included epidemiologic studies on pesticides.

Table 12. Summary table of epidemiologic studies of solvents and sleep outcomes.						
First Author, Year	Design (Location)	Characteristics (age group)	Pollutant Measure (method)	Sleep Measure (method)	Findings	Direction [†]
Kellerová, 1985[254]	CS (NA)	N=386 exposed and N=48 unexposed (Adults)	Benzene, toluene, xylene, vinyl chloride (air sampling for benzene, urinary phenols, occupational history)	Architecture, sleep timing (EEG)	Exposure to benzene associated with significantly faster SWS onset than those exposed to toluene and xylene	▲
Laine, 1993[255]	NRCT (NA)	N=21 males aged 19-23 (Adults)	M-xylene (administered in exposure chamber, blood measures of m-xylene with gas chromatography)	Proportions of "active" and "quiet" sleep, duration (static charge sensitive bed, questionnaire)	M-xylene exposure caused N=8/10 to have longer duration of in-bed time; however, no differences in proportions of "active" or "quiet" sleep or sleep quality	—▲
Elofsson, 1980[256]	CS (Europe)	N=80 exposed painters, N=80 unexposed (Adults)	Solvent exposure from painting (~20 different compounds) (environmental sampling of 20 workshops)	Duration (reduced or increased sleep), nightmares (questionnaire)	No differences in self-reported increased sleep or decreased sleep prevalence; nightmares more prevalent among solvent-exposed compared to reference group 2, but not reference group 1 (p<0.05)	▼—
Saygun, 2012[257]	CS (Middle East)	N=193 exposed and N=196 unexposed	Toluene, acetone, butanol, xylene, benzene, trichloroethylene (known	Duration (questionnaire)	Solvent exposure not associated with differences in sleep	—

		males (Adults)	occupational exposure and questionnaire)		duration.	
Godderis, 2011[250]	CS (NA)	N=21 exposed and N=27 unexposed workers (Adults)	Toluene, trichloroethylene, aromatic and aliphatic hydrocarbons (questionnaire on occupational history, exposure index)	Total sleeping time (questionnaire) and OSA, AHI (PSG, Alice 3 Healthdyne)	Solvent exposure associated with higher occurrence of central apneas compared to control workers, but no significant difference in total sleeping time or mean AHI; greater exposure duration and greater exposure index were positively correlated with AHI	▼ —
Laire, 1997[251]	CS (Europe)	N=21 exposed and N=21 unexposed (Adults)	Toluene, mesitylene, benzenes, xylenes, methylpentane, hexane, heptane, methylenechloride, trichloroethane, tetrachloroethane, cyclohexane, methylcyclohexane, ethoxyacetate, 1-methoxy-2-propanol, ethylacetate, n-butylacetate, iso-propanol, iso-butanol, tert-butanol (personal sampling at worksite, occupational history)	Oxygen desaturation during sleep (oximetry during sleep at home with Palco 400 pulse oximeter), duration (Neurotoxicity Symptom Checklist (NCS-60)	Solvent exposure associated with frequency and duration of oxygen desaturation during sleep, but no difference between self-reported sleep problems or sleep duration	▼ —
Ulfberg, 1997[252]	CS (Europe)	N=763 exposed and N=585 unexposed (Adults)	Solvents (questionnaire on occupational exposure and duration)	OSA (oximetry and actigraphy with static charge-sensitive bed)	No difference in solvent exposure by OSA, but when stratified by sex, males with whole workdays exposure to solvents had increased odds of OSA (OR=1.91, CI: 1.19-3.04), but not lower frequencies of exposure.	▼ —
Heiskel, 2002[258]	CS (Europe)	N varies by exposure type and reference group; N=158 cases with some solvent exposure, N=285 cases with no solvent exposure	Solvents (and gasoline, diesel fuel, paints) (questionnaire on occupation and frequency)	OSA (PSG)	Exposure was not associated with OSA	—
Monstad, 1992[249]	CS (Europe)	N=67 exposed, N=47 unexposed (Adults)	Solvents (occupational history)	Apnea index (PSG, Oxford Medilog 9000)	Occupational solvent exposure was associated with higher apnea index; among the exposed, those with more recent exposure had higher frequency of apneas, and a subset diagnosed with OSA demonstrated reduced apnea index after removal from exposure and increased apnea	▼ —

					index soon after exposure in repeated measures	
Lundberg, 1995[248]	CS (Europe)	N=135 exposed male painters, N=71 unexposed carpenters (Adults)	Painting as proxy for solvent exposure (interview)	Sleeping problems, quality, sleep apnea, trouble falling asleep, fragmented sleep, early awakening, disturbed sleep, onset latency (interview, insomnia questionnaire)	There were no differences in sleeping problems between painters and carpenters (PR=1.9, 0.8-4.4), sleep apnea, trouble falling sleep, wake after sleep onset, early morning awakening, disturbed sleep, or sleep onset latency; but greater prevalence of sleeping problems among highly exposed painters (PR=3.8, CI:1.2-12), impaired sleep quality, wake after sleep onset, early morning awakening, and disturbed sleep	▼ —
Sekkal, 2016[247]	CS (Africa)	N=250 exposed and N=250 unexposed males aged 20-60 (Adults)	Working with petroleum products as proxy for exposure to solvents and petroleum-derived hydrocarbons (occupational history, questionnaire)	Difficulty falling asleep, waking up during the night, early awakening, bad sleep quality, lack of sleep (questionnaire) and SDB (Berlin questionnaire)	Exposure positively associated with difficulty falling asleep (OR=3.5, 1.9-6.2), waking up during the night (OR=4.9, 2.3-10.2), early wake up (OR=2.6, 1.4-4.6), bad sleep quality (OR=3.6, 1.9-6.8), lack of sleep (OR=4.6, CI=2.4-8.6), and sleep apnea events (OR=2.2, 1.1-4.2)	▼
Escalona, 1995[259]	CS (South America)	N=67 exposed and N=82 unexposed males (Adults)	Heptane, n-hexane, pentane, toluene, xylene, benzene, others (environmental samples of 2 work areas provided by company, occupational history)	Insomnia, nightmares (questionnaire)	Solvent exposure not associated with prevalence of insomnia (PR=1.1, 0.9-4.5), but was associated with nightmares (PR=1.6, 1.2-2.4)	—
Joseph, 2002[260]	E (North America)	NA; N=61 cases with insomnia in 1992, N=259 cases of insomnia in 1997	Methyl tertiary butyl ether (MTBE) (known introduction of chemical in region's gasoline)	Insomnia (ICD9 codes -780.5 - from medical records)	Increase in insomnia cases in a Philadelphia hospital pulmonary division and general medicine division comparing ICD9 codes from before and after MTBE introduction (137% increase, p<0.001)	▼
Kilburn, 1999[261]	CS (North America)	N=154 exposed jet engine repair workers, N=112 unexposed (Adults)	Jet engine repair work as proxy for exposure to solvents and metals (personal air sampling for 6 people, questionnaires)	Insomnia, waking frequently, short sleep duration (questionnaire)	Jet engine repair workers had high prevalence of inability to fall asleep, frequent waking, and sleeping only a few hours compared to unexposed	▼
Keogh, 1980[262]	CS (North America)	N=141 exposed, N=75 unexposed	Dimethylaminopropionitrile (DMAPN) (occupational)	Insomnia (questionnaire)	DMAPN exposure positively associated	▼

			history)		with insomnia prevalence (31% vs. 4%, p<0.01)	
Indulski, 1996[263]	CS (Europe)	N=175 exposed, N=175 unexposed (Adults)	Xylenes, ethyltoluenes, trimethylbenzenes, propylbenzene, ethylbenzene, toluene, benzene, aliphatic hydrocarbons, naptha (measured with individual sampling of air breathing zone)	Sleep disorders (questionnaire)	Exposure associated with increased self-reported sleep disorders in men (self-calculated OR=8.4, 2.4-29.3) and women (self-calculated OR=2.9, 1.1-7.2).	▼
Hänninen, 1976[264]	CS (Europe)	N=100 exposed, N=101 unexposed (Adults)	Spray-painting work as proxy for solvent exposure (toluene, xylenes, aliphatic hydrocarbons, alcohols, esters, ketones, terpenes) (air measured in 6 garages, occupational history)	Sleep disturbances (questionnaire)	No differences in sleep disturbances by exposure	—
Ng, 1990[265]	CS (Asia)	N=78 exposed, N=145 unexposed males (Adults)	Mixture of organic solvents such as toluene, xylene, isopropanol, isobutanol, ethyl acetate, n-butyl acetate, trichloroethylene, perchloroethylene, 1.1,1,1-trichloroethane, isophorone, acetone, methyl ethyl ketone, and methyl iso-butyl ketone; ethylene glycol ethers such as methyl, ethyl, butyl and phenyl "cellosolve" and "cellosolve acetate" (occupational history)	Difficulty falling asleep, unpleasant dreams, waking frequently during sleep (questionnaire interview by trained nurse)	Exposure not associated with difficulty falling asleep (p=0.054); (however, did have higher frequency of unpleasant dreams (p<0.001) compared to unexposed)	▼ —
Chen, 1994[266]	CS (Asia)	N=233 exposed, N=241 unexposed (Adults)	Solvents (mostly toluene and xylenes) (blood and urine measured, interview and questionnaire)	Difficulty sleeping, nightmares (questionnaire)	Exposed had higher prevalence of difficulty sleeping and nightmares (self-calculated unOR=2.8, 1.85-4.29 and for nightmares unOR=2.49, 1.56-3.97)	▼
Daniell, 1999[267]	CS (North America)	N=89 exposed retired male painters, N=126 unexposed carpenters (Adults)	Painting as proxy for solvent exposure (occupational history and questionnaire)	Difficulty falling asleep, sleeping more [questionnaire]	No differences in difficulty falling asleep by exposure, but painters (not aerospace workers) reported sleeping more compared to carpenters	— ▲
Struwe, 1983[246]	CS (Europe)	N=117 exposed painters and printers, N=80 unexposed (Adults)	Solvents (toluene, xylene, petrol) (personal air sampling measured with chromatography)	Early awakening, reduced/increased sleep, nightmares (questionnaire)	Painters, but not printers, had slightly higher prevalence of self-reported early awakening and nightmares compared to controls ($\chi^2=3.84$ and 3.90, p<0.05).	▼ —
Kaukiainen, 2004[245]	CS (Europe)	N=1,000 exposed painters, N=1,000 unexposed (Adults)	Painting as proxy for solvent exposure (questionnaire)	Difficulty falling asleep, broken sleep, waking up too early (Euroquest questionnaire)	No dose-response association with sleep; exposed did not have higher prevalence of aggregated sleep disturbances	▼ —

					compared to unexposed, but did have higher prevalence of broken sleep (OR=2.36, CI:1.33-4.19) and waking up too early (OR=2.74, CI:1.54-4.88) among the most highly exposed compared to unexposed, but not other exposure levels	
Sińczuk-Walczak, 1997[268]	CS (Europe)	N=116 exposed viscose spinners, N=122 unexposed (Adults)	Carbon disulfide (CS ₂) (some plant measures and individual dosimetry, occupational history)	Sleep disorders (questionnaire)	Workers exposed to CS ₂ had higher prevalence of sleep disorders (self-calculated OR=3.8, CI:1.8-8.1)	▼
Godderis, 2006[269]	CS (Europe)	N=85 exposed male workers, N=66 unexposed (Adults)	Carbon disulfide (CS ₂) (personal air sampling, occupational history)	Sleeping problems (NSC-60 questionnaire)	Workers exposed to CS ₂ did not have higher prevalence of sleep problems compared to unexposed workers (OR=2.1, CI: 1.0-4.3, p=0.07)	—
Knave, 1978[270]	CS (Europe)	N=30 exposed males, N=30 unexposed (Adults)	Solvents in jet fuel (aromatic hydrocarbons (benzene, toluene), olephin hydrocarbons, saturated hydrocarbons (paraffins, cycloparaffins, etc.) (workplace air vapors measured with AAS, occupational history)	Sleep disturbance (interview)	Exposed had higher prevalence of sleep disturbances compared to unexposed (self-calculated OR=6, CI:1.17-30.73)	▼
Mitran, 1997[271]	CS (Europe)	N=187 exposed, N=234 unexposed (Adults)	Solvents (acetone, methyl ethyl ketone (MEK), cyclohexane) (some measurement with unclear methods, occupational history)	Sleep disturbances (questionnaire)	Higher prevalence of sleep disturbances among solvent-exposed workers compared to controls (self-calculated crude OR=4.7, CI:2.7-8.3)	▼
Orbaek, 1985[272]	CS (Europe)	N=50 exposed paint company workers, N=50 unexposed sugar refinery workers (Adults)	Solvents (sporadic workplace air measurements, occupational history and standards)	Sleep disturbance, increased sleep, difficulty falling asleep, early awakening, use of sleeping medication (questionnaire)	No differences in prevalence of sleep disturbance or difficulty in falling asleep, early awakening, or use of sleeping pills; however, exposed had higher prevalence of increased sleep	▼ —
Ukai, 1993[273]	CS (Asia)	N=452 exposed, N=517 unexposed ranging in age from 16-60+ (Both)	Solvents (toluene) (personal air sampling and urine measurement)	Difficulty in sleep, nightmares (questionnaire)	Higher prevalence of sleep difficulties among exposed (41.1% vs. 30.2%, p<0.01), but no strong evidence for dose-response or difference in nightmare prevalence	▼ —
Viaene, 2001[274]	CS (NA)	N=117 exposed, N=64 controls (Adults)	Styrene (blood levels of microsomal epoxide hydrolases, personal air sampling, occupational history)	Sleeping difficulties, duration (NSC-60 questionnaire)	Prevalence of sleeping difficulties among current and formerly exposed workers did not differ from controls	—
Vouriot,	CS	N=22 exposed,	Benzenic hydrocarbons	Quality (PSQI)	No difference in self-	—

2005[275]	(Europe)	N=21 unexposed (Adults)	and 1-methoxy-2-propyl acetate (personal breathing zone sampled and measured with gas chromatography)		reported sleep quality (PSQI) between workers exposed and unexposed to solvents ($z=-0.11$, $p>0.05$).	
Lindelof, 1992[276]	CS (Europe)	N=85 exposed and N=77 unexposed (Adults)	Solvents (known occupational exposure, referral to hospital for solvent exposure related health issues)	Duration in bed, timing, quality, onset latency, difficulty falling asleep, use of sleeping medication (questionnaire)	Compared to asbestos-exposed workers, solvent-exposure associated with longer sleep onset latency (median=30 and 15 min), greater frequency in difficulty falling asleep, and "bad" or "very bad" sleep quality ($\chi^2=19.63$, $p<0.01$), and use of hypnotics ($\chi^2=17.39$, $p<0.01$); however, there were no differences in duration or timing	▼ —
<p>[†]Downward pointing red triangle symbol represents sleep disruption, black dash symbol represents null finding, and upward pointing blue triangle represents improved sleep outcome (not necessarily indicative of a healthy outcome) in relation to exposure.</p> <p>Abbreviations: AAS=atomic absorption spectrometry; CS=cross-sectional; E=ecological; EEG=electroencephalography; HPLC=high-performance liquid chromatography; ICP-MS=inductively coupled mass spectrometry; N=number; NA=not provided; NSC= Neurosymptom Screening Checklist; NRCT=Non-randomized clinical trial, crossover design; PC=prospective cohort; PSG=polysomnography; PSQI=Pittsburgh Sleep Quality Index; OR=odds ratio; OSA=obstructive sleep apnea; SDB=sleep-disordered breathing</p>						

Table 13. Summary table of case studies / case series of solvents and sleep outcomes.

First Author, Year	Location	Characteristics (age group)	Pollutant Measure (method)	Sleep Measure (method)*	Findings
Kraut, 1988[253]	North America	N=19 male workers aged 24-62 (Adults)	Solvents from sewage treatment plant (benzene, toluene) (workplace sampling, urinary phenol and hippuric acid measures)	Duration (self-reported increased sleep requirement)	N=5/19 reported increased sleep requirement and N=3/19 had elevated urinary phenols (indicative of benzene exposure); overall evidence is fair
Singer, 1987[277]	NA	N=3 male workers aged 38, 41, and 49 (Adults)	Toluene diisocyanate (known occupational exposure)	Quality / sleep disturbance (self-report)	Sleep disturbance a chronic symptom after exposure; overall evidence is fair
Wise, 1983[278]	North America	N=1 male aged 20	Trichloroethane (self-report, known occupational history)	SDB (guardian-reported and doctor diagnosed)	OSA symptoms following high exposure to trichloroethane; overall evidence is fair
Lee, 2003[279]	Asia	N=1 male aged 38, glue stirrer	Toluene, other solvents from glue manufacture (known occupational history)	Insomnia (self-report)	Insomnia symptoms followed occupational exposure; overall evidence is poor
Peters, 1982[280]	North America	N=7 aged 20-56 years	Carbon disulfide (CS ₂), fumigants, pesticides, malathion (known occupational exposure)	OSA (EEG) and insomnia (self-reported)	N=4/6 tested positive for OSA; N=1 reporting insomnia after working with fumigants and pesticides for 9 years; multiple exposures among patients, most/all with co-exposure to pesticides; overall evidence is fair
Callender, 1993[281]	North America	N=33, 4 females and 29 males aged 19-63	Multiple; solvents, metals, pesticides (self-report, occupational history)	Insomnia (self-report), OSA (EEG)	N=1/33 with insomnia, N=2/33 with OSA; overall evidence is poor

		(Adults)			
Linz, 1986[282]	North America	N=15, 3 females aged 24-37 and 12 males aged 33-56 (Adults)	Painting as proxy for solvent exposure (toluene, xylene, methyl ethyl ketone, acetone, ethyl acetate, ethyl benzene, isobutyl acetate, n-butyl acetate, hexane E, mineral spirits, naphthalenes, paraffins, trichloroethylene, methylene chloride, petroleum distillates) (self-report and occupational history)	Sleep disturbances (self-report)	10 cases reported sleep disturbances, but overall evidence is poor
Monstad, 1987[283]	Europe	N=15, 4 females aged 34-55 and 11 males aged 28-63 (Adults)	Solvents (white spirit, acetone, trichlorethane, toluene, xylol) (self-report)	OSA, architecture (PSG, either Nihon Kohden 16-channel EEG or 8-channel Medilog 9000 recorder)	Overall evidence is fair
Teelucksingh, 1991[284]	NA	N=1 14-year old male (Pediatric)	Toluene (blood levels measured, self-report)	OSA (sleep study)	Many symptoms resolved after removal from exposure, overall evidence is good
Minami, 1992[285]	NA	N=1 female aged 40 (Adult)	Noxious gases from cleaning products (chlorine / chloramine, inferred through working conditions)	Insomnia (self-report)	Patient experienced insomnia after exposure; overall evidence is fair
Kilburn, 1995[286]*	North America	N=7, 3 females aged 11-35 and 4 males aged 19-54 (Both)	Chlorine (N=6 with exposure based on proximity to known emission of 43 tons from factory, N=1 with known occupational exposure)	Quality, difficulty sleeping (self-report)	N=4/7 cases reported difficulty sleeping after exposure; overall evidence is fair
<p><i>*Note: Method of self-report for sleep outcomes were not always explicitly stated in case studies, symptoms assumed reported to physician unless stated otherwise.</i></p> <p><i>Abbreviations: EEG=electroencephalography; N=number; OSA=obstructive sleep apnea; PSG=polysomnography; SDB=sleep-disordered breathing</i></p>					




Figure 7. Chart depicting RoB ratings across evaluation domains for included epidemiologic studies on solvents.





Figure 8. Summary of pollutant and outcome associations supported by the included literature and possible biological mechanisms underlying the relationships. (GWI=Gulf War Illness; NO₂=nitrogen dioxide; OPs=organophosphates; PBDEs=poly-brominated diphenyl ethers; PCBs=polychlorinated biphenyls; PM=particulate matter; SDB=sleep disordered breathing; SHS=secondhand smoke)



Supplemental Figure 1. Plot of Risk of Bias determination for case studies by exposure pollutant group.

Bibliography

- Zielinski, M.R., McKenna, J.T., and McCarley, R.W. (2016). Functions and mechanisms of sleep. *AIMS Neurosci.* 3, 67–104.
- Buysse, D.J. (2014). Sleep health: can we define it? Does it matter? *Sleep* 37, 9–17.
- Hale, L., Troxel, W., and Buysse, D.J. (2020). Sleep health: an opportunity for public health to address health equity. *Annu. Rev. Public Health* 41, 81–99.
- Chattu, V.K., Manzar, M.D., Kumary, S., Burman, D., Spence, D.W., and Pandi-Perumal, S.R. (2018). The global problem of insufficient sleep and its serious public health implications. *Healthcare (Basel)* 7.
- Stranges, S., Tigbe, W., Gómez-Olivé, F.X., Thorogood, M., and Kandala, N.-B. (2012). Sleep problems: an emerging global epidemic? Findings from the INDEPTH WHO-SAGE study among more than 40,000 older adults from 8 countries across Africa and Asia. *Sleep* 35, 1173–1181.
- Wheaton, A.G., Olsen, E.O., Miller, G.F., and Croft, J.B. (2016). Sleep Duration and Injury-Related Risk Behaviors Among High School Students--United States, 2007-2013. *MMWR Morb Mortal Wkly Rep* 65, 337–341.
- Liu, Y., Wheaton, A.G., Chapman, D.P., Cunningham, T.J., Lu, H., and Croft, J.B. (2016). Prevalence of Healthy Sleep Duration among Adults--United States, 2014. *MMWR Morb Mortal Wkly Rep* 65, 137–141.
- Wheaton, A.G., and Claussen, A.H. (2021). Short Sleep Duration Among Infants, Children, and Adolescents Aged 4 Months-17 Years - United States, 2016-2018. *MMWR Morb Mortal Wkly Rep* 70, 1315–1321.
- Lyons, M.M., Bhatt, N.Y., Pack, A.I., and Magalang, U.J. (2020). Global burden of sleep-disordered breathing and its implications. *Respirology* 25, 690–702.
- Roth, T. (2007). Insomnia: definition, prevalence, etiology, and consequences. *J. Clin. Sleep Med.* 3, S7-10.

11. Leproult, R., and Van Cauter, E. (2010). Role of sleep and sleep loss in hormonal release and metabolism. *Endocr. Dev.* 17, 11–21.
12. Van Cauter, E., Spiegel, K., Tasali, E., and Leproult, R. (2008). Metabolic consequences of sleep and sleep loss. *Sleep Med.* 9 Suppl 1, S23-8.
13. Davidson, J.R., Moldofsky, H., and Lue, F.A. (1991). Growth hormone and cortisol secretion in relation to sleep and wakefulness. *J. Psychiatry Neurosci.* 16, 96–102.
14. Czeisler, C.A., and Klerman, E.B. (1999). Circadian and sleep-dependent regulation of hormone release in humans. *Recent Prog. Horm. Res.* 54, 97–130; discussion 130.
15. Vallat, R., Shah, V.D., Redline, S., Attia, P., and Walker, M.P. (2020). Broken sleep predicts hardened blood vessels. *PLoS Biol.* 18, e3000726.
16. Dzierzewski, J.M., Donovan, E.K., Kay, D.B., Sannes, T.S., and Bradbrook, K.E. (2020). Sleep inconsistency and markers of inflammation. *Front. Neurol.* 11, 1042.
17. Irwin, M.R., Olmstead, R., and Carroll, J.E. (2016). Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. *Biol. Psychiatry* 80, 40–52.
18. Irwin, M.R. (2019). Sleep and inflammation: partners in sickness and in health. *Nat. Rev. Immunol.* 19, 702–715.
19. Covassin, N., and Singh, P. (2016). Sleep duration and cardiovascular disease risk: epidemiologic and experimental evidence. *Sleep Med. Clin.* 11, 81–89.
20. Huang, T., Mariani, S., and Redline, S. (2020). Sleep Irregularity and Risk of Cardiovascular Events: The Multi-Ethnic Study of Atherosclerosis. *J. Am. Coll. Cardiol.* 75, 991–999.
21. Daghlal, I., Dashti, H.S., Lane, J., Aragam, K.G., Rutter, M.K., Saxena, R., and Vetter, C. (2019). Sleep duration and myocardial infarction. *J. Am. Coll. Cardiol.* 74, 1304–1314.
22. Tobaldini, E., Fiorelli, E.M., Solbiati, M., Costantino, G., Nobili, L., and Montano, N. (2019). Short sleep duration and cardiometabolic risk: from pathophysiology to clinical evidence. *Nat. Rev. Cardiol.* 16, 213–224.
23. Roenneberg, T., Allebrandt, K.V., Mellow, M., and Vetter, C. (2012). Social jetlag and obesity. *Curr. Biol.* 22, 939–943.
24. Parsons, M.J., Moffitt, T.E., Gregory, A.M., Goldman-Mellor, S., Nolan, P.M., Poulton, R., and Caspi, A. (2015). Social jetlag, obesity and metabolic disorder: investigation in a cohort study. *Int J Obes (Lond)* 39, 842–848.
25. Wong, P.M., Hasler, B.P., Kamarck, T.W., Muldoon, M.F., and Manuck, S.B. (2015). Social jetlag, chronotype, and cardiometabolic risk. *J. Clin. Endocrinol. Metab.* 100, 4612–4620.
26. Taylor, B.J., Matthews, K.A., Hasler, B.P., Roecklein, K.A., Kline, C.E., Buysse, D.J., Kravitz, H.M., Tiani, A.G., Harlow, S.D., and Hall, M.H. (2016). Bedtime variability and metabolic health in midlife women: the SWAN sleep study. *Sleep* 39, 457–465.
27. Huang, T., and Redline, S. (2019). Cross-sectional and Prospective Associations of Actigraphy-Assessed Sleep Regularity With Metabolic Abnormalities: The Multi-Ethnic Study of Atherosclerosis. *Diabetes Care* 42, 1422–1429.
28. Rangaraj, V.R., and Knutson, K.L. (2016). Association between sleep deficiency and cardiometabolic disease: implications for health disparities. *Sleep Med.* 18, 19–35.

- 15 29. St-Onge, M.-P., Grandner, M.A., Brown, D., Conroy, M.B., Jean-Louis, G., Coons, M., Bhatt, D.L., and
16 American Heart Association Obesity, Behavior Change, Diabetes, and Nutrition Committees of the
17 Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young;
18 Council on Clinical Cardiology; and Stroke Council (2016). Sleep duration and quality: impact on lifestyle
19 behaviors and cardiometabolic health: A scientific statement from the american heart association.
20 *Circulation* 134, e367–e386.
- 21 30. Borbély, A.A., Daan, S., Wirz-Justice, A., and Deboer, T. (2016). The two-process model of sleep
22 regulation: a reappraisal. *J. Sleep Res.* 25, 131–143.
- 23 31. Holst, S.C., and Landolt, H.-P. (2022). Sleep-Wake Neurochemistry. *Sleep Med. Clin.* 17, 151–160.
- 24 32. Scammell, T.E., Arrigoni, E., and Lipton, J.O. (2017). Neural circuitry of wakefulness and sleep. *Neuron*
25 93, 747–765.
- 26 33. Saper, C.B., and Fuller, P.M. (2017). Wake-sleep circuitry: an overview. *Curr. Opin. Neurobiol.* 44, 186–
27 192.
- 28 34. Grandner, M.A., Patel, N.P., Gehrman, P.R., Xie, D., Sha, D., Weaver, T., and Gooneratne, N. (2010).
29 Who gets the best sleep? Ethnic and socioeconomic factors related to sleep complaints. *Sleep Med.* 11,
30 470–478.
- 31 35. Schwartz, D.A., Vinnikov, D., and Blanc, P.D. (2017). Occupation and Obstructive Sleep Apnea: A
32 Meta-Analysis. *J. Occup. Environ. Med.* 59, 502–508.
- 33 36. Kecklund, G., and Axelsson, J. (2016). Health consequences of shift work and insufficient sleep. *BMJ*
34 355, i5210.
- 35 37. Billings, M.E., Hale, L., and Johnson, D.A. (2020). Physical and social environment relationship with
36 sleep health and disorders. *Chest* 157, 1304–1312.
- 37 38. Johnson, D.A., Billings, M.E., and Hale, L. (2018). Environmental determinants of insufficient sleep and
38 sleep disorders: implications for population health. *Curr. Epidemiol. Rep.* 5, 61–69.
- 39 39. Johnson, D.A., Jackson, C.L., Guo, N., Sofer, T., Laden, F., and Redline, S. (2021). Perceived home
40 sleep environment: associations of household-level factors and in-bed behaviors with actigraphy-based
41 sleep duration and continuity in the Jackson Heart Sleep Study. *Sleep* 44.
- 42 40. Basner, M., and McGuire, S. (2018). WHO environmental noise guidelines for the european region: A
43 systematic review on environmental noise and effects on sleep. *Int. J. Environ. Res. Public Health* 15.
- 44 41. Smith, M.G., Cordoza, M., and Basner, M. (2022). Environmental Noise and Effects on Sleep: An
45 Update to the WHO Systematic Review and Meta-Analysis. *Environ. Health Perspect.* 130, 76001.
- 46 42. Tähkämö, L., Partonen, T., and Pesonen, A.-K. (2019). Systematic review of light exposure impact on
47 human circadian rhythm. *Chronobiol. Int.* 36, 151–170.
- 48 43. Shin, J.C., Parab, K.V., An, R., and Grigsby-Toussaint, D.S. (2020). Greenspace exposure and sleep: A
49 systematic review. *Environ. Res.* 182, 109081.
- 50 44. Rifkin, D.I., Long, M.W., and Perry, M.J. (2018). Climate change and sleep: A systematic review of the
51 literature and conceptual framework. *Sleep Med. Rev.* 42, 3–9.
- 52 45. Mayne, S.L., Mitchell, J.A., Virudachalam, S., Fiks, A.G., and Williamson, A.A. (2021). Neighborhood
53 environments and sleep among children and adolescents: A systematic review. *Sleep Med. Rev.* 57,
54 101465.

- 35 46. Liu, J., Wu, T., Liu, Q., Wu, S., and Chen, J.-C. (2020). Air pollution exposure and adverse sleep health
36 across the life course: A systematic review. *Environ. Pollut.* 262, 114263.
- 37 47. Tenero, L., Piacentini, G., Nosetti, L., Gasperi, E., Piazza, M., and Zaffanello, M. (2017). Indoor/outdoor
38 not-voluptuary-habit pollution and sleep-disordered breathing in children: a systematic review. *Transl.*
39 *Pediatr.* 6, 104–110.
- 40 48. An, R., Shen, J., Ying, B., Tainio, M., Andersen, Z.J., and de Nazelle, A. (2019). Impact of ambient air
41 pollution on physical activity and sedentary behavior in China: A systematic review. *Environ. Res.* 176,
42 108545.
- 43 49. Clark, D.P.Q., Son, D.B., Bowatte, G., Senaratna, C.V., Lodge, C., Perret, J.L., Hamilton, G.S., and
44 Dharmage, S. (2020). The association between traffic-related air pollution and obstructive sleep apnea:
45 A systematic review. *Sleep Med. Rev.* 54, 101360.
- 46 50. Safa, F., Chaiton, M., Mahmud, I., Ahmed, S., and Chu, A. (2020). The association between exposure
47 to second-hand smoke and sleep disturbances: A systematic review and meta-analysis. *Sleep Health* 6,
48 702–714.
- 49 51. Jara, S.M., Benke, J.R., Lin, S.Y., and Ishman, S.L. (2015). The association between secondhand
50 smoke and sleep-disordered breathing in children: a systematic review. *Laryngoscope* 125, 241–247.
- 51 52. Ji, X., Grandner, M.A., and Liu, J. (2017). The relationship between micronutrient status and sleep
52 patterns: a systematic review. *Public Health Nutr.* 20, 687–701.
- 53 53. Jiang, X., Han, Y., Qiu, X., Chai, Q., Zhang, H., Chen, X., Cheng, Z., Wang, Y., Fan, Y., Xue, T., *et al.*
54 (2021). Organic Components of Personal PM_{2.5} Exposure Associated with Inflammation: Evidence from
55 an Untargeted Exposomic Approach. *Environ. Sci. Technol.* 55, 10589–10596.
- 56 54. Elder, A., Gelein, R., Silva, V., Feikert, T., Opanashuk, L., Carter, J., Potter, R., Maynard, A., Ito, Y.,
57 Finkelstein, J., *et al.* (2006). Translocation of inhaled ultrafine manganese oxide particles to the central
58 nervous system. *Environ. Health Perspect.* 114, 1172–1178.
- 59 55. Calderón-Garcidueñas, L., Maronpot, R.R., Torres-Jardon, R., Henríquez-Roldán, C., Schoonhoven,
60 R., Acuña-Ayala, H., Villarreal-Calderón, A., Nakamura, J., Fernando, R., Reed, W., *et al.* (2003). DNA
61 damage in nasal and brain tissues of canines exposed to air pollutants is associated with evidence of
62 chronic brain inflammation and neurodegeneration. *Toxicol. Pathol.* 31, 524–538.
- 63 56. Abadin, H., Ashizawa, A., Stevens, Y.-W., Lladós, F., Diamond, G., Sage, G., Citra, M., Quinones, A.,
64 Bosch, S.J., and Swarts, S.G. (2007). Toxicological profile for lead (Atlanta (GA): Agency for Toxic
65 Substances and Disease Registry (US)).
- 66 57. Allen, J.R., McWey, P.J., and Suomi, S.J. (1974). Pathobiological and behavioral effects of lead
67 intoxication in the infant rhesus monkey. *Environ. Health Perspect.* 7, 239–246.
- 68 58. Chuang, K.-J., Chan, C.-C., Su, T.-C., Lee, C.-T., and Tang, C.-S. (2007). The effect of urban air
69 pollution on inflammation, oxidative stress, coagulation, and autonomic dysfunction in young adults. *Am.*
70 *J. Respir. Crit. Care Med.* 176, 370–376.
- 71 59. Sun, Q., Wang, A., Jin, X., Natanzon, A., Duquaine, D., Brook, R.D., Aguinaldo, J.-G.S., Fayad, Z.A.,
72 Fuster, V., Lippmann, M., *et al.* (2005). Long-term air pollution exposure and acceleration of
73 atherosclerosis and vascular inflammation in an animal model. *JAMA* 294, 3003–3010.
- 74 60. Huang, T., Goodman, M., Li, X., Sands, S.A., Li, J., Stampfer, M.J., Saxena, R., Tworoger, S.S., and
75 Redline, S. (2021). C-reactive Protein and Risk of OSA in Four US Cohorts. *Chest* 159, 2439–2448.

61. Zanobetti, A., Redline, S., Schwartz, J., Rosen, D., Patel, S., O'Connor, G.T., Lebowitz, M., Coull, B.A., and Gold, D.R. (2010). Associations of PM10 with sleep and sleep-disordered breathing in adults from seven U.S. urban areas. *Am. J. Respir. Crit. Care Med.* 182, 819–825.
62. Taranto-Montemurro, L., Messineo, L., Azarbarzin, A., Vena, D., Hess, L.B., Calianese, N.A., White, D.P., Wellman, A., and Sands, S.A. (2020). Effects of the combination of atomoxetine and oxybutynin on OSA endotypic traits. *Chest* 157, 1626–1636.
63. Reale, M., Velluto, L., Di Nicola, M., D'Angelo, C., Costantini, E., Marchioni, M., Cerroni, G., and Guarnieri, B. (2020). Cholinergic markers and cytokines in OSA patients. *Int. J. Mol. Sci.* 21.
64. Zhu, L., Chamberlin, N.L., and Arrigoni, E. (2019). Muscarinic Inhibition of Hypoglossal Motoneurons: Possible Implications for Upper Airway Muscle Hypotonia during REM Sleep. *J. Neurosci.* 39, 7910–7919.
65. Darwiche, W., Gay-Quéheillard, J., Delanaud, S., El Khayat El Sabbouri, H., Khachfe, H., Joumaa, W., Bach, V., and Ramadan, W. (2018). Impact of chronic exposure to the pesticide chlorpyrifos on respiratory parameters and sleep apnea in juvenile and adult rats. *PLoS ONE* 13, e0191237.
66. Mikati, I., Benson, A.F., Luben, T.J., Sacks, J.D., and Richmond-Bryant, J. (2018). Disparities in distribution of particulate matter emission sources by race and poverty status. *Am. J. Public Health* 108, 480–485.
67. Payne-Sturges, D.C., Gee, G.C., and Cory-Slechta, D.A. (2021). Confronting racism in environmental health sciences: moving the science forward for eliminating racial inequities. *Environ. Health Perspect.* 129, 55002.
68. Jacobs, D.E. (2011). Environmental health disparities in housing. *Am. J. Public Health* 101 Suppl 1, S115-22.
69. Liu, J., Clark, L.P., Bechle, M.J., Hajat, A., Kim, S.-Y., Robinson, A.L., Sheppard, L., Szpiro, A.A., and Marshall, J.D. (2021). Disparities in Air Pollution Exposure in the United States by Race/Ethnicity and Income, 1990-2010. *Environ. Health Perspect.* 129, 127005.
70. Jackson, C.L., Redline, S., and Emmons, K.M. (2015). Sleep as a potential fundamental contributor to disparities in cardiovascular health. *Annu. Rev. Public Health* 36, 417–440.
71. Billings, M.E., Cohen, R.T., Baldwin, C.M., Johnson, D.A., Palen, B.N., Parthasarathy, S., Patel, S.R., Russell, M., Tapia, I.E., Williamson, A.A., *et al.* (2021). Disparities in sleep health and potential intervention models: A focused review. *Chest* 159, 1232–1240.
72. Giddens, N.T., Juneau, P., Manza, P., Wiers, C.E., and Volkow, N.D. (2022). Disparities in sleep duration among American children: effects of race and ethnicity, income, age, and sex. *Proc Natl Acad Sci USA* 119, e2120009119.
73. Zanoibetti, A., Ryan, P.H., Coull, B., Brokamp, C., Datta, S., Blossom, J., Lothrop, N., Miller, R.L., Beamer, P.I., Visness, C.M., *et al.* (2022). Childhood asthma incidence, early and persistent wheeze, and neighborhood socioeconomic factors in the ECHO/CREW consortium. *JAMA Pediatr.* 176, 759–767.
74. Bryant-Stephens, T. (2009). Asthma disparities in urban environments. *J. Allergy Clin. Immunol.* 123, 1199–206; quiz 1207.
75. Johnson, D.A., Ohanele, C., Alcántara, C., and Jackson, C.L. (2022). The need for social and environmental determinants of health research to understand and intervene on racial/ethnic disparities in obstructive sleep apnea. *Clin. Chest Med.* 43, 199–216.

76. Landrigan, P.J., Kimmel, C.A., Correa, A., and Eskenazi, B. (2004). Children's health and the environment: public health issues and challenges for risk assessment. *Environ. Health Perspect.* 112, 257–265.
77. Gaston, S.A., and Jackson, C.L. (2021). Strengthening the case for early-life interventions to address racial/ethnic sleep disparities across the life-course using an exposome approach. *Sleep* 44.
78. Nwanaji-Enwerem, J.C., Jackson, C.L., Ottinger, M.A., Cardenas, A., James, K.A., Malecki, K.M.C., Chen, J.-C., Geller, A.M., and Mitchell, U.A. (2021). Adopting a “compound” exposome approach in environmental aging biomarker research: A call to action for advancing racial health equity. *Environ. Health Perspect.* 129, 45001.
79. Jackson, C.L., Powell-Wiley, T.M., Gaston, S.A., Andrews, M.R., Tamura, K., and Ramos, A. (2020). Racial/ethnic disparities in sleep health and potential interventions among women in the united states. *J Womens Health (Larchmt)* 29, 435–442.
80. Tchounwou, P.B., Yedjou, C.G., Patlolla, A.K., and Sutton, D.J. (2012). Heavy Metals Toxicity and the Environment. *EXS* 101, 133–164.
81. Murad, M.H., Sultan, S., Haffar, S., and Bazerbachi, F. (2018). Methodological quality and synthesis of case series and case reports. *BMJ Evid. Based Med.* 23, 60–63.
82. Buysse, D.J., Reynolds, C.F., Monk, T.H., Berman, S.R., and Kupfer, D.J. (1989). The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. *Psychiatry Res.* 28, 193–213.
83. Wang, Y., Liu, X., Chen, G., Tu, R., Abdulai, T., Qiao, D., Liu, X., Dong, X., Luo, Z., Wang, Y., *et al.* (2020). Association of long-term exposure to ambient air pollutants with prolonged sleep latency: The Henan Rural Cohort Study. *Environ. Res.* 191, 110116.
84. He, Y., Liu, X., Luo, Z., Wang, Y., Fan, K., Tu, R., Wu, X., Chen, G., Hou, J., Mao, Z., *et al.* (2021). Long-term exposure to ambient PM1 strengthened the association of depression/anxiety symptoms with poor sleep quality: The Henan Rural Cohort study. *Ecotoxicol. Environ. Saf.* 211, 111932.
85. Chen, G., Xiang, H., Mao, Z., Huo, W., Guo, Y., Wang, C., and Li, S. (2019). Is long-term exposure to air pollution associated with poor sleep quality in rural China? *Environ. Int.* 133, 105205.
86. Yu, Z., Wei, F., Wu, M., Lin, H., Shui, L., Jin, M., Wang, J., Tang, M., and Chen, K. (2021). Association of long-term exposure to ambient air pollution with the incidence of sleep disorders: A cohort study in China. *Ecotoxicol. Environ. Saf.* 211, 111956.
87. Li, W., Bertisch, S.M., Mostofsky, E., Vgontzas, A., and Mittleman, M.A. (2020). Associations of daily weather and ambient air pollution with objectively assessed sleep duration and fragmentation: a prospective cohort study. *Sleep Med.* 75, 181–187.
88. Pelgrims, I., Devleesschauwer, B., Guyot, M., Keune, H., Nawrot, T.S., Remmen, R., Saenen, N.D., Trabelsi, S., Thomas, I., Aerts, R., *et al.* (2021). Association between urban environment and mental health in Brussels, Belgium. *BMC Public Health* 21, 635.
89. Accinelli, R.A., Llanos, O., López, L.M., Matayoshi, S., Oros, Y.P., Kheirandish-Gozal, L., and Gozal, D. (2015). Caregiver perception of sleep-disordered breathing-associated symptoms in children of rural Andean communities above 4000 masl with chronic exposure to biomass fuel. *Sleep Med.* 16, 723–728.
90. Manzoni, F., Tentoni, S., Nasetti, L., Niespolo, A., Monestier, A., and Montomoli, C. (2018). INTERNATIONAL PERSPECTIVES. *Journal of Environmental Health* 81, E1. Available at: <https://www.jstor.org/stable/26575111> [Accessed February 23, 2022].

91. Gokdemir, Y., Civelek, E., Cakir, B., Demir, A., Kocabas, C.N., Ikizoglu, N.B., Karakoc, F., Karadag, B., and Ersu, R. (2021). Prevalence of sleep-disordered breathing and associated risk factors in primary school children in urban and rural environments. *Sleep Breath.* 25, 915–922.
92. Li, L., Zhang, W., Xie, L., Jia, S., Feng, T., Yu, H., Huang, J., and Qian, B. (2020). Effects of atmospheric particulate matter pollution on sleep disorders and sleep duration: a cross-sectional study in the UK biobank. *Sleep Med.* 74, 152–164.
93. Heyes, A., and Zhu, M. (2019). Air pollution as a cause of sleeplessness: Social media evidence from a panel of Chinese cities. *Journal of Environmental Economics and Management* 98, 102247.
94. Tang, M., Li, D., Liew, Z., Wei, F., Wang, J., Jin, M., Chen, K., and Ritz, B. (2020). The association of short-term effects of air pollution and sleep disorders among elderly residents in China. *Sci. Total Environ.* 708, 134846.
95. Chen, C., Liu, G.G., Sun, Y., Gu, D., Zhang, H., Yang, H., Lu, L., Zhao, Y., and Yao, Y. (2020). Association between household fuel use and sleep quality in the oldest-old: Evidence from a propensity-score matched case-control study in Hainan, China. *Environ. Res.* 191, 110229.
96. Ekici, M., Ekici, A., Keles, H., Akin, A., Karlidag, A., Tunckol, M., and Kocyigit, P. (2008). Risk factors and correlates of snoring and observed apnea. *Sleep Med.* 9, 290–296.
97. Gan, D., Huang, D., Yang, J., Zhang, L., Ou, S., Feng, Y., Peng, Y., Peng, X., Zhang, Z., and Zou, Y. (2020). Assessment of kitchen emissions using a backpropagation neural network model based on urinary hydroxy polycyclic aromatic hydrocarbons. *Environ. Pollut.* 265, 114915.
98. Djeddi, D., Stephan-Blanchard, E., Léké, A., Ammari, M., Delanaud, S., Lemaire-Hurtel, A.-S., Bach, V., and Telliez, F. (2018). Effects of Smoking Exposure in Infants on Gastroesophageal Reflux as a Function of the Sleep-Wakefulness State. *J. Pediatr.* 201, 147–153.
99. Veronda, A.C., Irish, L.A., and Delahanty, D.L. (2020). Effect of smoke exposure on young adults' sleep quality. *Nurs. Health Sci.* 22, 57–63.
100. Yu, H., An, R., and Andrade, F. (2017). Ambient fine particulate matter air pollution and physical activity: A longitudinal study of university retirees in Beijing, China. *Am. J. Health Behav.* 41, 401–410.
101. Ju, Y.J., Lee, J.E., Choi, D.-W., Han, K.-T., and Lee, S.Y. (2021). Association between perceived environmental pollution and poor sleep quality: results from nationwide general population sample of 162,797 people. *Sleep Med.* 80, 236–243.
102. Nakata, A., Takahashi, M., Haratani, T., Ikeda, T., Hojou, M., Fujioka, Y., and Araki, S. (2008). Association of active and passive smoking with sleep disturbances and short sleep duration among Japanese working population. *Int. J. Behav. Med.* 15, 81–91.
103. Zhou, B., Ma, Y., Wei, F., Zhang, L., Chen, X., Peng, S., Xiong, F., Peng, X., NiZam, B., Zou, Y., *et al.* (2018). Association of active/passive smoking and urinary 1-hydroxypyrene with poor sleep quality: A cross-sectional survey among Chinese male enterprise workers. *Tob. Induc. Dis.* 16, 23.
104. Davis, C.L., Tingen, M.S., Jia, J., Sherman, F., Williams, C.F., Bhavsar, K., Wood, N., Kobleur, J., and Waller, J.L. (2016). Passive smoke exposure and its effects on cognition, sleep, and health outcomes in overweight and obese children. *Child. Obes.* 12, 119–125.
105. Sánchez, T., Rojas, C., Casals, M., Bennett, J.T., Gálvez, C., Betancur, C., Mesa, J.T., and Brockmann, P.E. (2018). [Prevalence and risk factors for sleep-disordered breathing in Chilean schoolchildren]. *Rev. Chil. Pediatr.* 89, 718–725.

106. Newman, R.B., Momirova, V., Dombrowski, M.P., Schatz, M., Wise, R., Landon, M., Rouse, D.J., Lindheimer, M., Caritis, S.N., Sheffield, J., *et al.* (2010). The effect of active and passive household cigarette smoke exposure on pregnant women with asthma. *Chest* 137, 601–608.
107. Groner, J.A., Nicholson, L., Huang, H., and Bauer, J.A. (2019). Secondhand Smoke Exposure and Sleep-Related Breathing Problems in Toddlers. *Acad. Pediatr.* 19, 835–841.
108. Yolton, K., Xu, Y., Khoury, J., Succop, P., Lanphear, B., Beebe, D.W., and Owens, J. (2010). Associations between secondhand smoke exposure and sleep patterns in children. *Pediatrics* 125, e261-8.
109. Morioka, H., Jike, M., Kanda, H., Osaki, Y., Nakagome, S., Otsuka, Y., Kaneita, Y., Itani, O., Higuchi, S., and Ohida, T. (2018). The association between sleep disturbance and second-hand smoke exposure: a large-scale, nationwide, cross-sectional study of adolescents in Japan. *Sleep Med.* 50, 29–35.
110. Tjalvin, G., Hollund, B.E., Lygre, S.H.L., Moen, B.E., and Bråtveit, M. (2015). Subjective health complaints among workers in the aftermath of an oil tank explosion. *Arch. Environ. Occup. Health* 70, 332–340.
111. Hlodversdottir, H., Petursdottir, G., Carlsen, H.K., Gislason, T., and Hauksdottir, A. (2016). Long-term health effects of the Eyjafjallajökull volcanic eruption: a prospective cohort study in 2010 and 2013. *BMJ Open* 6, e011444.
112. Fukuda, K., Nisenbaum, R., Stewart, G., Thompson, W.W., Robin, L., Washko, R.M., Noah, D.L., Barrett, D.H., Randall, B., Herwaldt, B.L., *et al.* (1998). Chronic multisymptom illness affecting Air Force veterans of the Gulf War. *JAMA* 280, 981–988.
113. Kroenke, K., Koslowe, P., and Roy, M. (1998). Symptoms in 18,495 Persian Gulf War veterans. Latency of onset and lack of association with self-reported exposures. *J. Occup. Environ. Med.* 40, 520–528.
114. Steele, L. (2000). Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. *Am. J. Epidemiol.* 152, 992–1002.
115. Sunderram, J., Weintraub, M., Black, K., Alimokhtari, S., Twumasi, A., Sanders, H., Udasin, I., Harrison, D., Chitkara, N., de la Hoz, R.E., *et al.* (2019). Chronic rhinosinusitis is an independent risk factor for OSA in world trade center responders. *Chest* 155, 375–383.
116. de la Hoz, R.E., Aurora, R.N., Landsbergis, P., Bienenfeld, L.A., Afilaka, A.A., and Herbert, R. (2010). Snoring and obstructive sleep apnea among former World Trade Center rescue workers and volunteers. *J. Occup. Environ. Med.* 52, 29–32.
117. de la Hoz, R.E., Mallea, J.M., Kramer, S.J., Bienenfeld, L.A., Wisnivesky, J.P., and Aurora, R.N. (2012). Polysomnographic diagnoses among former world trade center rescue workers and volunteers. *Arch. Environ. Occup. Health* 67, 239–242.
118. Ahuja, S., Zhu, Z., Shao, Y., Berger, K.I., Reibman, J., and Ahmed, O. (2018). Obstructive sleep apnea in community members exposed to world trade center dust and fumes. *J. Clin. Sleep Med.* 14, 735–743.
119. Sunderram, J., Udasin, I., Kelly-McNeil, K., Ko, S., Cepeda, C., Marroccoli, B., Perret, C., Ohman-Strickland, P., Scardella, A., and Kipen, H. (2011). Unique features of obstructive sleep apnea in World Trade Center responders with aerodigestive disorders. *J. Occup. Environ. Med.* 53, 975–980.
120. Webber, M.P., Lee, R., Soo, J., Gustave, J., Hall, C.B., Kelly, K., and Prezant, D. (2011). Prevalence and incidence of high risk for obstructive sleep apnea in World Trade Center-exposed rescue/recovery workers. *Sleep Breath.* 15, 283–294.

121. Glaser, M.S., Shah, N., Webber, M.P., Zeig-Owens, R., Jaber, N., Appel, D.W., Hall, C.B., Weakley, J., Cohen, H.W., Shulman, L., *et al.* (2014). Obstructive sleep apnea and World Trade Center exposure. *J. Occup. Environ. Med.* *56 Suppl 10*, S30-4.
122. Duffy, F.H., Burchfiel, J.L., Bartels, P.H., Gaon, M., and Sim, V.M. (1979). Long-term effects of an organophosphate upon the human electroencephalogram. *Toxicol. Appl. Pharmacol.* *47*, 161–176.
123. Nakajima, T., Ohta, S., Fukushima, Y., and Yanagisawa, N. (1999). Sequelae of sarin toxicity at one and three years after exposure in Matsumoto, Japan. *J. Epidemiol.* *9*, 337–343.
124. Mousavi, S.S., Vahedi, E., Shohrati, M., Panahi, Y., and Parvin, S. (2017). Nocturnal serum melatonin levels in sulfur mustard exposed patients with sleep disorders. *J. R. Army Med. Corps* *163*, 411–415.
125. Chao, L.L., Abadjian, L.R., Esparza, I.L., and Reeb, R. (2016). Insomnia severity, subjective sleep quality, and risk for obstructive sleep apnea in veterans with gulf war illness. *Mil. Med.* *181*, 1127–1134.
126. Gray, G.C., Reed, R.J., Kaiser, K.S., Smith, T.C., and Gastañaga, V.M. (2002). Self-reported symptoms and medical conditions among 11,868 Gulf War-era veterans: the Seabee Health Study. *Am. J. Epidemiol.* *155*, 1033–1044.
127. Proctor, S.P., Heeren, T., White, R.F., Wolfe, J., Borgos, M.S., Davis, J.D., Pepper, L., Clapp, R., Sutker, P.B., Vasterling, J.J., *et al.* (1998). Health status of Persian Gulf War veterans: self-reported symptoms, environmental exposures and the effect of stress. *Int. J. Epidemiol.* *27*, 1000–1010.
128. Beydoun, H.A., Beydoun, M.A., Jeng, H.A., Zonderman, A.B., and Eid, S.M. (2016). Bisphenol-A and Sleep Adequacy among Adults in the National Health and Nutrition Examination Surveys. *Sleep* *39*, 467–476.
129. Erden, E.S., Genc, S., Motor, S., Ustun, I., Ulutas, K.T., Bilgic, H.K., Oktar, S., Sungur, S., Erem, C., and Gokce, C. (2014). Investigation of serum bisphenol A, vitamin D, and parathyroid hormone levels in patients with obstructive sleep apnea syndrome. *Endocrine* *45*, 311–318.
130. Ji, H., Liang, H., Wang, Z., Miao, M., Wang, X., Zhang, X., Wen, S., Chen, A., Sun, X., and Yuan, W. (2019). Associations of prenatal exposures to low levels of Polybrominated Diphenyl Ether (PBDE) with thyroid hormones in cord plasma and neurobehavioral development in children at 2 and 4 years. *Environ. Int.* *131*, 105010.
131. Neuberger, M. (1998). Chloracne and morbidity after dioxin exposure (preliminary results). *Toxicol. Lett.* *96–97*, 347–350.
132. Fitzgerald, E.F., Weinstein, A.L., Youngblood, L.G., Standfast, S.J., and Melius, J.M. (1989). Health effects three years after potential exposure to the toxic contaminants of an electrical transformer fire. *Arch. Environ. Health* *44*, 214–221.
133. Sears, C.G., and Braun, J.M. (2021). Urinary phthalate metabolite concentrations and adolescent sleep duration. *Environ. Epidemiol.* *5*, e134.
134. Kondo, H., Tanio, K., Nagaura, Y., Nagayoshi, M., Mitoma, C., Furue, M., and Maeda, T. (2018). Sleep disorders among Yusho patients highly intoxicated with dioxin-related compounds: A 140-case series. *Environ. Res.* *166*, 261–268.
135. Wright, J., Kenneally, M., Ross, K., and Walker, S. (2020). Environmental methamphetamine exposures and health effects in 25 case studies. *Toxics* *8*.
136. Huang, Y.-C.T., and Tsuang, W. (2014). Health effects associated with faulty application of spray polyurethane foam in residential homes. *Environ. Res.* *134*, 295–300.

137. Hatcher, K.M., Smith, R.L., Chiang, C., Li, Z., Flaws, J.A., and Mahoney, M.M. (2020). Association of phthalate exposure and endogenous hormones with self-reported sleep disruptions: results from the Midlife Women's Health Study. *Menopause* 27, 1251–1264.
138. Bowler, R.M., Gysens, S., Hartney, C., Ngo, L., Rauch, S.S., and Midtling, J. (2002). Increased medication use in a community environmentally exposed to chemicals. *Ind. Health* 40, 335–344.
139. Yalçın, S.S., Güneş, B., and Yalçın, S. (2020). Presence of melamine in human milk and the evaluation of the effects on mother-infant pairs in a cohort study. *Hum. Exp. Toxicol.* 39, 624–633.
140. Gallicchio, L., Miller, S.R., Greene, T., Zacur, H., and Flaws, J.A. (2011). Somatic symptoms among cosmetologists compared to women in other occupations. *J Womens Health (Larchmt)* 20, 605–615.
141. Shiue, I. (2015). Urinary thiocyanate concentrations are associated with adult cancer and lung problems: US NHANES, 2009–2012. *Environ. Sci. Pollut. Res. Int.* 22, 5952–5960.
142. Shiue, I. (2017). Urinary arsenic, pesticides, heavy metals, phthalates, polyaromatic hydrocarbons, and polyfluoroalkyl compounds are associated with sleep troubles in adults: USA NHANES, 2005–2006. *Environ. Sci. Pollut. Res. Int.* 24, 3108–3116.
143. Sińczuk-Walczak, H., Szymczak, M., Raźniewska, G., Matczak, W., and Szymczak, W. (2003). Effects of occupational exposure to aluminum on nervous system: clinical and electroencephalographic findings. *Int. J. Occup. Med. Environ. Health* 16, 301–310.
144. Handra, C.M., Ghita, I., Ulmeanu, A., Enache, A.-M., Epureanu, F., Coman, O.A., Coman, L., and Fulga, I. (2019). Depressive Clinical Manifestations Associated with Professional Aluminum Exposure. *Rev. Chim.* 70, 2162–2167.
145. Smith, R.G., Vorwald, A.J., Patil, L.S., and Mooney, T.F. (1970). Effects of exposure to mercury in the manufacture of chlorine. *Am. Ind. Hyg. Assoc. J.* 31, 687–700.
146. Decharat, S. (2018). Urinary Mercury Levels Among Workers in E-waste Shops in Nakhon Si Thammarat Province, Thailand. *J. Prev. Med. Public Health* 51, 196–204.
147. Lönnroth, E.-C., and Shahnavaz, H. (1997). Amalgam in dentistry A health hazard for dental personnel? *Int. J. Occup. Saf. Ergon.* 3, 151–160.
148. Naimi-Akbar, A., Svedberg, P., Alexanderson, K., Carlstedt-Duke, B., Ekstrand, J., and Englund, G.S. (2013). Health-related quality of life and symptoms in patients with experiences of health problems related to dental restorative materials. *Community Dent. Oral Epidemiol.* 41, 163–172.
149. Hilt, B., Svendsen, K., Syversen, T., Aas, O., and Qvenild, T. (2011). Occurrence of cognitive and neurological symptoms in norwegian dentists. *Saf. Health Work* 2, 176–182.
150. Nilsson, B., Gerhardsson, L., and Nordberg, G.F. (1990). Urine mercury levels and associated symptoms in dental personnel. *Sci. Total Environ.* 94, 179–185.
151. Awad el Karim, M.A., Hamed, A.S., Elhaimi, Y.A., and Osman, Y. (1986). Effects of exposure to lead among lead-acid battery factory workers in Sudan. *Arch. Environ. Health* 41, 261–265.
152. Malekiran, A.A., Oryan, S., Fani, A., Babapor, V., Hashemi, M., Baeeri, M., Bayrami, Z., and Abdollahi, M. (2010). Study on clinical and biochemical toxicity biomarkers in a zinc-lead mine workers. *Toxicol. Ind. Health* 26, 331–337.
153. Liu, J., Liu, X., Pak, V., Wang, Y., Yan, C., Pinto-Martin, J., and Dinges, D. (2015). Early blood lead levels and sleep disturbance in preadolescence. *Sleep* 38, 1869–1874.

154. Kruger, D.J., Kodjebacheva, G.D., and Cupal, S. (2017). Poor tap water quality experiences and poor sleep quality during the Flint, Michigan Municipal Water Crisis. *Sleep Health* 3, 241–243.
155. Jansen, E.C., Dunietz, G.L., Dababneh, A., Peterson, K.E., Chervin, R.D., Baek, J., O'Brien, L., Song, P.X.K., Cantoral, A., Hu, H., *et al.* (2019). Cumulative childhood lead levels in relation to sleep during adolescence. *J. Clin. Sleep Med.* 15, 1443–1449.
156. Kordas, K., Casavantes, K.M., Mendoza, C., Lopez, P., Ronquillo, D., Rosado, J.L., Vargas, G.G., and Stoltzfus, R.J. (2007). The association between lead and micronutrient status, and children's sleep, classroom behavior, and activity. *Arch. Environ. Occup. Health* 62, 105–112.
157. Brockhaus, A., Dolgner, R., Ewers, U., Krämer, U., Soddemann, H., and Wiegand, H. (1981). Intake and health effects of thallium among a population living in the vicinity of a cement plant emitting thallium containing dust. *Int. Arch. Occup. Environ. Health* 48, 375–389.
158. Aprea, M.C., Nuvolone, D., Petri, D., Voller, F., Bertelloni, S., and Aragona, I. (2020). Human biomonitoring to assess exposure to thallium following the contamination of drinking water. *PLoS ONE* 15, e0241223.
159. Ghaderi, A., NasehGhafoori, P., Rasouli-Azad, M., Sehat, M., Mehrzad, F., Nekuei, M., Aaseth, J., Banafshe, H.R., and Mehrpour, O. (2018). Examining of thallium in cigarette smokers. *Biol. Trace Elem. Res.* 182, 224–230.
160. Li, Y., Jing, D., Xiao, Y., Huang, X., and Shen, M. (2020). Patient-Reported Outcomes of Arsenic-Related Skin Lesions in China. *Biomed Res. Int.* 2020, 6195975.
161. Sińczuk-Walczak, H., Szymczak, M., and Hałatek, T. (2010). Effects of occupational exposure to arsenic on the nervous system: clinical and neurophysiological studies. *Int. J. Occup. Med. Environ. Health* 23, 347–355.
162. Malin, A.J., Bose, S., Busgang, S.A., Gennings, C., Thorpy, M., Wright, R.O., Wright, R.J., and Arora, M. (2019). Fluoride exposure and sleep patterns among older adolescents in the United States: a cross-sectional study of NHANES 2015-2016. *Environ. Health* 18, 106.
163. Gump, B.B., Gabrikova, E., Bendinskas, K., Dumas, A.K., Palmer, C.D., Parsons, P.J., and MacKenzie, J.A. (2014). Low-level mercury in children: associations with sleep duration and cytokines TNF- α and IL-6. *Environ. Res.* 134, 228–232.
164. Jansen, E.C., Hector, E.C., Goodrich, J.M., Cantoral, A., Téllez Rojo, M.M., Basu, N., Song, P.X.K., Olascoaga, L.T., and Peterson, K.E. (2020). Mercury exposure in relation to sleep duration, timing, and fragmentation among adolescents in Mexico City. *Environ. Res.* 191, 110216.
165. Bose-O'Reilly, S., Schierl, R., Nowak, D., Siebert, U., William, J.F., Owi, F.T., and Ir, Y.I. (2016). A preliminary study on health effects in villagers exposed to mercury in a small-scale artisanal gold mining area in Indonesia. *Environ. Res.* 149, 274–281.
166. Centers for Disease Control and Prevention (CDC) (1993). Lead poisoning in bridge demolition workers--Georgia, 1992. *MMWR Morb Mortal Wkly Rep* 42, 388–390.
167. Rae, C.E., Bell, C.N., Elliott, C.E., and Shannon, M. (1991). Ten cases of acute lead intoxication among bridge workers in Louisiana. *DICP* 25, 932–937.
168. Bowler, R.M., Roels, H.A., Nakagawa, S., Drezgic, M., Diamond, E., Park, R., Koller, W., Bowler, R.P., Mergler, D., Bouchard, M., *et al.* (2007). Dose-effect relationships between manganese exposure and neurological, neuropsychological and pulmonary function in confined space bridge welders. *Occup. Environ. Med.* 64, 167–177.

169. Josephs, K.A., Ahlskog, J.E., Klos, K.J., Kumar, N., Fealey, R.D., Trenerry, M.R., and Cowl, C.T. (2005). Neurologic manifestations in welders with pallidal MRI T1 hyperintensity. *Neurology* 64, 2033–2039.
170. Scinicariello, F., Buser, M.C., Feroe, A.G., and Attanasio, R. (2017). Antimony and sleep-related disorders: NHANES 2005-2008. *Environ. Res.* 156, 247–252.
171. Asker, S., Asker, M., Yeltekin, A.C., Aslan, M., and Demir, H. (2015). Serum levels of trace minerals and heavy metals in severe obstructive sleep apnea patients: correlates and clinical implications. *Sleep Breath.* 19, 547–552.
172. Sears, C.G., and Zierold, K.M. (2017). Health of children living near coal ash. *Glob. Pediatr. Health* 4, 2333794X17720330.
173. Luojus, M.K., Lehto, S.M., Tolmunen, T., Elomaa, A.-P., and Kauhanen, J. (2015). Serum copper, zinc and high-sensitivity C-reactive protein in short and long sleep duration in ageing men. *J. Trace Elem. Med. Biol.* 32, 177–182.
174. Song, C.-H., Kim, Y.-H., and Jung, K.-I. (2012). Associations of zinc and copper levels in serum and hair with sleep duration in adult women. *Biol. Trace Elem. Res.* 149, 16–21.
175. Hashimoto, A., Inoue, H., and Kuwano, T. (2020). Low energy intake and dietary quality are associated with low objective sleep quality in young Japanese women. *Nutr. Res.* 80, 44–54.
176. Akyuz, A., Ceppioglu, S.K., Yurdun, T., Pelin, Z., and Akyuz, S. (2013). Serum copper and zinc status in obstructive sleep apnea patients. *Turkish Journal Of Pharmaceutical Sciences* 10, 415–424.
177. Cofta, S., Wysocka, E., Torlinski, L., and Gozdzik, J. (2005). Copper and zinc concentrations in blood of patients with obstructive sleep apnea syndrome. *Trace Elements and Electrolytes* 22, 1–5.
178. Xu, S., Zou, D., Tang, R., Li, S., Chen, W., Wen, L., Liu, Y., Liu, Y., and Zhong, X. (2021). Levels of trace blood elements associated with severe sleep disturbance in maintenance hemodialysis patients. *Sleep Breath.* 25, 2007–2013.
179. Chen, P.C., Guo, C.H., Tseng, C.J., Wang, K.C., and Liu, P.J. (2013). Blood trace minerals concentrations and oxidative stress in patients with obstructive sleep apnea. *J. Nutr. Health Aging* 17, 639–644.
180. Grandner, M.A., Jackson, N., Gerstner, J.R., and Knutson, K.L. (2013). Dietary nutrients associated with short and long sleep duration. Data from a nationally representative sample. *Appetite* 64, 71–80.
181. Zhu, B., Grandner, M.A., Jackson, N.J., Pien, G.W., Srimoragot, M., Knutson, K.L., and Izci-Balserak, B. (2021). Associations between Diet and Sleep Duration in Different Menopausal Stages. *West. J. Nurs. Res.* 43, 984–994.
182. Li, N., and Gao, X. (2012). Selenium intakes and serum levels of healthy residents in Jinan, China. *Trace Elements & Electrolytes* 29, 34–41.
183. Saruhan, E., Sertoglu, E., Unal, Y., Bek, S., and Kutlu, G. (2021). The role of antioxidant vitamins and selenium in patients with obstructive sleep apnea. *Sleep Breath.* 25, 923–930.
184. Bener, A., Almehdi, A.M., Alwash, R., and Al-Neamy, F.R. (2001). A pilot survey of blood lead levels in various types of workers in the United Arab Emirates. *Environ. Int.* 27, 311–314.
185. Lilis, R., Valciukas, J.A., Weber, J.P., and Malkin, J. (1985). Effects of low-level lead and arsenic exposure on copper smelter workers. *Arch. Environ. Health* 40, 38–47.

186. Jeyaratnam, J., Boey, K.W., Ong, C.N., Chia, C.B., and Phoon, W.O. (1986). Neuropsychological studies on lead workers in Singapore. *Br. J. Ind. Med.* 43, 626–629.
187. Mohammadyan, M., Moosazadeh, M., Borji, A., Khanjani, N., and Rahimi Moghadam, S. (2019). Exposure to lead and its effect on sleep quality and digestive problems in soldering workers. *Environ. Monit. Assess.* 191, 184.
188. Mohammed, R.S., Ibrahim, W., Sabry, D., and El-Jaafary, S.I. (2020). Occupational metals exposure and cognitive performance among foundry workers using tau protein as a biomarker. *Neurotoxicology* 76, 10–16.
189. Joo, H., Choi, J.H., Burm, E., Park, H., Hong, Y.-C., Kim, Y., Ha, E.-H., Kim, Y., Kim, B.-N., and Ha, M. (2018). Gender difference in the effects of lead exposure at different time windows on neurobehavioral development in 5-year-old children. *Sci. Total Environ.* 615, 1086–1092.
190. Bowler, R.M., Adams, S.W., Wright, C.W., Kim, Y., Booty, A., Colledge, M., Gocheva, V.V., and Lobdell, D.T. (2016). Medication use associated with exposure to manganese in two Ohio towns. *Int. J. Environ. Health Res.* 26, 483–496.
191. Qin, J., Liu, W., Zhu, J., Weng, W., Xu, J., and Ai, Z. (2014). Health related quality of life and influencing factors among welders. *PLoS ONE* 9, e101982.
192. Sińczuk-Walczak, H., Jakubowski, M., and Matczak, W. (2001). Neurological and neurophysiological examinations of workers occupationally exposed to manganese. *Int. J. Occup. Med. Environ. Health* 14, 329–337.
193. Bouchard, M., Mergler, D., Baldwin, M.E., and Panisset, M. (2008). Manganese cumulative exposure and symptoms: a follow-up study of alloy workers. *Neurotoxicology* 29, 577–583.
194. Moen, B., Hollund, B., and Riise, T. (2008). Neurological symptoms among dental assistants: a cross-sectional study. *J. Occup. Med. Toxicol.* 3, 10.
195. Piikivi, L., and Hänninen, H. (1989). Subjective symptoms and psychological performance of chlorine-alkali workers. *Scand. J. Work Environ. Health* 15, 69–74.
196. Siblingud, R.L., Motl, J., and Kienholz, E. (1994). Psychometric evidence that mercury from silver dental fillings may be an etiological factor in depression, excessive anger, and anxiety. *Psychol. Rep.* 74, 67–80.
197. Ahumada, H.T. (1998). [Health status of the population in the vicinity of a waste recycling plant in Mexico]. *Rev. Panam. Salud Publica* 3, 15–20.
198. Dani, S.U. (2019). A curious association of chronic homeopathic arsenic ingestion with nonspecific symptoms in a Swiss teenager. *Swiss Med Wkly* 149, w20071.
199. Hasanato, R.M., and Almomen, A.M. (2015). Unusual presentation of arsenic poisoning in a case of celiac disease. *Ann. Saudi Med.* 35, 165–167.
200. Jones, J.A.H. (1990). Bipp: A case of toxicity? *Oral Surgery, Oral Medicine, Oral Pathology* 69, 668–671.
201. Kilburn, K.H., and McKinley, K.L. (1996). Persistent neurotoxicity from a battery fire: is cadmium the culprit? *South. Med. J.* 89, 693–698.
202. Mitsumoto, H., Wilbourn, A.J., and Subramony, S.H. (1982). Generalized myokymia and gold therapy. *Arch. Neurol.* 39, 449–450.

203. Boris, N.W., Hagino, O.R., and Steiner, G.P. (1996). Case study: hypersomnolence and precocious puberty in a child with pica and chronic lead intoxication. *J. Am. Acad. Child Adolesc. Psychiatry* 35, 1050–1054.
204. Cristante, A.F., de Souza, F.I., Barros Filho, T.E.P., Oliveira, R.P., and Marcon, R.M. (2010). Lead poisoning by intradiscal firearm bullet: a case report. *Spine* 35, E140-3.
205. Goldings, A.S., and Stewart, R.M. (1982). Organic lead encephalopathy: behavioral change and movement disorder following gasoline inhalation. *J. Clin. Psychiatry* 43, 70–72.
206. Fischbein, A., Sassa, S., Butts, G., and Kaul, B. (1991). Increased lead absorption in a potter and her family members. *N. Y. State J. Med.* 91, 317–319.
207. Farzaneh, E., Habibzadeh, A., and Mehrpour, O. (2017). Lead toxicity among oral opium addicts with abdominal pain: A case series of 17 cases. *Indian Journal of Forensic Medicine & Toxicology* 11, 22–25.
208. Verhoeven, W.M., Egger, J.I., and Kuijpers, H.J. (2011). Manganese and acute paranoid psychosis: a case report. *J. Med. Case Reports* 5, 146.
209. Haug, B.A., Schoenle, P.W., Karch, B.J., Bardosi, A., and Holzgraefe, M. (1989). Morvan's fibrillary chorea. *Clin. Neurol. Neurosurg.* 91, 53–59.
210. Barber, T.E. (1978). Inorganic mercury intoxication reminiscent of amyotrophic lateral sclerosis. *J. Occup. Med.* 20, 667–669.
211. Carter, M., Abdi, A., Naz, F., Thabet, F., and Vyas, A. (2017). A mercury toxicity case complicated by hyponatremia and abnormal endocrinological test results. *Pediatrics* 140.
212. Florentine, M.J., and Sanfilippo, D.J. (1991). Elemental mercury poisoning. *Clin. Pharm.* 10, 213–221.
213. Foley, M.M., Seidel, I., Sevier, J., Wendt, J., and Kogan, M. (2020). One man's swordfish story: The link between Alzheimer's disease and mercury exposure. *Complement. Ther. Med.* 52, 102499.
214. Haas, N.S., Shih, R., and Gochfeld, M. (2003). A patient with postoperative mercury contamination of the peritoneum. *J. Toxicol. Clin. Toxicol.* 41, 175–180.
215. Harada, M., Nakanishi, J., Yasoda, E., Pinheiro, M.C., Oikawa, T., de Assis Guimarães, G., da Silva Cardoso, B., Kizaki, T., and Ohno, H. (2001). Mercury pollution in the Tapajos River basin, Amazon: mercury level of head hair and health effects. *Environ. Int.* 27, 285–290.
216. Henningsson, C., Hoffmann, S., McGonigle, L., and Winter, J.S.D. (1993). Acute mercury poisoning (acrodynia) mimicking pheochromocytoma in an adolescent. *J. Pediatr.* 122, 252–253.
217. Huang, X., Law, S., Li, D., Yu, X., and Li, B. (2014). Mercury poisoning: a case of a complex neuropsychiatric illness. *Am. J. Psychiatry* 171, 1253–1256.
218. Do, S.Y., Lee, C.G., Kim, J.Y., Moon, Y.H., Kim, M.S., Bae, I.H., and Song, H.S. (2017). Cases of acute mercury poisoning by mercury vapor exposure during the demolition of a fluorescent lamp factory. *Ann. Occup. Environ. Med.* 29, 19.
219. Knobeloch, L., Steenport, D., Schrank, C., and Anderson, H. (2006). Methylmercury exposure in Wisconsin: A case study series. *Environ. Res.* 101, 113–122.
220. Michaeli-Yossef, Y., Berkovitch, M., and Goldman, M. (2007). Mercury intoxication in a 2-year-old girl: a diagnostic challenge for the physician. *Pediatr. Nephrol.* 22, 903–906.

221. Pelclova, D., Vlckova, S., Bezdicek, O., Vaneckova, M., Urban, P., Ridzon, P., Diblik, P., Navratil, T., Klusackova, P., Vlcek, K., *et al.* (2017). Is chelation therapy efficient for the treatment of intravenous metallic mercury intoxication? *Basic Clin. Pharmacol. Toxicol.* *120*, 628–633.
222. Roach, R.R., and Busch, S. (2004). Mercury exposure aboard an ore boat. *Environ. Health Perspect.* *112*, 910–913.
223. Vahabzadeh, M., and Balali-Mood, M. (2016). Occupational metallic mercury poisoning in gilders. *Int. J. Occup. Environ. Med.* *7*, 116–122.
224. Wössmann, W., Kohl, M., Grüning, G., and Bucsky, P. (1999). Mercury intoxication presenting with hypertension and tachycardia. *Arch. Dis. Child.* *80*, 556–557.
225. Zhou, Z., Zhang, X., Cui, F., Liu, R., Dong, Z., Wang, X., and Yu, S. (2014). Subacute motor neuron hyperexcitability with mercury poisoning: a case series and literature review. *Eur. Neurol.* *72*, 218–222.
226. Meggs, W.J., Hoffman, R.S., Shih, R.D., Weisman, R.S., and Goldfrank, L.R. (1994). Thallium poisoning from maliciously contaminated food. *J. Toxicol. Clin. Toxicol.* *32*, 723–730.
227. Metcalf, D.R., and Holmes, J.H. (1969). VII. Toxicology and physiology. EEG, psychological, and neurological alterations in humans with organophosphorus exposure. *Ann. N. Y. Acad. Sci.* *160*, 357–365.
228. Bakhsh, K., Ahmad, N., Kamran, M.A., Hassan, S., Abbas, Q., Saeed, R., and Hashmi, M.S. (2016). Occupational hazards and health cost of women cotton pickers in Pakistani Punjab. *BMC Public Health* *16*, 961.
229. Baumert, B.O., Carnes, M.U., Hoppin, J.A., Jackson, C.L., Sandler, D.P., Freeman, L.B., Henneberger, P.K., Umbach, D.M., Shrestha, S., Long, S., *et al.* (2018). Sleep apnea and pesticide exposure in a study of US farmers. *Sleep Health* *4*, 20–26.
230. Li, J., Hao, Y., Tian, D., He, S., Sun, X., and Yang, H. (2019). Relationship between cumulative exposure to pesticides and sleep disorders among greenhouse vegetable farmers. *BMC Public Health* *19*, 373.
231. Rubin, C., Esteban, E., Kieszak, S., Hill, R.H., Dunlop, B., Yacovac, R., Trottier, J., Boylan, K., Tomaszewski, T., and Pearce, K. (2002). Assessment of human exposure and human health effects after indoor application of methyl parathion in Lorain County, Ohio, 1995-1996. *Environ. Health Perspect.* *110 Suppl 6*, 1047–1051.
232. Branch, R.A., and Jacqz, E. (1986). Subacute neurotoxicity following long-term exposure to carbaryl. *Am. J. Med.* *80*, 741–745.
233. Beshwari, M.M.M., Bener, A., Ameen, A., Al-Mehdi, A.M., Ouda, H.Z., and Pasha, M.A.H. (1999). Pesticide-related health problems and diseases among farmers in the United Arab Emirates. *International Journal of Environmental Health Research* *9*, 213–221.
234. El-Desouky, M.A., and Hassan, R.Z. (1978). Exposure to pesticides in Kuwait. *J Kuwait Med Assoc* *12*, 215–227.
235. Malekirad, A.A., Faghih, M., Mirabdollahi, M., Kiani, M., Fathi, A., and Abdollahi, M. (2013). Neurocognitive, mental health, and glucose disorders in farmers exposed to organophosphorus pesticides. *Archives of Industrial Hygiene and Toxicology* *64*, 1–8.
236. Tawfik Khattab, A.M., Zayed, A.A., Ahmed, A.I., AbdelAal, A.G., and Mekdad, A.A. (2016). The role of PON1 and CYP2D6 genes in susceptibility to organophosphorus chronic intoxication in Egyptian patients. *Neurotoxicology* *53*, 102–107.

237. Sosan, M.B., and Akingbohunge, A.E. (2009). Occupational insecticide exposure and perception of safety measures among cacao farmers in southwestern Nigeria. *Arch. Environ. Occup. Health* 64, 185–193.
238. Stallones, L., and Beseler, C. (2002). Pesticide illness, farm practices, and neurological symptoms among farm residents in Colorado. *Environ. Res.* 90, 89–97.
239. Machado, A.K.F., Wendt, A., and Wehrmeister, F.C. (2018). Sleep problems and associated factors in a rural population of a Southern Brazilian city. *Rev. Saúde Pública* 52, 5s.
240. Kori, R., Thakur, R., Kumar, R., and Yadav, R. (2018). Assessment of Adverse Health Effects Among Chronic Pesticide-Exposed Farm Workers in Sagar District of Madhya Pradesh, India. *Int. J. Nutr. Pharmacol. Neurol. Dis.* 8, 153.
241. Amr, M., Allam, M., Osmaan, A.L., el-Batanouni, M., el Samra, G., and Halim, Z. (1993). Neurobehavioral changes among workers in some chemical industries in Egypt. *Environ. Res.* 63, 295–300.
242. Bradwell, R.H. (1994). Psychiatric sequelae of organophosphorous poisoning: a case study and review of the literature. *Behav. Neurol.* 7, 117–122.
243. Wood, W., Gabica, J., Brown, H.W., Watson, M., and Benson, W.W. (1971). Implication of organophosphate pesticide poisoning in the plane crash of a duster pilot. *Aerosp. Med.* 42, 1111–1113.
244. Tabershaw, I.R., and Cooper, W.C. (1966). Sequelae of acute organic phosphate poisoning. *J. Occup. Med.* 8, 5–20.
245. Kaukiainen, A., Riala, R., Martikainen, R., Akila, R., Reijula, K., and Sainio, M. (2004). Solvent-related health effects among construction painters with decreasing exposure. *Am. J. Ind. Med.* 46, 627–636.
246. Struwe, G., and Wennberg, A. (1983). Psychiatric and neurological symptoms in workers occupationally exposed to organic solvents--results of a differential epidemiological study. *Acta Psychiatr. Scand. Suppl.* 303, 68–80.
247. Sekkal, S., Casas, L., Haddam, N., Bouhacina, L., Scheers, H., Taleb, A., and Nemery, B. (2016). Sleep disturbances and neurotoxicity in workers exposed to hydrocarbons. An observational study from Algeria. *Am. J. Ind. Med.* 59, 129–136.
248. Lundberg, I., Michélsen, H., Nise, G., Hogstedt, C., Högberg, M., Alfredsson, L., Almkvist, O., Gustavsson, A., Hagman, M., and Herlofson, J. (1995). Neuropsychiatric function of housepainters with previous long-term heavy exposure to organic solvents. *Scand. J. Work Environ. Health* 21 Suppl 1, 1–44.
249. Monstad, P., Mellgren, S.I., and Sulg, I.A. (1992). The clinical significance of sleep apnoea in workers exposed to organic solvents: implications for the diagnosis of organic solvent encephalopathy. *J. Neurol.* 239, 195–198.
250. Godderis, L., Dours, G., Laire, G., and Viaene, M.K. (2011). Sleep apnoeas and neurobehavioral effects in solvent exposed workers. *Int. J. Hyg. Environ. Health* 214, 66–70.
251. Laire, G., Viaene, M.K., Veulemans, H., Masschelein, R., and Nemery, B. (1997). Nocturnal oxygen desaturation, as assessed by home oximetry, in long-term solvent-exposed workers. *Am. J. Ind. Med.* 32, 656–664.
252. Ulfberg, J., Carter, N., Talbäck, M., and Edling, C. (1997). Occupational exposure to organic solvents and sleep-disordered breathing. *Neuroepidemiology* 16, 317–326.

253. Kraut, A., Lilis, R., Marcus, M., Valciukas, J.A., Wolff, M.S., and Landrigan, P.J. (1988). Neurotoxic effects of solvent exposure on sewage treatment workers. *Arch. Environ. Health* 43, 263–268.
254. Kellerová, V. (1985). Electroencephalographic findings in workers exposed to benzene. *J. Hyg. Epidemiol. Microbiol. Immunol.* 29, 337–346.
255. Laine, A., Savolainen, K., Riihimäki, V., Matikainen, E., Salmi, T., and Juntunen, J. (1993). Acute effects of m-xylene inhalation on body sway, reaction times, and sleep in man. *Int. Arch. Occup. Environ. Health* 65, 179–188.
256. Elofsson, S.A., Gamberale, F., Hindmarsh, T., Iregren, A., Isaksson, A., Johnsson, I., Knave, B., Lydahl, E., Mindus, P., Persson, H.E., *et al.* (1980). Exposure to organic solvents. A cross-sectional epidemiologic investigation on occupationally exposed care and industrial spray painters with special reference to the nervous system. *Scand. J. Work Environ. Health* 6, 239–273.
257. Saygun, M., Ekici, A., Muluk, N.B., Cakmak, A., Pinar, T., Dağ, E., and Ekici, M. (2012). Effects of long-term low-level solvent exposure on cognitive function. *Clin. Invest. Med.* 35, E190-205.
258. Heiskel, H., Gunzenhäuser, D., Seidler, A., Volk, S., Pflug, B., Kauppinen, T., and Elsner, G. (2002). Sleep apnea and occupational exposure to solvents. *Scand. J. Work Environ. Health* 28, 249–255.
259. Escalona, E., Yanes, L., Feo, O., and Maizlish, N. (1995). Neurobehavioral evaluation of Venezuelan workers exposed to organic solvent mixtures. *Am. J. Ind. Med.* 27, 15–27.
260. Joseph, P.M., and Weiner, M.G. (2002). Visits to physicians after the oxygenation of gasoline in Philadelphia. *Arch. Environ. Health* 57, 137–154.
261. Kilburn, K.H. (1999). Neurobehavioral and respiratory findings in jet engine repair workers: A comparison of exposed and unexposed volunteers. *Environ. Res.* 80, 244–252.
262. Keogh, J.P., Pestronk, A., Wertheimer, D., and Moreland, R. (1980). An epidemic of urinary retention caused by dimethylaminopropionitrile. *JAMA* 243, 746–749.
263. Indulski, J.A., Sińczuk-Walczak, H., Szymczak, M., and Wesołowski, W. (1996). Neurological and neurophysiological examinations of workers occupationally exposed to organic solvent mixtures used in the paint and varnish production. *Int. J. Occup. Med. Environ. Health* 9, 235–244.
264. Hänninen, H., Eskelinen, L., Husman, K., and Nurminen, M. (1976). Behavioral effects of long-term exposure to a mixture of organic solvents. *Scand. J. Work Environ. Health* 2, 240–255.
265. Ng, T.P., Ong, S.G., Lam, W.K., and Jones, G.M. (1990). Neurobehavioural effects of industrial mixed solvent exposure in chinese printing and paint workers. *Neurotoxicol. Teratol.* 12, 661–664.
266. Chen, Z., Liu, S.J., Cai, S.X., Yao, Y.M., Yin, H., Ukai, H., Uchida, Y., Nakatsuka, H., Watanabe, T., and Ikeda, M. (1994). Exposure of workers to a mixture of toluene and xylenes. II. Effects. *Occup. Environ. Med.* 51, 47–49.
267. Daniell, W.E., Claypoole, K.H., Checkoway, H., Smith-Weller, T., Dager, S.R., Townes, B.D., and Rosenstock, L. (1999). Neuropsychological function in retired workers with previous long-term occupational exposure to solvents. *Occup. Environ. Med.* 56, 93–105.
268. Sińczuk-Walczak, H., and Szymczak, M. (1997). Rhythm patterns of basic brain bioelectric activity in workers chronically exposed to carbon disulfide. *Int. J. Occup. Med. Environ. Health* 10, 429–440.
269. Godderis, L., Braeckman, L., Vanhoorne, M., and Viaene, M. (2006). Neurobehavioral and clinical effects in workers exposed to CS(2). *Int. J. Hyg. Environ. Health* 209, 139–150.

270. Knave, B., Olson, B.A., Elofsson, S., Gamberale, F., Isaksson, A., Mindus, P., Persson, H.E., Struwe, G., Wennberg, A., and Westerholm, P. (1978). Long-term exposure to jet fuel. II. A cross-sectional epidemiologic investigation on occupationally exposed industrial workers with special reference to the nervous system. *Scand. J. Work Environ. Health* 4, 19–45.
271. Mitran, E., Callender, T., Orha, B., Dragnea, P., and Botezatu, G. (1997). Neurotoxicity associated with occupational exposure to acetone, methyl ethyl ketone, and cyclohexanone. *Environ. Res.* 73, 181–188.
272. Orbaek, P., Risberg, J., Rosén, I., Haeger-Aronsen, B., Hagstadius, S., Hjortsberg, U., Regnell, G., Rehnström, S., Svensson, K., and Welinder, H. (1985). Effects of long-term exposure to solvents in the paint industry. A cross-sectional epidemiologic study with clinical and laboratory methods. *Scand. J. Work Environ. Health* 11 Suppl 2, 1–28.
273. Ukai, H., Watanabe, T., Nakatsuka, H., Satoh, T., Liu, S.J., Qiao, X., Yin, H., Jin, C., Li, G.L., and Ikeda, M. (1993). Dose-dependent increase in subjective symptoms among toluene-exposed workers. *Environ. Res.* 60, 274–289.
274. Viaene, M.K., Pauwels, W., Veulemans, H., Roels, H.A., and Masschelein, R. (2001). Neurobehavioural changes and persistence of complaints in workers exposed to styrene in a polyester boat building plant: influence of exposure characteristics and microsomal epoxide hydrolase phenotype. *Occup. Environ. Med.* 58, 103–112.
275. Vouriot, A., Hannhart, B., Gauchard, G.C., Barot, A., Ledin, T., Mur, J.-M., and Perrin, P.P. (2005). Long-term exposure to solvents impairs vigilance and postural control in serigraphy workers. *Int. Arch. Occup. Environ. Health* 78, 510–515.
276. Lindelof, B., Almkvist, O., and Göthe, C.J. (1992). Sleep disturbances and exposure to organic solvents. *Arch. Environ. Health* 47, 104–106.
277. Singer, R., and Scott, N.E. (1987). Progression of neuropsychological deficits following toluene diisocyanate exposure. *Arch. Clin. Neuropsychol.* 2, 135–144.
278. Wise, M.G., Fisher, J.G., and de la Pena, A.M. (1983). Trichloroethane (TCE) and central sleep apnea: a case study. *J. Toxicol. Environ. Health* 11, 101–104.
279. Lee, Y.L., Pai, M.C., Chen, J.H., and Guo, Y.L. (2003). Central neurological abnormalities and multiple chemical sensitivity caused by chronic toluene exposure. *Occup Med (Lond)* 53, 479–482.
280. Peters, H.A., Levine, R.L., Matthews, C.G., Sauter, S.L., and Rankin, J.H. (1982). Carbon disulfide-induced neuropsychiatric changes in grain storage workers. *Am. J. Ind. Med.* 3, 373–391.
281. Callender, T.J., Morrow, L., Subramanian, K., Duhon, D., and Ristovv, M. (1993). Three-dimensional brain metabolic imaging in patients with toxic encephalopathy. *Environ. Res.* 60, 295–319.
282. Linz, D.H., de Garmo, P.L., Morton, W.E., Wiens, A.N., Coull, B.M., and Maricle, R.A. (1986). Organic solvent-induced encephalopathy in industrial painters. *J. Occup. Med.* 28, 119–125.
283. Monstad, P., Nissen, T., Sulg, I.A., and Mellgren, S.I. (1987). Sleep apnoea and organic solvent exposure. *J. Neurol.* 234, 152–154.
284. Teelucksingh, S., Steer, C.R., Thompson, C.J., Seckl, J.R., Douglas, N.J., and Edwards, C.R. (1991). Hypothalamic syndrome and central sleep apnoea associated with toluene exposure. *Q. J. Med.* 78, 185–190.
285. Minami, M., Katsumata, M., Miyake, K., Inagaki, H., Fan, X.H., Kubota, H., Yamano, Y., and Kimura, O. (1992). Dangerous mixture of household detergents in an old-style toilet: a case report with simulation experiments of the working environment and warning of potential hazard relevant to the general environment. *Hum. Exp. Toxicol.* 11, 27–34.

286. Kilburn, K.H. (1995). Evidence that inhaled chlorine is neurotoxic and causes airways obstruction. *International Journal of Occupational Medicine and Toxicology* 4, 267–276.
287. Peeples, L. (2020). News Feature: How air pollution threatens brain health. *Proc Natl Acad Sci USA* 117, 13856–13860.
288. Calderón-Garcidueñas, L., Azzarelli, B., Acuna, H., Garcia, R., Gambling, T.M., Osnaya, N., Monroy, S., DEL Tizapantzi, M.R., Carson, J.L., Villarreal-Calderon, A., *et al.* (2002). Air pollution and brain damage. *Toxicol. Pathol.* 30, 373–389.
289. Campbell, A., Oldham, M., Becaria, A., Bondy, S.C., Meacher, D., Sioutas, C., Misra, C., Mendez, L.B., and Kleinman, M. (2005). Particulate matter in polluted air may increase biomarkers of inflammation in mouse brain. *Neurotoxicology* 26, 133–140.
290. Haghani, A., Johnson, R., Safi, N., Zhang, H., Thorwald, M., Mousavi, A., Woodward, N.C., Shirmohammadi, F., Coussa, V., Wise, J.P., *et al.* (2020). Toxicity of urban air pollution particulate matter in developing and adult mouse brain: Comparison of total and filter-eluted nanoparticles. *Environ. Int.* 136, 105510.
291. Arito, H., Uchiyama, I., and Yokoyama, E. (1992). Acute effects of ozone on EEG activity, sleep-wakefulness and heart rate in rats. *Ind. Health* 30, 23–34.
292. Alfaro-Rodríguez, A., and González-Piña, R. (2005). Ozone-induced paradoxical sleep decrease is related to diminished acetylcholine levels in the medial preoptic area in rats. *Chem. Biol. Interact.* 151, 151–158.
293. Paz, C., and Bazan-Perkins, B. (1992). Sleep-wake disorganization in cats exposed to ozone. *Neurosci. Lett.* 140, 270–272.
294. Paz, C., and Huitron-Resendiz, S. (1996). The effects of ozone exposure on the sleep-wake cycle and serotonin contents in the pons of the rat. *Neurosci. Lett.* 204, 49–52.
295. González-Piña, R., and Alfaro-Rodríguez, A. (2003). Ozone exposure alters 5-hydroxy-indole-acetic acid contents in dialysates from dorsal raphe and medial preoptic area in freely moving rats. Relationships with simultaneous sleep disturbances. *Chem. Biol. Interact.* 146, 147–156.
296. Miyata, R., and van Eeden, S.F. (2011). The innate and adaptive immune response induced by alveolar macrophages exposed to ambient particulate matter. *Toxicol. Appl. Pharmacol.* 257, 209–226.
297. Murrison, L.B., Brandt, E.B., Myers, J.B., and Hershey, G.K.K. (2019). Environmental exposures and mechanisms in allergy and asthma development. *J. Clin. Invest.* 129, 1504–1515.
298. Anenberg, S.C., Mohegh, A., Goldberg, D.L., Kerr, G.H., Brauer, M., Burkart, K., Hystad, P., Larkin, A., Wozniak, S., and Lamsal, L. (2022). Long-term trends in urban NO₂ concentrations and associated paediatric asthma incidence: estimates from global datasets. *Lancet Planet. Health* 6, e49–e58.
299. Billings, M.E., Gold, D., Szpiro, A., Aaron, C.P., Jorgensen, N., Gasset, A., Leary, P.J., Kaufman, J.D., and Redline, S.R. (2019). The Association of Ambient Air Pollution with Sleep Apnea: The Multi-Ethnic Study of Atherosclerosis. *Ann. Am. Thorac. Soc.* 16, 363–370.
300. Sánchez, T., Castro-Rodríguez, J.A., and Brockmann, P.E. (2016). Sleep-disordered breathing in children with asthma: a systematic review on the impact of treatment. *J. Asthma Allergy* 9, 83–91.
301. Jaehne, A., Loessl, B., Bárkai, Z., Riemann, D., and Hornyak, M. (2009). Effects of nicotine on sleep during consumption, withdrawal and replacement therapy. *Sleep Med. Rev.* 13, 363–377.

302. Davila, D.G., Hurt, R.D., Offord, K.P., Harris, C.D., and Shepard, J.W. (1994). Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. *Am. J. Respir. Crit. Care Med.* 150, 469–474.
303. Davila, E.P., Lee, D.J., Fleming, L.E., LeBlanc, W.G., Arheart, K., Dietz, N., Lewis, J.E., McCollister, K., Caban-Martinez, A., and Bandiera, F. (2010). Sleep disorders and secondhand smoke exposure in the U.S. population. *Nicotine Tob. Res.* 12, 294–299.
304. Panagiotakos, D.B., Pitsavos, C., Chrysohooou, C., Skoumas, J., Masoura, C., Toutouzas, P., Stefanadis, C., and ATTICA study (2004). Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. *Am. J. Med.* 116, 145–150.
305. White, R.F., Steele, L., O'Callaghan, J.P., Sullivan, K., Binns, J.H., Golomb, B.A., Bloom, F.E., Bunker, J.A., Crawford, F., Graves, J.C., *et al.* (2016). Recent research on Gulf War illness and other health problems in veterans of the 1991 Gulf War: Effects of toxicant exposures during deployment. *Cortex* 74, 449–475.
306. Parihar, V.K., Hattiangady, B., Shuai, B., and Shetty, A.K. (2013). Mood and memory deficits in a model of Gulf War illness are linked with reduced neurogenesis, partial neuron loss, and mild inflammation in the hippocampus. *Neuropsychopharmacology* 38, 2348–2362.
307. Shih, T.M., Hulet, S.W., and McDonough, J.H. (2006). The effects of repeated low-dose sarin exposure. *Toxicol. Appl. Pharmacol.* 215, 119–134.
308. Lippmann, M., Cohen, M.D., and Chen, L.-C. (2015). Health effects of World Trade Center (WTC) Dust: An unprecedented disaster's inadequate risk management. *Crit. Rev. Toxicol.* 45, 492–530.
309. Lioy, P.J., Weisel, C.P., Millette, J.R., Eisenreich, S., Vallero, D., Offenber, J., Buckley, B., Turpin, B., Zhong, M., Cohen, M.D., *et al.* (2002). Characterization of the dust/smoke aerosol that settled east of the World Trade Center (WTC) in lower Manhattan after the collapse of the WTC 11 September 2001. *Environ. Health Perspect.* 110, 703–714.
310. Diamanti-Kandarakis, E., Bourguignon, J.-P., Giudice, L.C., Hauser, R., Prins, G.S., Soto, A.M., Zoeller, R.T., and Gore, A.C. (2009). Endocrine-disrupting chemicals: an Endocrine Society scientific statement. *Endocr. Rev.* 30, 293–342.
311. Mong, J.A., Baker, F.C., Mahoney, M.M., Paul, K.N., Schwartz, M.D., Semba, K., and Silver, R. (2011). Sleep, rhythms, and the endocrine brain: influence of sex and gonadal hormones. *J. Neurosci.* 31, 16107–16116.
312. Mong, J.A., and Cusmano, D.M. (2016). Sex differences in sleep: impact of biological sex and sex steroids. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* 371, 20150110.
313. Cusmano, D.M., Hadjimarkou, M.M., and Mong, J.A. (2014). Gonadal steroid modulation of sleep and wakefulness in male and female rats is sexually differentiated and neonatally organized by steroid exposure. *Endocrinology* 155, 204–214.
314. Harris, C.A., Henttu, P., Parker, M.G., and Sumpter, J.P. (1997). The estrogenic activity of phthalate esters in vitro. *Environ. Health Perspect.* 105, 802–811.
315. Darnerud, P.O., Eriksen, G.S., Jóhannesson, T., Larsen, P.B., and Viluksela, M. (2001). Polybrominated diphenyl ethers: occurrence, dietary exposure, and toxicology. *Environ. Health Perspect.* 109 Suppl 1, 49–68.
316. Shekhar, S., Hall, J.E., and Klubo-Gwiedzinska, J. (2021). The hypothalamic pituitary thyroid axis and sleep. *Current Opinion in Endocrine and Metabolic Research* 17, 8–14.

317. Xie, H.Q., Xu, H.-M., Fu, H.-L., Hu, Q., Tian, W.-J., Pei, X.-H., and Zhao, B. (2013). AhR-mediated effects of dioxin on neuronal acetylcholinesterase expression in vitro. *Environ. Health Perspect.* *121*, 613–618.
318. Wang, C., Zhang, Z.-M., Xu, C.-X., and Tischkau, S.A. (2014). Interplay between Dioxin-mediated signaling and circadian clock: a possible determinant in metabolic homeostasis. *Int. J. Mol. Sci.* *15*, 11700–11712.
319. La Merrill, M., Emond, C., Kim, M.J., Antignac, J.-P., Le Bizec, B., Clément, K., Birnbaum, L.S., and Barouki, R. (2013). Toxicological function of adipose tissue: focus on persistent organic pollutants. *Environ. Health Perspect.* *121*, 162–169.
320. Taheri, S. (2006). The link between short sleep duration and obesity: we should recommend more sleep to prevent obesity. *Arch. Dis. Child.* *91*, 881–884.
321. Jehan, S., Zizi, F., Pandi-Perumal, S.R., Wall, S., Auguste, E., Myers, A.K., Jean-Louis, G., and McFarlane, S.I. (2017). Obstructive sleep apnea and obesity: implications for public health. *Sleep Med. Disord.* *1*.
322. Boucher, J.G., Boudreau, A., Ahmed, S., and Atlas, E. (2015). In Vitro Effects of Bisphenol A β -D-Glucuronide (BPA-G) on Adipogenesis in Human and Murine Preadipocytes. *Environ. Health Perspect.* *123*, 1287–1293.
323. Kim, M.-J., Marchand, P., Henegar, C., Antignac, J.-P., Alili, R., Poitou, C., Bouillot, J.-L., Basdevant, A., Le Bizec, B., Barouki, R., *et al.* (2011). Fate and complex pathogenic effects of dioxins and polychlorinated biphenyls in obese subjects before and after drastic weight loss. *Environ. Health Perspect.* *119*, 377–383.
324. EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF) (2015). Scientific Opinion on the risks to public health related to the presence of bisphenol A (BPA) in foodstuffs. *EFSA Journal* *13*, 3978.
325. Parmalee, N.L., and Aschner, M. (2017). Metals and circadian rhythms. *Adv. Neurotoxicol.* *1*, 119–130.
326. Takahata, R., Matsumura, H., Kantha, S.S., Kubo, E., Kawase, K., Sakai, T., and Hayaishi, O. (1993). Intravenous administration of inorganic selenium compounds, inhibitors of prostaglandin D synthase, inhibits sleep in freely moving rats. *Brain Res.* *623*, 65–71.
327. Matsumura, H., Takahata, R., and Hayaishi, O. (1991). Inhibition of sleep in rats by inorganic selenium compounds, inhibitors of prostaglandin D synthase. *Proc Natl Acad Sci USA* *88*, 9046–9050.
328. Urade, Y., and Hayaishi, O. (2011). Prostaglandin D2 and sleep/wake regulation. *Sleep Med. Rev.* *15*, 411–418.
329. Lidsky, T.I., and Schneider, J.S. (2003). Lead neurotoxicity in children: basic mechanisms and clinical correlates. *Brain* *126*, 5–19.
330. Dietert, R.R., Lee, J.-E., Hussain, I., and Piepenbrink, M. (2004). Developmental immunotoxicology of lead. *Toxicol. Appl. Pharmacol.* *198*, 86–94.
331. Kalahasthi, R., Nagaraju, R., Balachandar, R., and Bagepally, B.S. (2022). Association between occupational lead exposure and immunotoxicity markers: A systematic review and meta-analysis. *Toxicology* *465*, 153047.
332. O'Neal, S.L., and Zheng, W. (2015). Manganese toxicity upon overexposure: a decade in review. *Curr. Environ. Health Rep.* *2*, 315–328.

- 24 333. Harischandra, D.S., Ghaisas, S., Zenitsky, G., Jin, H., Kanthasamy, A., Anantharam, V., and
25 Kanthasamy, A.G. (2019). Manganese-Induced Neurotoxicity: New Insights Into the Triad of Protein
26 Misfolding, Mitochondrial Impairment, and Neuroinflammation. *Front. Neurosci.* 13, 654.
- 27 334. Roussel, B., and Renaud, B. (1977). Effect of chronic manganese intoxication on the sleep-wake cycle
28 in the rat. *Neurosci. Lett.* 4, 55–60.
- 29 335. Bouabid, S., Fifel, K., Benazzouz, A., and Lakhdar-Ghazal, N. (2016). Consequences of manganese
30 intoxication on the circadian rest-activity rhythms in the rat. *Neuroscience* 331, 13–23.
- 31 336. Li, H., Fan, X., Luo, Y., Song, S., Liu, J., and Fan, Q. (2017). Repeated manganese administration
32 produced abnormal expression of circadian clock genes in the hypothalamus and liver of rats.
33 *Neurotoxicology* 62, 39–45.
- 34 337. Ajsuvakova, O.P., Tinkov, A.A., Aschner, M., Rocha, J.B.T., Michalke, B., Skalnaya, M.G., Skalny, A.V.,
35 Butnariu, M., Dadar, M., Sarac, I., *et al.* (2020). Sulfhydryl groups as targets of mercury toxicity. *Coord.*
36 *Chem. Rev* 417.
- 37 338. Kobayashi, H., Yuyama, A., Matsusaka, N., Takeno, K., and Yanagiya, I. (1979). Effects of
38 methylmercury chloride on various cholinergic parameters in vitro. *J. Toxicol. Sci.* 4, 351–362.
- 39 339. Dwivedi, C., Raghunathan, R., Joshi, B.C., and Foster, H.W. (1980). Effect of mercury compounds on
40 cholineacetyl transferase. *Res. Commun. Chem. Pathol. Pharmacol.* 30, 381–384.
- 41 340. Monnet-Tschudi, F., Zurich, M.G., and Honegger, P. (1996). Comparison of the developmental effects
42 of two mercury compounds on glial cells and neurons in aggregate cultures of rat telencephalon. *Brain*
43 *Res.* 741, 52–59.
- 44 341. Basu, N., Kwan, M., and Chan, H.M. (2006). Mercury but not organochlorines inhibits muscarinic
45 cholinergic receptor binding in the cerebrum of ringed seals (*Phoca hispida*). *J. Toxicol. Environ. Health*
46 *Part A* 69, 1133–1143.
- 47 342. Basu, N., Scheuhammer, A.M., Rouvinen-Watt, K., Grochowina, N., Klenavic, K., Evans, R.D., and
48 Chan, H.M. (2006). Methylmercury impairs components of the cholinergic system in captive mink
49 (*Mustela vison*). *Toxicol. Sci.* 91, 202–209.
- 50 343. Algarve, T.D., Assmann, C.E., Aigaki, T., and da Cruz, I.B.M. (2020). Parental and preimaginal
51 exposure to methylmercury disrupts locomotor activity and circadian rhythm of adult *Drosophila*
52 *melanogaster*. *Drug Chem. Toxicol.* 43, 255–265.
- 53 344. Arito, H., Hara, N., and Torii, S. (1983). Effect of methylmercury chloride on sleep-waking rhythms in
54 rats. *Toxicology* 28, 335–345.
- 55 345. Wolansky, M.J., and Harrill, J.A. (2008). Neurobehavioral toxicology of pyrethroid insecticides in adult
56 animals: a critical review. *Neurotoxicol. Teratol.* 30, 55–78.
- 57 346. Picciotto, M.R., Higley, M.J., and Mineur, Y.S. (2012). Acetylcholine as a neuromodulator: cholinergic
58 signaling shapes nervous system function and behavior. *Neuron* 76, 116–129.
- 59 347. Jouvet, M. (1972). The role of monoamines and acetylcholine-containing neurons in the regulation of
60 the sleep-waking cycle. *Ergeb. Physiol.* 64, 166–307.
- 61 348. Watson, C.J., Baghdoyan, H.A., and Lydic, R. (2010). Neuropharmacology of Sleep and Wakefulness.
62 *Sleep Med. Clin.* 5, 513–528.
- 63 349. Brown, R.E., Basheer, R., McKenna, J.T., Strecker, R.E., and McCarley, R.W. (2012). Control of sleep
64 and wakefulness. *Physiol. Rev.* 92, 1087–1187.

350. Stallones, L., and Beseler, C.L. (2016). Assessing the connection between organophosphate pesticide poisoning and mental health: A comparison of neuropsychological symptoms from clinical observations, animal models and epidemiological studies. *Cortex* 74, 405–416.
351. Grob, D., and Harvey, J.C. (1958). Effects in man of the anticholinesterase compound sarin (isopropyl methyl phosphonofluoridate). *J. Clin. Invest.* 37, 350–368.
352. Rogers, S.L., Doody, R.S., Mohs, R.C., and Friedhoff, L.T. (1998). Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. *Arch. Intern. Med.* 158, 1021–1031.
353. Cooke, J.R., Lored, J.S., Liu, L., Marler, M., Corey-Bloom, J., Fiorentino, L., Harrison, T., and Ancoli-Israel, S. (2006). Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease. *Drugs Aging* 23, 503–511.
354. Moraes, W. dos S., Poyares, D.R., Guilleminault, C., Ramos, L.R., Bertolucci, P.H.F., and Tufik, S. (2006). The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. *Sleep* 29, 199–205.
355. Timofeeva, O.A., and Gordon, C.J. (2001). Changes in EEG power spectra and behavioral states in rats exposed to the acetylcholinesterase inhibitor chlorpyrifos and muscarinic agonist oxotremorine. *Brain Res.* 893, 165–177.
356. Quistad, G.B., Sparks, S.E., and Casida, J.E. (2001). Fatty acid amide hydrolase inhibition by neurotoxic organophosphorus pesticides. *Toxicol. Appl. Pharmacol.* 173, 48–55.
357. Boger, D.L., Sato, H., Lerner, A.E., Hedrick, M.P., Fecik, R.A., Miyauchi, H., Wilkie, G.D., Austin, B.J., Patricelli, M.P., and Cravatt, B.F. (2000). Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. *Proc Natl Acad Sci USA* 97, 5044–5049.
358. Murillo-Rodríguez, E., Sánchez-Alavez, M., Navarro, L., Martínez-González, D., Drucker-Colín, R., and Prospéro-García, O. (1998). Anandamide modulates sleep and memory in rats. *Brain Res.* 812, 270–274.
359. Herrera-Solís, A., Vásquez, K.G., and Prospéro-García, O. (2010). Acute and subchronic administration of anandamide or oleamide increases REM sleep in rats. *Pharmacol. Biochem. Behav.* 95, 106–112.
360. Glatfelter, G.C., Jones, A.J., Rajnarayanan, R.V., and Dubocovich, M.L. (2021). Pharmacological actions of carbamate insecticides at mammalian melatonin receptors. *J. Pharmacol. Exp. Ther.* 376, 306–321.
361. Popovska-Gorevski, M., Dubocovich, M.L., and Rajnarayanan, R.V. (2017). Carbamate insecticides target human melatonin receptors. *Chem. Res. Toxicol.* 30, 574–582.
362. Attia, A., Reiter, R., Nonaka, K., Mostafa, M., Soliman, S., and Elsebae, A. (1991). Carbaryl-induced changes in indoleamine synthesis in the pineal gland and its effects on nighttime serum melatonin concentrations. *Toxicology* 65, 305–314.
363. Attia, A.M., Reiter, R.J., Withyachumnarnkul, B., Mostafa, M.H., Soliman, S.A., and el-sebae, A.K. (1991). Chronic administration of sublethal doses of carbaryl increases pineal N-acetyltransferase and hydroxyindole-O-methyltransferase activities and serum melatonin levels. *J. Pineal Res.* 10, 49–54.
364. Tackenberg, M.C., Giannoni-Guzmán, M.A., Sanchez-Perez, E., Doll, C.A., Agosto-Rivera, J.L., Broadie, K., Moore, D., and McMahon, D.G. (2020). Neonicotinoids disrupt circadian rhythms and sleep in honey bees. *Sci. Rep.* 10, 17929.

365. Tasman, K., Hidalgo, S., Zhu, B., Rands, S.A., and Hodge, J.J.L. (2021). Neonicotinoids disrupt memory, circadian behaviour and sleep. *Sci. Rep.* 11, 2061.
366. Evans, E.B., and Balster, R.L. (1991). CNS depressant effects of volatile organic solvents. *Neurosci. Biobehav. Rev.* 15, 233–241.
367. Bushnell, P.J., Shafer, T.J., Bale, A.S., Boyes, W.K., Simmons, J.E., Eklund, C., and Jackson, T.L. (2005). Developing an exposure-dose-response model for the acute neurotoxicity of organic solvents: overview and progress on in vitro models and dosimetry. *Environ. Toxicol. Pharmacol.* 19, 607–614.
368. Riegel, A.C., Zapata, A., Shippenberg, T.S., and French, E.D. (2007). The abused inhalant toluene increases dopamine release in the nucleus accumbens by directly stimulating ventral tegmental area neurons. *Neuropsychopharmacology* 32, 1558–1569.
369. Williams, J.M., Stafford, D., and Steketee, J.D. (2005). Effects of repeated inhalation of toluene on ionotropic GABA A and glutamate receptor subunit levels in rat brain. *Neurochem. Int.* 46, 1–10.
370. Bale, A.S., Smothers, C.T., and Woodward, J.J. (2002). Inhibition of neuronal nicotinic acetylcholine receptors by the abused solvent, toluene. *Br. J. Pharmacol.* 137, 375–383.
371. Alfaro-Rodríguez, A., Bueno-Nava, A., González-Piña, R., Arch-Tirado, E., Vargas-Sánchez, J., and Avila-Luna, A. (2011). Chronic exposure to toluene changes the sleep-wake pattern and brain monoamine content in rats. *Acta Neurobiol Exp (Wars)* 71, 183–192.
372. Arito, H., Tsuruta, H., and Nakagaki, K. (1984). Acute effects of toluene on circadian rhythms of sleep-wakefulness and brain monoamine metabolism in rats. *Toxicology* 33, 291–301.
373. Arito, H., Tsuruta, H., and Oguri, M. (1988). Changes in sleep and wakefulness following single and repeated exposures to toluene vapor in rats. *Arch. Toxicol.* 62, 76–80.
374. Hisanaga, N., and Takeuchi, Y. (1983). Changes in sleep cycle and EEG of rats exposed to 4000 ppm toluene for four weeks. *Ind. Health* 21, 153–164.
375. Arito, H., Tsuruta, H., Nakagaki, K., and Tanaka, S. (1985). Partial insomnia, hyperactivity and hyperdipsia induced by repeated administration of toluene in rats: Their relation to brain monoamine metabolism. *Toxicology* 37, 99–110.
376. Eastwood, P.R., Platt, P.R., Shepherd, K., Maddison, K., and Hillman, D.R. (2005). Collapsibility of the upper airway at different concentrations of propofol anesthesia. *Anesthesiology* 103, 470–477.
377. Lauderdale, D.S., Knutson, K.L., Yan, L.L., Liu, K., and Rathouz, P.J. (2008). Self-reported and measured sleep duration: how similar are they? *Epidemiology* 19, 838–845.
378. Jackson, C.L., Patel, S.R., Jackson, W.B., Lutsey, P.L., and Redline, S. (2018). Agreement between self-reported and objectively measured sleep duration among white, black, Hispanic, and Chinese adults in the United States: Multi-Ethnic Study of Atherosclerosis. *Sleep* 41.
379. Mazzotti, D.R., Haendel, M.A., McMurphy, J.A., Smith, C.J., Buysse, D.J., Roenneberg, T., Penzel, T., Purcell, S., Redline, S., Zhang, Y., et al. (2022). Sleep and circadian informatics data harmonization: a workshop report from the Sleep Research Society and Sleep Research Network. *Sleep* 45.
380. Dallmann, R., Okyar, A., and Lévi, F. (2016). Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy. *Trends Mol. Med.* 22, 430–445.
381. Vokac, Z., Gundersen, N., Magnus, P., Jebens, E., and Bakka, T. (1980). Circadian rhythmicity of the urinary excretion of mercury, potassium and catecholamines in unconventional shift-work systems. *Scand. J. Work Environ. Health* 6, 188–196.

382. Hooven, L.A., Sherman, K.A., Butcher, S., and Giebultowicz, J.M. (2009). Does the clock make the poison? Circadian variation in response to pesticides. *PLoS ONE* 4, e6469.
383. Zheng, X., Zhang, K., Zhao, Y., and Fent, K. (2021). Environmental chemicals affect circadian rhythms: An underexplored effect influencing health and fitness in animals and humans. *Environ. Int.* 149, 106159.
384. Zmrzljak, U.P., and Rozman, D. (2012). Circadian regulation of the hepatic endobiotic and xenobiotic detoxification pathways: the time matters. *Chem. Res. Toxicol.* 25, 811–824.
385. Hill, V.M., O'Connor, R.M., Sissoko, G.B., Irobunda, I.S., Leong, S., Canman, J.C., Stavropoulos, N., and Shirasu-Hiza, M. (2018). A bidirectional relationship between sleep and oxidative stress in *Drosophila*. *PLoS Biol.* 16, e2005206.
386. Donley, N., Bullard, R.D., Economos, J., Figueroa, I., Lee, J., Liebman, A.K., Martinez, D.N., and Shafiei, F. (2022). Pesticides and environmental injustice in the USA: root causes, current regulatory reinforcement and a path forward. *BMC Public Health* 22, 708.
387. Johnson, D.A., Jackson, C.L., Williams, N.J., and Alcántara, C. (2019). Are sleep patterns influenced by race/ethnicity - a marker of relative advantage or disadvantage? Evidence to date. *Nat. Sci. Sleep* 11, 79–95.
388. Chen, X., Wang, R., Zee, P., Lutsey, P.L., Javaheri, S., Alcántara, C., Jackson, C.L., Williams, M.A., and Redline, S. (2015). Racial/Ethnic Differences in Sleep Disturbances: The Multi-Ethnic Study of Atherosclerosis (MESA). *Sleep* 38, 877–888.
389. Eskenazi, B., Bradman, A., and Castorina, R. (1999). Exposures of children to organophosphate pesticides and their potential adverse health effects. *Environ. Health Perspect.* 107 Suppl 3, 409–419.

Figure 1. PRISMA flowchart detailing screening and inclusion of studies in this review.

